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ABSTRACT 
 
DISCOVERING PATHWAY AND CELL TYPE SIGNATURES IN TRANSCRIPTOMIC 
COMPENDIA WITH MACHINE LEARNING 
Gregory Philip Way 
Casey S. Greene 
Gene expression measurements capture downstream biological responses to 
molecular perturbations. This systems biology perspective can be investigated using 
both supervised and unsupervised machine learning approaches to rapidly derive 
insight, including cell type and pathway signatures, from transcriptomic compendia. 
Machine learning applied to transcriptomic compendia can aid in biological discovery, 
hypothesis generation, and precision medicine. We introduce these topics and discuss 
their impact in Chapter 1. In Chapters 2-4, we describe and extend a supervised learning 
approach to detect aberrant gene and pathway activity in cancer. We apply this 
approach to identify patient tumors, cell lines, and patient derived xenograft models with 
TP53 loss of function, Ras signaling activation, and NF1 loss. This approach facilitates 
the discovery of phenocopying variants and potential hidden responders to specific 
therapies. In Chapters 5-6, we focus on deriving transcriptomic signatures using 
unsupervised learning. We show that unsupervised learning can identify disease 
subtypes and can be used to develop gene expression signatures without the need to 
specify labels a priori. In Chapter 5, we assess the reproducibility of high grade serous 
ovarian cancer (HGSC) gene expression subtypes across populations and clustering 
algorithms. In Chapter 6, we train a variational autoencoder on patient tumors and use 
latent space arithmetic to identify gene signatures most distinguishing HGSC subtypes. 
Lastly, in Chapter 7, we develop an approach to rapidly interpret compressed features 
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engineered in unsupervised learning algorithms. We train a series of unsupervised 
models across a wide range of latent space dimensions and develop a network-based 
method for interpreting these compressed gene expression features. Using this 
approach, we observe that modifying the hidden layer dimensionality impacts the 
identification of specific geneset and cell-type activation patterns in cancer and normal 
tissue. Machine learning models scale to large genomic datasets and have provided 
state of the art results in a variety of biomedical domains. However, model interpretation 
is critical to build knowledge and to generate hypotheses. 
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Chapter 1. 
An Introduction to discovering pathway and cell type signatures in transcriptomic 
compendia with machine learning  
This chapter was adapted from: Way, Gregory, P. and Greene, Casey, S. 
“Discovering pathway and cell type signatures in transcriptomic compendia with machine 
learning.” To appear in Annual Review of Biomedical Data Science, 2019. Preprint: 
https://peerj.com/preprints/27229/ 
1.1. Introduction 
The quantity of biological data and the pace of their generation have increased 
dramatically over the past several years (1). Biological data are also increasing in 
complexity, as multiple genomic modalities are being measured with improving 
resolution. One such modality measures the transcriptome—the complete RNA products 
of about 30,000 genes in a given organism, tissue, or cell. From the relatively low 
sample sizes and early days of microarray technology to the large data sets currently 
generated through RNA sequencing (RNA-seq) today, researchers have used 
transcriptome measurements to interrogate various biological hypotheses (2). RNA 
measurements can be used to investigate changes to specific expression patterns of 
single genes or pathways. RNA measurements can also be examined from a systems 
biology perspective, in which entire biological systems are studied rather than individual 
parts. From this perspective, the transcriptome represents downstream molecular 
consequences of perturbation or disease and captures alterations to gene regulatory 
networks and environmental stimuli (3). In this dissertation, we consider the systems 
biology perspective that transcriptome measurements provide (Figure 1.1). 
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Figure 1.1: RNA sequencing (RNA-seq) provides a systems biology perspective 
The downstream response to various molecular and environmental perturbations can be 
captured as signals in RNA-seq data. Supervised and unsupervised machine learning 
applied to RNA-seq interrogates this property to reveal expression signatures of cell type 
and pathway activity. 
 
A significant challenge to transcriptome analyses is making sense of the high-
dimensional data. After data processing, there are many mechanisms by which 
hypotheses can be tested and generated (4). One strategy uses machine learning, 
which is capable of rapidly deriving insights and providing accurate results. Machine 
learning is a branch of computer science used to derive solutions based on high-
dimensional input data and a target goal. By optimizing the target goal, or objective 
function, the computer automatically learns a specific, and potentially insightful, solution. 
There are many different machine learning algorithms, each with different costs and 
benefits, including logistic regression, support vector machines (SVMs), random forests 
(RFs), neural networks (NNs), principal components analysis (PCA), non-negative matrix 
factorization (NMF), k-means clustering, and many more. Within each algorithm exists a 
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series of specific tunable knobs called hyperparameters. These knobs control how fast 
an algorithm learns, how many features are learned, how many times to cycle through 
data, and many other important considerations. Hyperparameter decisions can be 
configured through cross validation (CV) in a dataset specific fashion. CV optimizes 
performance by training on one portion of the data, evaluating performance on the 
remaining set, and alternating which portion of the data is removed from training. A 
common challenge in training these models is that the model performs well in training 
but fails to generalize to new data. To mitigate this problem, termed overfitting, 
researchers withhold a portion of the data from training and evaluate it later. 
There are two basic classes of machine learning: supervised and unsupervised 
learning. Each class can be used with varying goals, but the fundamental purpose of 
each is the same: to test how well the model captures the underlying target biology and 
to determine if the biology is consistent when the model is applied to new data. While 
there are other classes of machine learning, such as semisupervised learning, 
reinforcement learning, distantly and weakly supervised learning, and others (5), we 
focus here on supervised and unsupervised learning. We apply supervised learning 
approaches in Chapters 2, 3, and 4, and discuss unsupervised learning projects in 
Chapters 5 and 6. Lastly, we discuss mechanisms to explore the dimensionality of latent 
spaces and interpret unsupervised compression models in Chapter 7.  
Early efforts applying supervised machine learning to transcriptome data were 
largely successful. However, the approaches involved relatively simple supervised 
classification tasks such as cancer versus normal detection (6, 7), outcome prediction 
(8), or gene module detection (9, 10). Additionally, unsupervised tasks like cancer 
subtype discovery (11) and gene pattern identification (12) were also applied in early 
research. These pioneering studies included relatively few samples, and the target 
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biology resulted in large sources of variation. Larger data sets have allowed 
investigators to test more specific hypotheses and extract more subtle expression 
patterns. Many current machine learning algorithms applied to transcriptome data 
involve more subtle tasks, including the detection and characterization of pathway- and 
cell type–based signatures that exist in an underlying subspace of the observable data. 
The extraction of pathway– and cell type–specific gene expression signatures can 
reveal the function and heterogeneity of transcriptome data, and these signatures are 
often the result of molecular perturbations that may be important to a disease or 
phenotype of interest (13–16). Machine learning methods can extract biological signals 
(17). In this introduction, we highlight specific machine learning techniques applied to 
transcriptomic compendia to reveal underlying patterns representing cell type and 
pathway signatures. We discuss supervised and unsupervised machine learning for 
tasks including cell type deconvolution, expression signature discovery for the prediction 
of pathway activity, and the use of dimensionality reduction, or compression, to uncover 
and explain hidden cellular states. We also discuss recent machine learning approaches 
to extract pathway activity in single-cell data and recent deep learning algorithm 
advancements. Lastly, we focus on specific challenges associated with interpreting 
machine learning models. 
1.2. Supervised learning to isolate expression signatures 
Supervised machine learning applied to transcriptome data is a powerful approach to 
test hypotheses about a given model system and to make predictions based on target 
biology. Leveraging the ability of the transcriptome to capture the differential 
mechanisms underlying biological states (see Figure 1.1), supervised machine learning 
can stratify samples and states that are based on specific cell type or pathway 
signatures. In the following subsection, we (a) broadly introduce supervised learning 
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methodology, (b) briefly discuss initial landmark studies applying supervised machine 
learning to transcriptome data, and (c) conclude with a review of current studies that 
train supervised models on large transcriptomic compendia to derive pathway and cell 
type signatures. 
1.2.1. A brief overview of supervised machine learning methodology 
The goal of supervised machine learning is to train a computer to determine the 
status of a known sample and to make accurate predictions on a new sample (18). 
Generally, the models receive as input an n × p data matrix X and a vector y of length n. 
Here, n is the number of samples, p is the number of features, and y represents the 
predefined status, or target classes. In many supervised learning algorithms, the models 
reach a solution of weights w that are optimized against the classification or regression 
task, often through an iterative learning process, such as stochastic gradient descent. 
Additionally, various algorithms place different emphasis on the training process and 
restricting, or regularizing, the solution of weights. For example, one common algorithm 
is logistic regression, which can add penalty terms like Lasso or elastic net into the 
objective function, which will enforce sparse solutions (19, 20). SVMs maximize the 
distance between class labels in feature space, and RFs will determine over many 
iterations features used to split samples based on information content (21, 22). There 
have been many applications of supervised machine learning across a variety of 
domains. Here, we focus on supervised learning applied to deriving cell type and 
pathway signatures. In Chapters 2, 3, and 4, we apply supervised learning approaches 
to detect aberrant pathway activity in cancer. 
1.2.2. Initial successes of supervised machine learning applied to transcriptome data 
Various supervised learning algorithms have been applied to transcriptome data for 
nearly two decades (23). In this setting, the input matrix X is typically n samples by p 
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gene expression features, and the vector y is defined by a target hypothesis or 
measured value. When it is important that only a few genes explain the target 
hypothesis, a researcher may prefer models that are constrained to provide sparse 
solutions, whereby only a small percentage of measurable genes contribute to 
performance. Sparsity may be helpful to define biomarker panels for downstream 
analyses. For example, a sparse classifier predicted metastases in breast cancer (24). 
This discovery led to the 70-gene Mammaprint panel, demonstrating that only 70 genes 
need to be measured to predict breast cancer severity. However, careful validation of 
prognostic signatures must be performed, as over 90% of gene signatures with 100 
random genes were associated with breast cancer outcomes (25). Additional pioneering 
applications of supervised learning to gene expression data have identified top genes 
that differentiate acute lymphoblastic leukemia from acute myeloid leukemia (7), 
distinguished tumor from normal biopsies (6), predicted treatment response in lymphoma 
(8), and predicted the function of novel yeast open reading frames (9). These studies 
were performed on microarray data and were limited to small sample sizes. Therefore, 
the target goals of these approaches required that the two classes contain large 
differences in signal. While these studies did not directly interrogate hypotheses relating 
to cell type and pathway activity, the signals identified may have represented differential 
cell type or pathway expression. Current applications train machine learning models on 
data sets that are orders of magnitude larger, and can thus detect more subtle 
signatures hidden in the data. 
1.2.3. Supervised machine learning to derive cell type and pathway signatures 
Applying supervised machine learning to large transcriptomic compendia allows 
researchers to test specific hypotheses about cell type and pathway signatures (Figure 
1.2). For example, many cell type deconvolution methods perform supervised learning to 
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estimate cell type proportions in samples from bulk tissue expression. In a supervised 
setting, deconvolution uses regression and borrows information from sets of predefined 
marker genes or proportion estimates associated with specific cell types. One method, 
CIBERSORT, requires an input signature matrix of immune cell marker genes that, 
through support vector regression (SVR), deconvolves an input gene expression matrix  
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Figure 1.2: Supervised machine learning to derive cell type and pathway signatures 
(top) Supervised cell type deconvolution methods require a signature matrix as input that 
has predefined marker genes or proportion estimates of cell types. Some form of linear 
regression incorporates this information to generate estimates of cell type proportion. 
(bottom) Supervised learning applied to large transcriptomic compendia with a targeted 
hypothesis can stratify samples based on pathway activity. The models can be used in 
classification or regression to provide binary labels or continuous activation estimates, 
respectively. 
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from bulk tissue (26). Similar approaches use linear regression based on other 
predefined cell type signature matrices to deconvolve immune cell types. This approach 
has been applied to bulk cancer and systemic lupus erythematosus gene expression 
data (27, 28). Other deconvolution algorithms implement least squares regression with 
input proportion matrices predefined in various ways. For example, the matrices can be 
defined by cell type–specific probes (29), by using purified reference samples (30), or 
from a pathologist’s estimation (31). In a related study with different goals, an in-silico 
dissection approach trained an SVM on bona fide cell type–specific genes to identify 
other genes in a guilt-by-association analysis (32). Other cell type deconvolution 
methods exist (reviewed in Reference 33), and many are based on unsupervised 
learning to reveal underlying patterns (discussed in Section 1.3). 
Another use case for supervised learning stratifies samples based on pathway 
activity (Figure 1.2). A key step in this process is to assign accurate labels to samples 
that exhibit pathway misregulation. Assigning the correct status to a sample is costly, 
difficult, and often inaccurate. Therefore, this assignment is usually determined through 
orthogonal means (e.g., pathway mutation status in cancer). Despite this challenge, 
many studies have revealed interesting insights. For example, Guinney et al. (34) trained 
an elastic net classifier on colon cancer transcriptomes to detect KRAS-mutated tumors 
resistant to EGFR (epidermal growth factor receptor) inhibition therapy. The model 
generalized to unseen data sets, and misregulation was associated with survival and 
response to MEK inhibition. In other words, the model identified a subspace that 
separated wild-type KRAS samples from KRAS-mutant samples, which was validated in 
an external cell line data set. In Chapter 2, we discuss a similar approach applied to 
detecting NF1 loss of function in glioblastoma patients. We found that this model 
generalized to a series of patient-derived xenograft models (35). In this study, because 
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there was a relatively low number of positive examples, an ensemble logistic regression 
model was implemented. An ensemble machine learning model trains several classifiers 
on a single task and can help assess solution stability (36). In Chapter 3, we introduce a 
machine learning Ras classifier based on logistic regression with an elastic net penalty. 
We trained the model using data from The Cancer Genome Atlas (TCGA) PanCanAtlas 
project (37). The model predicted Ras activation across a variety of cancer types, 
including colon cancer, and generalized to alternative data sets and tissues. Additionally, 
sensitivity to MEK inhibition was strongly correlated with classifier scores in wild-type 
Ras cell lines. We also discuss a similar model applied to detecting TP53 inactivation in 
Chapter 4 (38). This model revealed an inactivating silent mutation in the splice donor of 
TP53 exon 4, which was corroborated by orthogonal exon–exon splice junction evidence 
(39). 
Other supervised learning algorithms and custom modifications have been applied to 
detecting pathway activity in transcriptomes. For example, custom SVM variants and 
boosting methods have been applied to identify mechanisms that increase malignancy in 
tumors (40). Including biological knowledge a priori in the classification task during 
training can also aid in feature selection and pathway activity stratification (41). 
Furthermore, one-class learning regression algorithms train models on gold standard 
gene expression of specific tissues or pathways, and can generalize to other data sets 
without knowledge of negative labels (42). This approach was recently applied to predict 
oncogenic potential, or stemness, in TCGA PanCanAtlas tumors (43). A similar 
approach, termed positive unlabeled learning, uses gold standard positively labeled 
genes alone to implicate other disease-associated genes (44). Supervised learning has 
also been applied to single-cell transcriptome data. For example, supervised learning 
has been applied to detect marker genes in neocortical cells (45). An NN-based 
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approach can also be used to predict cellular state and cell type (46). Generative 
adversarial networks, which train two competing NNs (47), have been trained to simulate 
single-cell gene expression profiles, which can identify rare cell populations (48, 49). In 
conclusion, supervised learning can determine specific cell type and pathway activity 
and can test hypotheses directly. However, sample labels are costly and often 
inaccurate. It is also important to assess the performance of these models in alternative 
data sets and to provide orthogonal biological evidence when making conclusions. 
1.3. Unsupervised learning to discover hidden expression states 
Unsupervised machine learning identifies underlying structures in data without the 
need for sample labels (50). The goals of unsupervised learning include clustering 
samples into similar groups and identifying hidden, or latent, variables present in lower-
dimensional subspaces. Applied to gene expression data, unsupervised learning has 
been used to identify disease subtypes (11), deconvolve cell types (33), and extract 
underlying gene expression modules present in various percentages in lower-
dimensional data representations (51). In the following subsection, we (a) broadly 
introduce unsupervised learning methodology, (b) discuss the extraction of cell types 
from expression data in an unsupervised manner, and (c) review a series of recent 
publications that train dimensionality reduction, or compression, models on large 
transcriptomic compendia to uncover hidden representations in data that reflect pathway 
activity. In Chapter 5, we apply unsupervised learning approaches to determine the 
concordance of high grade ovarian cancer subtypes (HGSC) across populations. In 
Chapter 6, we train a variational autoencoder (VAE) on gene expression data and 
perform latent space arithmetic to reveal underlying differences between these HGSC 
subtypes. 
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1.3.1. A brief overview of unsupervised machine learning algorithms 
In many unsupervised algorithms, the models learn through minimizing 
reconstruction cost, in an n × p input data matrix X, where n and p are defined as above. 
The algorithms reconstruct the input matrix after passing the data through one or more 
intermediate layers and projecting the matrix back onto input feature space. Most often, 
the intermediate layers have fewer dimensions than the number of input features and 
are considered bottleneck layers. Additionally, most algorithms use only a single-
bottleneck layer. Dimensionality-reduction algorithms such as PCA, independent 
components analysis (ICA), NMF, and autoencoders are often evaluated by their ability 
to reconstruct input data. Researchers can add various constraints on the reconstruction 
loss to help increase feature sparsity or penalize the model to enforce specific feature 
learning. In each compression algorithm, there are two distinct and valuable matrices 
extracted that require interpretation. The matrices represent the learned components 
scores across samples, as well as the relative contribution of each expression feature to 
each component. In all cases, the researcher must select the bottleneck dimensionality 
or rely on heuristics. 
The application of unsupervised machine learning to growing transcriptomic 
compendia has facilitated the rapid generation of biological hypotheses. Compression 
algorithms receive input gene expression from thousands of samples and apply a 
bottleneck layer to learn the most important sources of variation. These sources are 
learned in different ways. For example, PCA learns sources of variation that are 
orthogonal and that explain a decreasing amount of variation in the data. ICA solves a 
signal processing problem of disentangling sources of independent signals, which are 
not necessarily orthogonal. NMF, which has widely been used in the deconvolution 
literature, identifies so-called metagenes, or modules of genes with coordinated 
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expression patterns (52). NMF is also popular for cell type deconvolution because cell 
types exist in positive, linear proportions in bulk tissue. NN-based compression 
algorithms, such as autoencoders and their many variations, also compress data into 
lower dimensions (53, 54). These methods compress data with a nonlinear activation 
and can therefore learn subtle, nonlinear patterns in gene expression data given enough 
samples. Applied to transcriptomic compendia, compression algorithms have provided 
insights into underlying pathway activity. 
Other instances of unsupervised learning algorithms involve clustering, including k-
means clustering, Gaussian mixture models, hierarchical clustering, t-distributed 
stochastic neighbor embedding (t-SNE), and many more (55). These models use 
distance measures in various ways to group similar samples together for class 
stratification and class discovery. There are many examples of unsupervised learning 
applied to cluster gene expression data for subtype identification and gene module 
detection. For example, Hoadley et al. grouped tens of thousands of tumor samples from 
TCGA to highlight subtypes found independent of tissue of origin (56). We specifically 
discuss an application of k-means clustering and non-negative matrix factorization to 
various HGSC datasets in Chapter 5 (57). However, in this introductory section, we do 
not focus on clustering applications and instead focus on compression algorithms 
applied to uncover cell type and pathway signatures. 
1.3.2. Unsupervised machine learning to uncover cell types 
Unsupervised learning can be used as a powerful approach to extract cell type 
signatures in transcriptomic compendia (Figure 1.3). Several unsupervised algorithms 
have been used for cell type deconvolution, including self-organizing maps, hierarchical 
clustering, and matrix decomposition methods like NMF and singular value 
decomposition (33, 52, 58). NMF is used to deconvolve gene expression data to identify 
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differentially expressed genes when no marker genes or reference data exist (59, 60). 
The NMF core algorithm can be guided to identify cell types by restricting the component 
matrix columns to sum to one (61). Additionally, a Markov chain Monte Carlo approach 
has been proposed to estimate cell type proportions in an unsupervised fashion (62). 
Nearest shrunken centroids, a technique that minimizes the number of genes required to 
describe subtypes (63), was also used to deconvolve tumors into malignant, 
nonmalignant, and stroma components (64). It is likely that other compression 
algorithms, in addition to NMF, also capture cell type associations in their compressed 
latent spaces. However, proper interpretation of learned gene expression components is 
required to determine if the observed signatures are representative of cell type 
expression. 
One mechanism to obviate cell type deconvolution is to directly measure single-cell 
expression profiles. There has been a recent explosion of unsupervised learning 
algorithms, including NMF and autoencoders, applied to derive insights from single-cell 
transcriptome data (65–74). The application goals are usually batch correction, 
imputation, visualization, cell state identification, or identifying pathway activity 
underlying homogeneous cell type populations. These differential patterns of pathway 
activity can aid in cell state identification. For example, differential pathway activity in a 
homogenous population of B cells in lupus patients was predictive of patient outcome 
(75). Additionally, by applying methods to increase the distance between points in a 
homogeneous cell type population of Schistosoma parasites, Tarashansky et al. 
identified subsets of cells that do not express specific marker genes previously thought 
to be omnipresent (71). Therefore, unsupervised models can keep pace with expanding 
data and extract patterns at increasing resolution. 
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Figure 1.3: Unsupervised machine learning is used to discover cell type proportion 
and pathway signatures 
 
(top) An illustrated example of unsupervised machine learning for cell type 
deconvolution. The input gene expression matrix is compressed into two component 
matrices, a signature matrix and a proportion matrix. The proportion matrix can be 
associated with cell type proportion in a given sample, and the signature matrix 
represents gene contributions to each signature. (bottom) Compression algorithms 
applied to a high-dimensional input matrix will automatically aggregate gene features 
into a lower-dimensional latent space. These latent spaces may represent pathway 
activities and other biological processes. Abbreviations: ICA, independent components 
analysis; NMF, non-negative matrix factorization; PCA, principal components analysis. 
 
1.3.3. Unsupervised machine learning reveals underlying gene expression states 
Compression algorithms applied to transcriptome data reveal pathway signatures 
hidden in latent spaces that represent a lower-dimensional data manifold (Figure 1.3). 
For example, PCA applied to a large compendium of nearly 80,000 transcriptomes 
showed a strong contribution of copy number alterations to disruptive gene signatures in 
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cancer (76). ICA has also been applied to transcriptome data to assign genes to gene 
modules and to identify pathway signatures and other hidden transcriptional programs 
(51, 77, 78); reviewed in Reference (79). In a direct comparison, ICA outperformed PCA 
in identifying gene modules significantly related to pathway activity in breast cancer 
samples (78). NMF is increasingly becoming the method of choice to derive pathway- 
and cell type–specific signatures from transcriptomic compendia (80–82). NMF does not 
constrain solutions to be orthogonal, and can therefore identify interconnected biological 
processes. A similar constrained latent variable approach provides interpretable pathway 
signatures and can identify pathway-specific activities while isolating technical artifacts 
(83). This method, called PLIER (pathway-level information extractor), has also been 
applied to large compendia to train a model that can provide insights into rare diseases 
through transfer learning (84). Other similar methods use Bayesian optimizations of 
matrix factorization to uncover patterns of biological processes hidden in transcriptome 
data (82, 85). 
NMF identifies nonorthogonal linear patterns in data, which can be helpful in many 
tasks. Different techniques can use nonlinear activation functions to identify pathway 
activity from transcriptomic compendia. For example, denoising autoencoders (DAEs) 
trained on a large compendia of publicly available Pseudomonas transcriptomes were 
able to uncover biological pathways associated with the pathogen’s response to media 
and oxygen exposure (86, 87). In this setting, the DAE was shallow, consisting of only 
one hidden latent space layer with a nonlinear activation function. DAE and stacked 
DAEs were also applied to yeast transcriptome data to reveal cell cycle expression 
signatures (88). DAEs compress input data through noise corruption and then 
reconstruct the original input through a nonlinear bottleneck layer (89). The corruption 
process provides regularization, permitting increased generalizability. More recent 
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applications have converted the autoencoder architecture into a generative model. A 
generative model learns a specific latent code that can be sampled from to simulate new 
data. VAEs are generative models (90, 91) and have gained popularity in transcriptome 
applications for a variety of purposes, including improving visualization and extracting 
hidden patterns underlying data (92). In Chapter 6, we discuss a VAE trained on TCGA 
PanCanAtlas expression data. This model revealed biological patterns associated with 
patient sex and various patterns of cell type and pathway activity, including immune cell 
infiltration (93). VAEs have also identified patterns of response to drug treatment in a 
panel of cell lines (94). However, it remains to be determined what other features are 
being compressed from transcriptomic compendia and what other signals representing 
known and potentially novel biology are being aggregated. In conclusion, unsupervised 
machine learning applied to transcriptomic compendia can reveal underlying patterns of 
cell type and pathway variation. 
1.4. Interpreting machine learning models applied to transcriptomes 
Machine learning models enable the accurate detection of cellular states and robust 
predictions of pathway activity. In addition, interpreting supervised and unsupervised 
models can reveal important biology. Model interpretation is crucial to the success of any 
machine learning algorithm applied to transcriptome data. In Chapter 7, we discuss a 
novel approach to interpret compressed gene expression features using network 
projection. 
1.4.1. Supervised learning models reveal differences between sample statuses 
Supervised learning models assign weights, or importance scores, to each gene 
expression feature given a classification or regression task. For example, an RF model 
will determine important gene expression features to split classes. Many methods have 
been developed to rank RF feature importance, including an integration of Gene 
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Ontology (GO) terms to predict gene expression changes. This technique has been 
applied to determine important genes in the aging process and response to chemical 
compounds in Caenorhabditis elegans (95, 96). Likewise, regression models and SVMs 
identify a subspace that represents specific activation patterns in the input feature 
space. The magnitude of these features can be interpreted as the most important genes 
for the classification task. Several methods penalize scores using recursive feature 
elimination and use hinge loss penalties to reduce the number of explanatory genes 
(97–99). A logistic regression model predicting Ras pathway activation identified similar 
genes as a differential expression analysis comparing Ras wild-type to mutant tumors 
(37). However, caution must be exercised when interpreting gene importance scores, 
since the algorithms can rely heavily on initializations, and different solutions are likely to 
implicate different genes (100). Models may select correlated genes and ignore causal 
genes, which is detrimental to downstream interpretation. NN models are also 
particularly difficult to interpret. The often black box models learn many layers of features 
with increasing complexity, and it is important not to over interpret what the models are 
learning. For instance, a sparse stacked autoencoder trained on yeast transcriptomes 
revealed transcription factor machinery in intermediate layers, but hidden layers are 
especially difficult to interpret (101). 
1.4.2. Unsupervised learning models require interpretation of compressed features 
Compression algorithms applied to transcriptome data output features with different 
combinations of gene weights, or importance scores, that can be interpreted to represent 
biological processes. There are many mechanisms by which ranked gene lists can be 
interpreted, including overrepresentation pathway analysis and gene set enrichment 
analysis (102). However, the interpretation of compressed features in gene expression 
space has many open-ended questions. When trained on the same data set, the 
18	
	
distribution of feature importance scores across different algorithms has different skews 
and kurtosis values (Figure 1.4A). Therefore, it is not clear that interpreting compression 
features is equivalent across algorithms. Furthermore, with the exception of the positive 
values learned by NMF, all other algorithms learn positive and negative signatures. It is 
not apparent if these values represent one general feature, two independent features, or 
something else. It is also not clear if the compressed features are learning single 
sources of variation, entangled sources of variation, or noise associated with technical 
artifacts. Thus far, researchers have attempted to interpret compressed features from a 
variety of algorithms in several ways (Figure 1.4B). For example, one can set a cutoff on 
gene importance scores based on two or three standard deviations above or below the 
mean (87, 103). Another strategy consists of sequentially removing top weighted genes 
from positive and negative tails and performing Lilliefors test of normality until the 
compressed feature resembles a normal distribution (77, 104). The removed genes 
represent a ranked gene list of the feature-specific genes. Another strategy is to use 
counterfactual analysis to observe which genes are strongly associated with covariates 
and to weight their importance to the biological source (105). In Chapter 7, we introduce 
a network projection approach that considers the full distribution of compressed gene 
expression features. We build gene set networks from publically available gene set 
compendia and determine enrichment of gene sets compared to permuted networks. 
Another important question concerns how many compressed features exist. In other 
words, how many sources of variation to be compressed are there that contain important 
biology in a population? Researchers using a gene expression compendium of over 
5,000 human tissues determined that only the first three principle components of a PCA 
contained biologically relevant information (106). However, a follow-up study using the 
same data extracted additional biologically meaningful features and reported that the low  
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Figure 1.4: Interpretation of compressed gene expression features 
 
(A) An example of a single random encoded feature of five different compression 
algorithms reveals the heterogeneity of the feature importance distribution. The input 
data are from The Cancer Genome Atlas PanCanAtlas gene expression data from 33 
different tissue types spanning over 10,000 patients. (B) Defining genes that contribute 
to compressed features. These genes can be extracted in different ways. After the 
feature-associated genes are defined, there are various options for interpreting these 
compressed features, including various pathway- and network-based options. 
Abbreviations: DAE, denoising autoencoder; ICA, independent components analysis; 
NMF, non-negative matrix factorization; PCA, principal components analysis; VAE, 
variational autoencoder. 
 
number of relevant compressed features was a sampling bias effect (107). Furthermore, 
an application of ICA to over 9,000 microarray samples revealed 423 components 
significantly associated with GO terms (51). A more recent analysis applying ICA to over 
97,000 microarray samples revealed a total of 139 reproducible transcriptome modules 
(108). An issue common to many compression algorithms is the requirement to set an 
internal dimensionality. Mao et al. included extra capacity in the bottleneck layer to pool 
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technical artifacts in regions without prior biological knowledge constraints (83). In fact, it 
has been posited that gene expression consists of a series of compressed composite 
measurements (109). Nevertheless, it is clear that compression algorithms extract 
sources of variation in the underlying biology that are dependent on the strength of the 
signal, the number of samples that contain the biology, the assumptions of the model 
(e.g., linear versus nonlinear), and the predefined internal dimensionality. In Chapter 7, 
we investigate the dimensionality of gene expression data by serially compressing input 
matrices with an increasing bottleneck layer. More specifically, compress the data into 2 
dimensions, 3 dimensions, 4 dimensions and so on up to 200. We project gene set 
networks onto the compressed features to quickly determine enriched gene sets 
captured in these features and determine how the bottleneck layer contributes to their 
identification. 
Lastly, the stability of unsupervised learning solutions is of utmost importance. 
Because many unsupervised models are trained through an iterative process, the 
solutions identified will be different depending on internal conditions. Therefore, it is 
important to recognize stable patterns identified across various initializations. To this 
end, a method called stability NMF evaluates solutions from multiple starting points and 
determines stable basis vectors, or principle patterns, if they are consistently identified 
and correlated (110). Ensemble models have been used to aggregate solutions into a 
single model (87). Other methods have also been proposed to assess the stability of 
solutions, including adding dropout to NN models at test time (111). Nevertheless, 
interpreting machine learning models, investigating model stability, and associating 
compressed features with real biology are of paramount importance. 
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1.5. Conclusion 
Machine learning applied to transcriptomic compendia reveals interesting 
substructures in high-dimensional data that often represent cell type and pathway 
signatures. Both supervised and unsupervised machine learning models have been 
successfully applied to derive expression signatures with a variety of goals. As 
transcriptomic compendia continue to grow in size and resolution, so will the need for 
rapid insight generation and decision making abilities. In many models, there are no 
restrictions on which signals the machine learning models use to learn, so they can 
include artifacts and batch effects. Therefore, models must be applied to independent 
data sets to confirm the learned target biology. In addition to testing alternative data, 
orthogonal evidence supporting the discovered biology can help determine which signals 
are accurately interpreted and repeatable, and then additional molecular experiments 
can confirm the model’s ability to identify biological signals. We are also in an age where 
computational experiments should be made reproducible (112). Therefore, software to 
reproduce machine learning models should be provided with publications to enable other 
researchers to quickly build upon work. Transcriptomic compendia contain vast amounts 
of signal and value, and machine learning is one technology that can tap into this 
resource. 
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Chapter 2. 
A machine learning classifier trained on cancer transcriptomes detects NF1 
inactivation signal in glioblastoma 
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Contributions: 
In the paper Way, Allaway et al. 2017, I was a co-first author. Specifically, I trained 
and evaluated the machine learning approach to detect NF1 loss of function. The other 
co-first author, Allaway, performed the molecular validation experiments. Allaway also 
wrote methods sections 2.3.5, 2.3.6, 2.3.7, and 2.3.9 and produced the western blot in 
Figure 2.2. He also wrote and interpreted the gene and pathway analysis in section 2.4.3 
and 2.5. I drafted all other sections and compiled all other figures. All authors provided 
comments on various revision versions and helped to design the study. 
 
2.1. Abstract 
2.1.1. Background 
We have identified molecules that exhibit synthetic lethality in cells with loss of the 
neurofibromin 1 (NF1) tumor suppressor gene. However, recognizing tumors that have 
inactivation of the NF1 tumor suppressor function is challenging because the loss may 
occur via mechanisms that do not involve mutation of the genomic locus. Degradation of 
the NF1 protein, independent of NF1 mutation status, phenocopies inactivating 
mutations to drive tumors in human glioma cell lines. NF1 inactivation may alter the 
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transcriptional landscape of a tumor and allow a machine learning classifier to detect 
which tumors will benefit from synthetic lethal molecules. 
2.1.2. Results 
We developed a strategy to predict tumors with low NF1 activity and hence tumors 
that may respond to treatments that target cells lacking NF1. Using RNAseq data from 
The Cancer Genome Atlas (TCGA), we trained an ensemble of 500 logistic regression 
classifiers that integrates mutation status with whole transcriptomes to predict NF1 
inactivation in glioblastoma (GBM). On TCGA data, the classifier detected NF1 mutated 
tumors (test set area under the receiver operating characteristic curve (AUROC) mean = 
0.77, 95% quantile = 0.53 – 0.95) over 50 random initializations. On RNA-Seq data 
transformed into the space of gene expression microarrays, this method produced a 
classifier with similar performance (test set AUROC mean = 0.77, 95% quantile = 0.53 – 
0.96). We applied our ensemble classifier trained on the transformed TCGA data to a 
microarray validation set of 12 samples with matched RNA and NF1 protein-level 
measurements. The classifier’s NF1 score was associated with NF1 protein 
concentration in these samples. 
2.1.3. Conclusions 
We demonstrate that TCGA can be used to train accurate predictors of NF1 
inactivation in GBM. The ensemble classifier performed well for samples with very high 
or very low NF1 protein concentrations but had mixed performance in samples with 
intermediate NF1 concentrations. Nevertheless, high-performing and validated 
predictors have the potential to be paired with targeted therapies and personalized 
medicine. 
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2.2. Background 
Genomic tools allow investigators to devise therapies targeting specific molecular 
abnormalities in tumors. One such alteration is the loss of neurofibromin 1 (NF1), an 
important tumor suppressor that regulates the activity of RAS GTPases (113, 114). 
Heterozygous mutation or deletion of NF1 causes neurofibromatosis type 1 (NF), one of 
the most frequently inherited genetic disorders (115). NF patients often develop 
plexiform neurofibromas (PNs), benign nerve tumors for which the only therapy is 
surgery. However, resection is often impossible due to the tumor’s intimate association 
with peripheral and cranial nerves (116). PNs can transform to malignant peripheral 
nerve sheath tumors (MPNSTs), which are chemo- and radiation-resistant sarcomas 
with a dismal 20% 5-year survival (117). In addition, patients with NF are susceptible to 
a broad spectrum of other tumors including low-grade/pilocytic astrocytomas, 
pheochromocytomas, optic nerve gliomas, and juvenile myelomonocytic leukemias 
(118). Many aggressive non-NF associated (sporadic) tumors have recently been shown 
to harbor NF1 mutations, including glioblastoma (GBM), neuroblastoma, melanoma, 
thyroid, ovarian, breast, and lung cancers (119). Therefore, somatic and inherited loss of 
NF1 function is emerging as a driver of tumors from different organ sites.  
Several groups including our own have been working to develop therapeutic 
approaches to target tumors with loss of NF1. Previously, our lab developed a high 
throughput approach using yeast and mammalian screening platforms to identify tool 
compounds and drug targets for cancer cells in which NF1 loss drives tumor formation. 
Our pipeline identified small molecules that selectively kill or stop the growth of MPNST 
cells carrying a mutation in NF1 or yeast lacking the NF1 homolog IRA2 (120). We also 
developed an assay in yeast to identify the targets of our lead tool compounds and found 
that one of these compounds (UC-1) shares a mechanism (phosphorylation of RNA Pol 
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II CTD Ser2/5) with experimental drugs in clinical trials (120). UC-1 impacts CTD 
phosphorylation, which is regulated by the CTD kinase Ctk1, the yeast homolog of 
human Cdk9. We showed that deletion of CTK1 was synthetic lethal with loss of the 
yeast NF1 homolog IRA2. Furthermore, we have found that inhibitors of this process 
(dinaciclib, SNS-032) can inhibit other types of RAS-dysregulated tumor cells (121).  
However, relying on genetic data alone to identify tumors that may be susceptible to 
therapies targeting NF1 loss may leave a proportion of potentially actionable tumors 
unrecognized. NF1 tumor suppressor activity can be lost via mutation of the genomic 
locus, proteasome-mediated degradation, inhibition by miRNA, de novo insertion of an 
ALU element, and C→U editing of the NF1 mRNA (122–126). This complexity presents 
challenges when trying to identify tumors that will benefit from molecules that exert 
synthetic lethality with dysregulation of NF1/RAS pathways. 
The Cancer Genome Atlas (TCGA) has released a large volume of data on several 
cancer tissues measured on a variety of genomic platforms. In the present study, we 
leverage TCGA GBM RNAseq expression data with matched mutation calls to construct 
a classifier capable of identifying an NF1 inactivation signature. This strategy sidesteps 
the problem of functional characterization of mutations by evaluating a regulator’s 
downstream gene expression activity. We applied this signature to predict NF1 
inactivation in a cohort of biobanked GBMs. In general, this approach can be 
translatable to any gene producing measurable downstream transcriptome-wide effects. 
2.3. Methods 
2.3.1. The Cancer Genome Atlas data used for building the classifier 
We downloaded RNAseq and mutation data from TCGA Pan Cancer project from the 
UCSC Xena data portal (127) and subset each dataset to only the GBMs (128). The 
data consists of 607 GBMs; of which 291 have mutation calls, 172 have RNAseq 
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measurements, and 149 have both RNAseq and mutation calls. Of these 149 samples, 
15 have inactivating NF1 mutations (10.1%) and were used as gold standard positives in 
building the classifier. Additionally, to reduce dimensionality while avoiding unexpressed 
and invariant genes, we subset to the top 8,000 most variably expressed genes by 
median absolute deviation. We z-scored all gene expression measurements. This 
resulted in the final input matrix with dimension 149 samples by 8,000 genes. For use in 
platform independent predictions, we used Training Distribution Matching (TDM) to 
transform the TCGA RNAseq data to match a microarray expression distribution (129). 
Since we are also aware of the NF1 mutation status for each of the samples, we 
form a supervised learning task – predicting when a sample has loss of NF1 activity. Our 
X matrix is formed by the RNAseq measurements for all 149 samples measured by 
8,000 genes, which are the features in the model. Our y vector consists of {0, 1} 
elements where a 1 corresponds to a sample with an inactivating NF1 mutation and a 0 
is an NF1 wildtype sample. The machine learning task is to find the feature weights, or 
gene coefficients, that best minimize our objective function. Along with these feature 
weights corresponding to the genes’ importance in the learning task, we also output a 
probability estimate for each sample that they have loss of NF1 activity. 
2.3.2. Hyperparameter optimization of the logistic regression classifier 
Using the GBM RNAseq data, we trained logistic regression classifiers with an 
elastic net penalty using stochastic gradient descent to detect tumors with NF1 
inactivation. We chose a penalized regression model because it is simple to train and 
has easily interpretable outputs including importance scores for each gene (feature 
weights) associated with the downstream consequences of NF1 loss of function and a 
probability for each sample that NF1 is lost. An elastic net logistic regression model has 
also been successfully implemented in similar studies (34, 130, 41).  
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We identified high-performing alpha and L1 mixing parameters using 5-fold cross 
validation ensuring balanced membership of NF1 mutations in each fold. Briefly, alpha 
controls how weight penalty and the L1 mixing parameter tunes the amount of test set 
regularization by controlling the sparsity of the features. An L1 mixing parameter value of 
zero corresponds to the L2 penalty and a value of one corresponds to the L1 penalty, 
with L1 bringing a sparser solution. We used python 3.5.1 and Sci-kit Learn for machine 
learning implementations (131). 
2.3.3. Ensemble classifier construction and application to the validation set 
After selecting optimal hyperparameters, we constructed 500 classifiers that would 
compose our ensemble model. Specifically, across 100 different random initializations, 
we subset the full TCGA GBM data into 5 folds and trained a single classifier for each 
training fold. 
We borrowed terminology from the epidemiology field to describe data partitioning. 
We trained our models on a “training” partition and assessed model performance on a 
“test” partition, which refers to the held out cross-validation fold. The independent 
“validation set” refers to the GBM dataset generated in a different lab (see Figure 2.1A).  
Because of the small number of gold standard positive training examples, we were 
concerned about the stability of our model solutions. Therefore, we constructed an 
ensemble classifier from the 500 models. Specifically, we assigned each classifier a 
weight using the specific randomization’s “test set” cross-validation AUROC. Lastly, for 
the final NF1 inactivation prediction, we used the mean of the weighted predictions 
across all iterations as the NF1 inactivation prediction. We applied this ensemble 
classifier to the validation set in which NF1 protein levels were directly measured. 
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2.3.4. Effect sizes and power analysis 
We calculated the decision function of each ensemble classifier applied to all 
samples in the training and testing 5-fold cross validation folds to calculate Cohen’s D 
effect size between predicted NF1 wildtype and NF1 inactive samples (132). The 
Cohen’s D metric quantifies the difference between NF1 wildtype and NF1 inactive 
samples according to the mean classifier score and directly demonstrates how different 
the ensemble model predicts the two groups to be.  
Moreover, we were also concerned that our relatively small validation set would not 
provide us with enough power to observe a detectable effect in the ensemble model’s 
final prediction. We performed a one-tailed Welch two-sample t-test comparing the NF1 
protein concentration of our validation samples that were predicted to be either NF1 
wildtype or NF1 deficient. Using the given sample size, Cohen’s D effect size, and a 
significance threshold of α = 0.05, we calculated the power of the prediction scores on 
the validation set. The power analysis was two-sample, one-tailed and incorporated 
unequal sample sizes in each group. 
2.3.5. Validation sample acquisition 
Thirteen flash-frozen, de-identified GBM samples were obtained from the Maine 
Medical Center Biobank. Samples were received on dry ice and stored at -80°C until 
isolation of DNA/RNA/protein. To isolate DNA, tumor fragments of approximately 20 mg 
in mass were harvested on an aluminum block pre-chilled on dry ice. Samples were then 
immediately transferred to a mortar and pestle containing a small volume of liquid 
nitrogen. The fragments were pulverized in the mortar and pestle, and the liquid nitrogen 
was allowed to evaporate. Next, samples were immediately processed with a 
DNA/RNA/Protein Purification Plus kit (Norgen Biotek) following the standard operating 
protocol for animal tissue. DNA concentration and quality were assessed using an ND-
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1000 (Nanodrop), a Qubit Fluorometer (Thermo Scientific), and a Fragment Analyzer 
(Advanced Analytical Technologies). To isolate RNA, -80 C tumor fragments were 
placed in 5-10 volumes of RNAlater-ICE Frozen Tissue Transition Solution (Ambion) and 
placed at -20°C until RNA extraction with a mirVana miRNA isolation kit, without phenol, 
following the standard operating protocol (Thermo Scientific). Samples were 
homogenized using a manual homogenizer in the presence of mirVana lysis buffer. RNA 
concentration and quality were determined using a Qubit Fluorometer (Thermo 
Scientific) and a Fragment Analyzer (Advanced Analytical Technologies). To isolate 
protein, small tumor fragments were pulverized and lysed in approximately 3 volumes of 
ice-cold radioimmunoprecipitation assay (RIPA) buffer (150 mM sodium chloride, 1% v/v 
nonidet P40, 0.5% w/v sodium deoxycholate, 0.05% w/v sodium dodecyl sulfate, 50 mM 
Tris pH 8.0) containing 1 mM sodium orthovanadate, 1 mM sodium fluoride, 1 mM 
phenylmethylsulfonyl fluoride, and 1X protease inhibitor cocktail (0.1 μg/mL leupeptin, 
100 μM benzamidine HCl, 1 μM aprotinin, 0.1 μg/mL soybean trypsin inhibitor, 0.1 μg/mL 
pepstatin, 0.1 μg/mL antipain). Samples were passed through a 25 ⅝ g needle and 
subsequently sonicated on ice to promote efficient lysis and DNA shearing. After a 30-
minute incubation on ice, lysates were cleared by centrifuging at 16100 x g for 20 
minutes. HEK293T, U87-MG, and U87-MG cells treated for two hours with 1 micromolar 
bortezomib (Selleckchem) and 10 micromolar MG132 (Selleckchem) were also prepared 
in RIPA buffer. Protein samples were stored at -80°C until analysis. 
2.3.6. Cell culture 
U87-MG and HEK293T cells were purchased from ATCC. Cell lines were regularly 
passaged and were cultured in Dulbecco’s Modified Eagle Medium (Corning) with 10% 
v/v fetal bovine serum (Gibco) at 37°C in 5% CO2. 
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Recent data regarding the U87MG cell line published by Allen et al suggest that the 
U87MG cell line distributed by ATCC is not from the same tumor as the cell line that was 
originally isolated in Uppsala. Transcriptome analysis comparing ATCC U87MG cell line 
to known tumor transcriptomes indicate that the ATCC U87MG cell line is a central 
nervous system tumor and is likely a glioblastoma cell line (133).  
In the present study, we employ this cell line as a control representing an NF1-
deficient tumor cell line. Previous studies have shown that the U87MG cell line has 
elevated proteasome-mediated degradation of NF1 and that this cell line required the 
loss of NF1 protein to promote tumorigenesis in xenograft tumor models (122). Given 
that the ATCC U87MG cell line is a well-characterized and broadly-used model of NF1 
deficient tumor cells (122, 134–136), we propose that the use of the ATCC U87MG cell 
line is an appropriate control for Figure 2.2. 
2.3.7. RNA microarray 
After RNA isolation and QC, samples were labeled for the GeneChip Human 
Transcriptome Array 2.0 (HTA 2.0, Affymetrix). Labeling was performed with Affymetrix 
Proprietary DNA Label (biotin-linked) using a WT Plus Kit (Affymetrix) provided with the 
HTA 2.0, following the standard operating protocol for HTA 2.0, including PolyA controls. 
Hybridization, washing, and staining were performed with the WT Plus Kit, following the 
standard operating protocol for HTA 2.0. Washing and staining were performed using a 
GeneChip Fluidics 450. Scanning was performed with a GeneChip Scanner 3000. These 
data were deposited in the Gene Expression Omnibus under accession GSE85033. 
2.3.8. Validation sample processing 
We applied a quality control pipeline (137) to all CEL files generated by the HTA 2.0.  
All validation samples passed processing quality control, which included an inspection of 
spatial artifacts, MA plots, probe distributions, and sample comparison boxplots. We 
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summarized transcript intensities using robust multi-array analysis (RMA) (138). We 
determined batch normalization was unnecessary after a guided principal components 
analysis (gPCA) using sample processing date and array plate ID as potential batch 
effect confounders (139).  Lastly, we collapsed HTA2.0 transcripts into gene level 
measurements using the `collapseRows()` function with the “maxmean“ method from the 
R package WGCNA (140). We used the pd.hta.2.0 platform design file (version 3.12.1) 
and the Bioconductor package “hta20sttranscriptcluster.db” (version 8.3.1) to map 
manufacturer transcript IDs to genes. We performed all preprocessing steps using R 
version 3.2.3.   
2.3.9. Western blotting 
Prior to sodium dodecyl sulfate polyacrylamide gel electrophoresis, protein sample 
concentration was determined using a Pierce BCA Protein Assay Kit (Thermo Scientific). 
Protein samples were prepared with 1X Laemmli sample buffer (50 mM Tris pH 6.8, 
0.02% w/v bromophenol blue, 2% w/v SDS, 10% v/v glycerol, 1% v/v beta-
mercaptoethanol, 12.5 mM EDTA) and 50 μg of tumor protein. Volumes were normalized 
with RIPA buffer including the protease/phosphatase inhibitors described above. SDS-
PAGE was performed using a 4-15% Mini-PROTEAN TGX gel (Bio-Rad) for 1 hour at 
120V. The samples were then transferred to a nitrocellulose membrane for 2 hours and 
45 minutes at 400 mA in cold transfer buffer (384 mM glycine, 50 mM Tris, 20% 
methanol, 0.005% w/v sodium dodecyl sulfate). Following this, the blots were then 
blocked in 5% w/v BSA or 5% w/v nonfat dry milk in Tris-buffered saline (137 mM NaCl, 
2.7 mM KCl, 19 mM Tris, 0.05% v/v Tween 20, pH 7.4) for 25 minutes. Immunoblotting 
was performed with the following antibodies and conditions (vendor, species, diluent, 
dilution, incubation time, incubation temperature): anti-NF1 D7R7D (Cell Signaling, 
rabbit, 2% BSA, 1:1000, overnight, 4°C), anti-tubulin B-1-2-5 (Santa Cruz, mouse, 2% 
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milk, 1:10000, 1 hour, RT), anti-EGFR D38B1 (Cell Signaling, rabbit, 2% milk, 1:1000-
1:2000, 1h, RT), p-ERK ½ (p44/42 MAPK) #9101 (Cell Signaling, rabbit, 2% BSA, 
1:2000, overnight, 4°C), SUZ12 D39F6 #3737 (Cell Signaling, rabbit, 2% milk, 1:1000, 
overnight, 4°C). Anti-NF1 D7R7D was a kind gift from Cell Signaling Technologies, Inc.   
The binding of the primary antibodies was detected by incubation with secondary 
antibodies goat anti-rabbit HRP 1:20000 or goat anti-mouse HRP 1:10000 (Jackson 
Immunoresearch Laboratories Inc.) at room temperature in 2% milk in TBST and 
detection of HRP activity using Pierce ECL Western Blotting substrate (Thermo 
Scientific), or in the case of NF1, SuperSignal West Femto Maximum Sensitivity 
Substrate (Thermo Scientific).  The chemiluminescent signal was captured with MED-B 
medical x-ray film (Med X Ray Company Inc.). Between primary antibodies, the 
membrane was stripped twice for 10 minutes at room temperature using a mild stripping 
buffer containing 1.5% w/v glycine, 0.1% w/v SDS, 1% v/v Tween 20 at pH 2.2 (Abcam). 
One sample was eliminated due to low yield, and apparent degradation as determined 
by western blotting (all proteins examined were undetectable with the exception of 
tubulin, not shown). Densitometry was performed using Li-COR Image Studio Lite 5.0. 
Briefly, intensity measurements for NF1 and tubulin were taken using equally-sized 
regions for all bands. The background was subtracted using the local median intensity 
from the left and right borders (size=2) of each measurement region. NF1 values were 
divided by tubulin intensity to adjust for protein loading.  All measurement ratios were 
then normalized by dividing values by the “U87+PI” measurement for each blot, 
respectively. 
2.3.10. Reproducibility of computational analyses 
We provide software with a permissive open source license to reproduce all 
computational analyses (141). Ensuring a stable compute environment, we performed all 
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analyses in a Docker image (142). This image and source code can be used to freely 
confirm, modify, and build upon this work. 
2.4. Results 
2.4.1. Classifier performance 
Using 5-fold cross validation across a parameter sweep, we identified optimal 
hyperparameters at alpha = 0.15 and L1 mixing = 0.1. To assess model performance, 
we performed 100 random initializations of five-fold cross-validation (Figure 2.1A). These 
models had mean test area under the receiver operating characteristic curve (AUROC) 
of 0.77 (95% Quantiles: 0.53 – 0.95) and a mean train AUROC of 0.997 (95% Quantile: 
0.98 – 1.00). We repeated this procedure after TDM transformation and achieved 
comparable results with alpha = 0.15 and l1 mixing = 0.1 (mean test AUROC = 0.77, 
95% Quantiles: 0.51 – 0.96; mean train AUROC = 0.998, 95% Quantiles: 0.99 – 1.00) 
(Figure 2.1). Because the validation set was measured by microarray, we used the 
classifier trained on TDM transformed data to construct our ensemble classifier. We also 
determined the Cohen’s D effect size estimate for all training and testing partitions 
across all 5-fold cross validation iterations of the TDM transformed model. The classifier 
consistently and robustly separated NF1 wildtype and NF1 inactivated GBM samples 
with high effect sizes (Training: mean Cohen’s D = 3.07, 95% CI = 2.24 – 4.16; Testing: 
mean Cohen’s D = 1.27, 95% CI = 0.19 – 2.67).  
2.4.2. Identification and characterization of NF1 deficient glioblastoma tumor 
samples 
We characterized NF1 protein concentrations as well as other molecules involved in 
RAS signaling in the 12 GBM samples (Figure 2.2A). Two samples (CB2, 3HQ) had no 
apparent NF1 protein. Eight other samples had similar or less NF1 signal than the U87-
MG NF1-low control (H5M, LNA, YXL, VVN, R7K, TRM, UNY, W31). Two samples	
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Figure 2.1: Ensemble classifier errors over 100 iterations for TCGA GBM RNAseq 
(A) Schematic describing the terms used for training, testing, and validating our model. 
We applied 5-fold cross validation to the full dataset which consists of training and 
testing splits in each fold. The model is then applied as an ensemble classifier on a set 
of in-house samples (validation set) (B) Receiver operating characteristic (ROC) curves 
for all 500 classifiers that make up the ensemble model applied to both training and 
testing set. Also shown is the aggregate performance of the ensemble classifier. (C) The 
cumulative density of area under the ROC curve (AUROC) for training and testing 
partitions. 
 
(PBH, RIW) had equal or greater NF1 than the positive control, U87-MG + proteasome 
inhibitors (preventing NF1 degradation). We also observed variable EGFR content in 
these samples, with non-existent to low levels (3HQ, YXL, R7K), or medium to large 
EGFR signal (CB2, H5M, PBH, LNA, YXL, VVN, RIW, TRM, UNY, W31).  
 All GBM samples had high concentrations of phospho-ERK1/2 signal relative to 
cell line controls. Samples with increased phospho-ERK1/2 may have greater Ras 
pathway activation. This can be attributed to multiple factors, including increased EGFR 
expression and/or NF1 inactivation.  
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Figure 2.2: Performance of our classifier on an external validation set 
(A) Two distinct western blots for each of our twelve samples. The controls are U87-MG, 
an NF1 WT glioblastoma cell line that exhibits proteasomal degradation of the NF1 
protein. U87+PI are U87-MG cells are treated with the proteasome inhibitors (PI) MG-
132 and bortezomib to block proteasome-mediated degradation of NF1. We used the 
NF1/tubulin ratio normalized to U87+PI as our NF1 protein level estimate. (B) Prediction 
scores for each of the 500 classifiers weighted by cross validation test set AUROC 
where a negative number indicates NF1 wildtype and a positive number indicates NF1 
inactivation. Increasing color intensity indicates higher observed NF1 protein 
concentrations. (C) We quantify protein against U87+PI and provide the mean of the 
weighted predictions. (D) Based on weighted predictions, we show the abundance of 
NF1 protein compared to U87+PI.  
 
Our ensemble classifier predicted four samples to have NF1 inactivation (CB2, UNY, 
R7K, and 3HQ) and eight samples to be NF1 wildtype (W31, TRM, PBH, VVN, LNA, 
RIW, H5M, and YXL) (Figure 2.2B). Because two samples, (CB2 and H5M) were 
measured on both western blots (Figure 2.2C), we used the mean of their NF1 protein 
level across both experiments.  
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We performed a one-tailed t-test to determine if NF1 protein concentrations were 
significantly higher in NF1 wildtype versus NF1 deficient samples based on our classifier 
predictions (Figure 2.2D). We did not observe a significant difference across groups (t = 
-1.38, p = 0.098, effect size = 0.699). Additionally, while the effect size was fairly large, a 
power analysis indicated that we required 22 samples per group to achieve a power = 
0.8. With a lack of glioblastoma samples with quantified NF1 protein available, the trend 
of less protein present in NF1 inactivated samples nevertheless remains promising.   
One of the samples predicted to be NF1 inactive contains detectable NF1 protein (R7K), 
suggesting that this sample may have NF1 inactivation not detectable by assaying 
protein, have a different alteration that phenocopies NF1 loss, or is incorrectly predicted 
by the classifier. Conversely, there are three samples predicted to be NF1 wildtype that 
have low or undetectable protein (YXL, VVN, W31), which either indicates unknown 
elements that confound the detection of some NF1 dysregulated tumors or a 
classification error. 
2.4.3. Highly contributing genes 
We observed several genes that consistently contributed to the ensemble classifier 
performance (Figure 2.3). Since we applied several classifiers to the validation set as an 
ensemble, we took the sum of all classifier’s gene weights across all 500 iterations to 
define these consistently contributing genes. While the data indicate that these genes 
have an impact on classifier performance, the data do not indicate whether changes in 
the expression of these genes are a direct consequence in changes in NF1 signaling. 
Expression of genes such as TXNIP, ARRDC4, ISPD, C10orf107, and DUSP18 appear 
to be predictive of intact NF1 signaling. Among the list of genes that appear to be 
expressed in tumors with loss of NF1 function are QPRT, ATF5, HUS1B, PEG10, 
HMGA2, RSL1D1, and NRG1. 
37	
	
 
Figure 2.3: Genes that contribute to the NF1 classifier performance 
Genes are shown ranked by their weighted contribution to the ensemble classifier. 
Weights are scaled to unit norm. The top 10 positive and top 10 negative contributing 
high weight genes are given on the right. 
 
We also performed over-representation analysis of the most influential genes in the 
classifier to identify gene ontology (GO) sets and pathways that may be predictive of 
NF1 status (143–146). For high-weight genes predictive of intact NF1 signaling, we 
observed GO sets involved in plasma membrane-localized proteins (GO:0005886, 
GO:0071944, GO:0016324) and homeostasis (GO:0048871, GO:0001659, 
GO:0048873, GO:0031224), among others. Annotated pathways associated with genes 
from this dataset include hematopoietic stem cell differentiation, thyroid cancer, voltage-
gated potassium channels, and RHO GTPase functional pathways.  
 For high-weight genes predictive of NF1 loss of function, we observed GO sets 
related to cellular adhesion (GO:0007155, GO:0098742), negative regulation of signaling 
(GO:0009968, GO:0023507, GO:0010648), and nervous system development 
(GO:0051962, GO0007416, GO: 0050808), among others. These genes were also 
enriched for elements of the phototransduction cascade and thyroxine production 
pathways. 
38	
	
2.5. Discussion 
A machine learning classifier, based on gene expression data, can capture signal 
associated with the inactivation of a tumor suppressor. Our classifier is able to detect 
subtle downstream changes in gene expression as a result of the tumor responding to 
NF1 loss of function. This finding supports using mRNA as a summary measurement 
capable of capturing system-wide responses to molecular events beyond transcription 
factor alterations. Machine learning has been applied to gene expression in a variety of 
studies with various goals (23, 86, 147–149). In a similar study, Guinney et al. trained a 
classifier to model RAS activity in colorectal cancer and demonstrated its clinical utility 
by predicting response to MEK inhibitors and anti-EGFR based treatments (34). With a 
wealth of signal embedded in gene expression and a rapidly growing library of datasets, 
the performance of machine learning models is likely to rapidly improve. An increase in 
performance leads to more reliable clinical applications that would potentially predict the 
effectiveness of pathway-specific targeted therapies. 
While our classifier was able to predict NF1 inactivation status to an extent, its 
performance is far from being clinically actionable. A major difficulty in developing a 
reliable classifier in this case is contamination in gold standard positives and negatives. 
While we aim to detect NF1 inactivation events, our gold standard positives can only 
include samples with known NF1 mutation status. Conversely, we expect that negative 
samples (about 90% of the data) are also contaminated with NF1 inactivated samples 
due to protein loss and other mechanisms. We cannot determine scenarios where NF1 
is inactivated beyond mutation at scale in the TCGA data. Another challenge with the 
construction of classifiers from such data is overfitting. Even after hyperparameter 
optimization we observed substantial overfitting (Figure 2.2), which has also been 
observed in competitions (see, for example, Supplementary Figure S2 of Noren et al. 
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2016 (150) in which the best performing algorithms also overfit). Finally with a small 
number of positive examples the model performance is unstable, which demonstrates 
high variability in gold standard samples used to train the model (151). We employed 
ensemble classification to mitigate this issue as averaging over heterogeneous models 
would result in a relatively stable classifier (see Figure 2.2B). In summary, our results 
are promising but these challenges are substantial and significant work remains to reach 
a robust classifier with clinical utility. 
The performance of the classifier appears to be impacted by many cancer related 
genes. For example, genes such as TXNIP and ARRDC4, which are both indicative of 
lactic acidosis, correlate with better clinical outcomes, and contribute to predicting 
tumors with intact NF1 signaling (152). We also observed transcripts that are more 
highly expressed in brain tissue than either other normal tissue (ISPD, C10orf107), or 
more highly expressed in normal brain tissue than glioma (EPHA5) (153–155). DUSP18 
contributes to the prediction of NF1 wildtype status and is a negative regulator of ERK 
phosphorylation, possibly by regulating SHP2 phosphorylation (156). It is unclear 
whether the expression of these genes is a direct result of NF1 expression, the result of 
signaling downstream of NF1, or a consequence of other phenomena (such as 
expression of SPRED1, an NF1 binding partner that is essential for NF1 signaling). 
Future studies could elucidate the potential connections between NF1 and the genes 
identified as important for the performance of this classifier. 
Over-representation analysis of these data highlighted changes in potassium 
channel expression. It was previously demonstrated that NF1 wild-type Schwann cells 
have altered K+ channel activity as compared to NF1-/- Schwann cells suggesting that 
this may be one factor by which NF1 mutant and wild-type cells can be distinguished 
(157). 
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Regarding prediction of NF1 inactivated tumors, we observed several genes that 
have been linked to cancer such as QPRT, which is highly expressed in malignant 
pheochromocytomas as compared to benign; RSL1D1 (CSIG), which stabilizes c-myc in 
hepatocellular carcinoma; PPEF, which is highly expressed in astrocytic gliomas as 
compared to normal brain tissue (158–160); and PEG10, a poor prognostic marker and 
regulator of proliferation, migration, and invasion in several tumor types (161–163). We 
also observed ATF5, a gene for which expression in malignant glioma is correlated with 
poor survival (164). Knockdown of ATF5 in GBM cells causes cell death in vitro and in 
vivo (165). Analysis of genes that contribute to the prediction of NF1 inactivation yielded 
several GO terms related to neural development. It is well established that loss of NF1 
can result in abnormal neural development and/or tumorigenesis (126, 166, 167). We 
also observed genes associated with the mesodermal commitment pathway, 
components of which are linked to the epithelial to mesenchymal transition in human 
cancer cells (168–170). Analysis of this pathway may be informative in identifying tumors 
with NF1 loss because mesenchymal GBMs are enriched for tumors with NF1 loss 
(171). 
Our ensemble classifier was able to robustly detect the samples with the highest and 
lowest NF1 protein concentrations, but it struggled with samples of intermediate NF1 
concentrations. This could be a result of an enrichment of mechanisms causing NF1 
inactivation beyond protein abundance, an overrepresentation of mesenchymal tumors 
in NF1 inactivated samples contaminating dataset splits (171), poor classifier 
generalizability, or incomplete data transformation between RNAseq and microarray 
data. Because training and testing performance were similar between transformed and 
non-transformed data, we don’t anticipate performance to be impacted much by platform 
differences or classifier generalizability. Nevertheless, we demonstrated the ability of 
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system-wide gene expression measurements to capture downstream consequences of a 
complex biological mechanism that would otherwise require several different types of 
data acquisition to capture.   
2.6. Conclusions 
A machine learning classifier for transcriptomic data was able to detect signal 
associated with the inactivation of NF1, a tumor suppressor gene. The gene is an 
important regulator of the oncogene RAS and is inactivated frequently in GBM and in 
other tumors. The measurement of NF1 inactivity cannot be comprehensively captured 
by any single genomic characterization such as targeted sequencing or fluorescence in 
situ hybridization. This difficulty arises from diverse and complex biological mechanisms 
that inactivate the tumor suppressor in a variety of ways. However, we demonstrated 
that measuring system-wide RNA can capture subtle downstream changes that occur in 
response to NF1 inactivation. Improving classification performance is required before 
transitioning such a model into clinical use, but our method could be used to 
characterize cell lines or patient-derived xenograft (PDX) models with inactive NF1. 
Eventually, with more data and improved classification, we expect machine-learning 
models constructed on system-wide transcriptomics will translate into clinically relevant 
predictions that will guide targeted therapy. 
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Chapter 3. 
Machine learning detects pan-cancer Ras pathway activation in The Cancer 
Genome Atlas 
This chapter was originally published as: Way, Gregory, P., Sanchez-Vega, 
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In the paper Way et al. 2018, I was the first author. Specifically, I trained and 
evaluated the machine learning approach to detect Ras activity in the PanCanAtlas. I 
wrote the full manuscript and created all figures. The other co-authors contributed as 
specified above. 
 
3.1. Summary 
Precision oncology uses genomic evidence to match patient with treatment, but often 
fails to identify all patients who may respond. The transcriptome of these “hidden 
responders” may reveal responsive molecular states. We describe and evaluate a 
machine learning approach to classify aberrant pathway activity in tumors, which may 
aid in hidden responder identification. The algorithm integrates RNA-seq, copy number, 
and mutations from 33 different cancer-types across The Cancer Genome Atlas (TCGA) 
PanCanAtlas project to predict aberrant molecular states in tumors. Applied to the Ras 
pathway, the method detects Ras activation across cancer-types and identifies 
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phenocopying variants. The model, trained on human tumors, can predict response to 
MEK inhibitors in wild-type Ras cell-lines. We also present data that suggest multiple hits 
in the Ras pathway confer increased Ras activity. The transcriptome is underused in 
precision oncology and, combined with machine learning, can aid in the identification of 
hidden responders. 
3.2. Introduction 
Precision oncology matches cancer patients to specific therapies based on genomic 
evidence, but has benefited only a relatively low proportion of cancer patients to date 
(172, 173). While clinically promising, precision oncology lacks complete and accurate 
matching strategies and fails to identify many patients that could be matched using 
alternative approaches (174). Cataloging transcriptome measurements across 
thousands of tumors enables a systems biology perspective into the downstream 
consequences of molecular perturbation. Detecting these perturbations using 
transcriptomic states can improve precision oncology efforts toward more accurate and 
complete pairing of patients to effective treatments (175).  
In the largest uniformly processed cancer dataset to date, TCGA PanCanAtlas has 
released multi-platform genomic measurements across thousands of tumors from 33 
different cancer-types (176). With this scale of data, researchers can build and evaluate 
statistical models that stratify tumors based on aberrant gene and pathway function. 
Previously, strategies have been explored using expression signatures to stratify 
patients (177). Some strategies have used data from individual cancer-types. For 
example, gene expression signatures in colon adenocarcinoma (COAD) and 
glioblastoma (GBM) stratified tumors with aberrant KRAS and NF1 function, respectively 
(34, 35). Furthermore, data integration approaches incorporating pathway connectivity, 
including PARADIGM, are used to characterize pathway activity and infer gain or loss of 
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function events (41, 178, 179). An unsupervised approach decomposing gene 
expression states in cell lines to map pathway activity has been proposed (180). Here, 
we introduce an elastic net penalized logistic regression classifier to learn signatures of 
gene or pathway alterations from gene expression assays of tumor biopsies across 
cancer-types. Our method is applied across cancer-types to learn an independent, pan-
cancer signature of pathway aberration. Our method can be used to identify 
phenocopying variants and requires only gene expression data for inference on new 
data. We apply our method to detect Ras pathway activation pan-cancer. 
The Ras pathway is frequently altered in many different cancer-types (181). When 
the pathway is activated, often by gain of function KRAS, NRAS, or HRAS mutations or 
through NF1 loss of function events, cells increase their translational output and 
unchecked cellular proliferation occurs (182, 183). Certain cancer-types, such as 
pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), thyroid 
carcinoma (THCA), lung adenocarcinoma (LUAD), and colon adenocarcinoma (COAD) 
are known to be largely driven by mutations in Ras pathway genes (184–187). 
Additionally, mutations in the Ras pathway have been observed to be early events 
driving tumorigenesis and have also been associated with poor survival and treatment 
resistance (188–191). Because the Ras pathway is ubiquitously misregulated, 
developing specific therapeutic targets is one of the National Cancer Institute’s key 
initiatives. However, Ras is also notoriously difficult to therapeutically target and 
accurate detection of its malfunction is paramount (192).  
The most direct method of assessing Ras activation is by targeted sequencing of 
Ras. However, these methods would fail to detect unknown variants in other genes that 
phenocopy Ras activating mutations. Detecting such tumors may enable more patients 
to be targeted therapeutically. In the following study, we describe our machine learning 
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approach that integrates bulk RNA-seq, copy number, and mutation data from the 
PanCanAtlas. We apply the method to Ras genes and demonstrate that our method can 
detect Ras activation pan-cancer. The classifier also identifies NF1 phenocopying events 
in TCGA and prioritizes Ras wild-type cell lines that respond to MEK inhibitors. Manually 
curated oncogenic variants in Ras pathway genes were assigned higher classification 
scores than variants with unknown significance. Our method can be applied to other 
cancer-associated genes and pathways as well. For example, the DNA Damage Repair 
PanCanAtlas analysis working group (AWG) applied this approach to detecting TP53 
inactivation (38). 
3.3. Results 
3.3.1. Machine learning models to predict pathway activity 
We developed a machine learning approach to detect aberrant pathway activity in 
tumors. The method integrated RNA-seq, copy number, and mutation data. The models 
were trained using tumors from TCGA PanCanAtlas with a complete set of these 
measurements; which included 9,075 tumors across 33 different cancer-types. The 
method is based on a logistic regression classifier framework regularized with an elastic 
net penalty. We used RNA-seq as a measurement describing the expression state of a 
tumor, and trained the classifier to detect downstream gene expression patterns 
consistent with aberrant pathway activity (Figure 3.1A). The algorithm learned a 
combination of gene importance scores, or weights (w), that together learn to best 
separate aberrant from wild-type expression patterns. As input during training, tumors 
with any non-silent somatic variants in target genes were included in the positive set 
(Figure 3.1B). We also included copy number gains for oncogenes, and deep copy 
number loss for tumor suppressor genes (Figure 3.1B). For complete details about the 
model and training approach, refer to the methods section (section 3.4). In principle, this 
46	
	
approach could be applied to predict other gene or pathway events. Here, we applied 
the method to classifying Ras activity. 
 
Figure 3.1: Supervised machine learning and data integration for TCGA PanCanAtlas 
(A) RNAseq data (X) is multiplied by a vector of gene weights (w) where the optimization 
task is to find the optimal w to correctly classify the pathway status matrix (y). We train 
the model with the train partition and evaluate performance on a held-out test set. (B) 
The status matrix y is constructed by integrating mutations and copy number alterations 
(CNA). We consider activating or loss of function mutations and high copy number gain 
and deep copy number loss for oncogenes and tumor suppressor genes, respectively. 
Black squares indicate aberrant events. For the Ras classifier, we used non-silent 
somatic mutations and high copy gains in the oncogenes KRAS, NRAS, and HRAS. 
 
3.3.2. Detecting Ras activation pan cancer 
We trained a classifier to detect aberrant Ras activity in tumors using knowledge of 
KRAS, HRAS, and NRAS mutations and copy number gains (see Figure 3.1). These 3 
core Ras genes differed greatly in variant prevalence across cancer-types. In the 
PanCanAtlas, KRAS mutations were widespread in PAAD (72%), COAD (45%), rectum 
adenocarcinoma (READ, 42%), and LUAD (31%), while NRAS mutations were common 
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in SKCM (31%) (Figure 3.2A). We performed a differential expression analysis of 
PanCanAtlas tumors, controlled for cancer-type, comparing wild-type against aberrant 
Ras tumors (Figure 3.2B). 
 
Figure 3.2: Ras pathway alteration percentages in TCGA PanCanAtlas 
(A) Percentage of KRAS, HRAS, and NRAS mutations and copy number gains across 
33 different cancer-types from TCGA PanCanAtlas. (B) Differentially expressed genes 
between Ras aberrant and Ras wild-type PanCanAtlas tumors. The analysis is 
controlled for cancer-type. 
 
In the classifier, to enforce a more balanced class representation and to reduce 
performance metric inflation (193), we used samples from 16 of 33 cancer-types for 
training (Figure 3.3A). We also used the top 8,000 most variably expressed genes by 
median absolute deviation (MAD) (see methods section for details). We then randomly 
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held out 10% of the samples (n = 476) to create a test set. The test set was selected to 
have the same proportion of cancer-types and Ras statuses as the training set. The 
training set consisted of the remaining 90% (n = 4,283), which included 3,374 Ras wild-
type and 909 tumors with non-silent somatic Ras variants. Within the training set we 
performed five-fold cross validation (CV). We report training (“training”), cross-validation 
(“CV”), and held-out test set (“testing”) performance using these cancer-types. We also 
evaluated the final classifier on cancer-types that were initially filtered from training.  
Overall, the classifier showed high performance, with an area under the receiver 
operating characteristic (AUROC) curve above 84% and an area under the precision 
recall (AUPR) curve above 63% in the CV and testing sets (Figure 3.3B). For the 
samples initially filtered from training, we also observed reasonable performance, with 
an AUROC = 75.2% and an AUPR = 24.7%. Therefore, the classifier detected Ras 
activation signal in tissues it was not exposed to during training. Applying the final 
classifier to all 9,075 samples, we observed an 86.7% AUROC and a 61.2% AUPR.  
The Ras classifier consisted of automatically learned gene weights, or importance 
scores. Training with an elastic net penalty resulted in a sparse classifier, with only 185 
genes contributing to classification. Genes and covariates with weights above zero can 
be interpreted as being up-regulated in tumors with activated Ras while negative weight 
genes are characteristic of tumors with wild-type Ras (Figure 3.3C). However, caution 
must be exercised in interpreting these coefficients as our elastic net regularization 
approach induces sparsity, which means that the solution represents a subset of genes 
associated with, and therefore useful for identifying, Ras activation. A differential 
expression analysis of Ras aberrant to wild-type tumors would reveal these downstream 
genes. 
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Figure 3.3: Evaluating machine learning classification of Ras activation 
(A) Cancer-type specific percentages of Ras aberration by copy number gain and 
deleterious mutation in KRAS, HRAS, or NRAS. The colored squares indicate if the 
cancer-type was included in model training. (B) Predicting Ras pathway activation 
metrics. The grey lines represent classifier predictions on a randomly shuffled gene 
expression matrix. Left: Receiver operating characteristic (ROC) curve and Area under 
the ROC (AUROC) curve given for training, testing, and cross-validation (CV) sets. The 
dotted navy line represents a hypothetical random classifier. Right: Precision Recall (PR) 
Curve and corresponding area under the PR (AUPR) curve for each evaluation set. (C) 
Sparse classifier coefficients indicate which genes impact classifier performance. 
Log10_mut represents tumor-specific non-silent mutation rate. (D) Cancer-type specific 
performance for the pan-cancer model compared to separate models trained on each 
cancer-type independently.  
 
Nevertheless, many of the classifier implicated genes are known modulators of the 
Ras/MAPK pathway. For instance, high expression of ERRFI1 contributed to predicting 
tumors with activated Ras. ERRFI1 is a tumor suppressor of various receptors in the 
Ras pathway (194). The top positive gene, PBX3, is a transcription factor previously 
implicated in certain astrocytomas (195). The second top positive gene, SPRY2, inhibits 
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FGFR signaling and interacts with ERBB1. The negatively associated genes are 
indicative of expression profiles of wild-type Ras tumors. For example, CDK13 was the 
most predictive gene and is involved in regulating transcription; which potentially 
indicates an alternative mechanism driving transcriptional disruption in wild-type Ras 
tumors.  We also compared pan-cancer classification with classifiers trained 
independently within each cancer-type. Both the cancer-type specific and pan-cancer 
classifiers had variable performance across cancer-types, with the pan-cancer model 
outperforming the models optimized within cancer-types approximately half of the time 
(Figure 3.3D).  
3.3.3. Ras classifier benchmarking analyses 
We performed several analyses to evaluate the robustness of the Ras classifier. A 
null model trained on a randomly shuffled gene expression matrix performed with about 
50% AUROC and 20% AUPR in holdout test and CV sets, which indicates strong 
performance of the model over this baseline (Figure 3.4A-B). We also assessed 
performance of the classifier for detecting Ras mutations and Ras copy number gains 
separately. Performance was similar with the mutations-only model performing better 
than the combined model and the copy number-only model performing worst (Figure 
3.4C). Our model was robust to dropping KRAS, NRAS, and HRAS and 11 other 
Rasopathy genes from the gene expression matrix (Figure 3.4D). Lastly, performance 
was not impacted by covariate information (Figure 3.4E).  
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Figure 3.4: Benchmarking PanCanAtlas Ras classifiers 
(A) Receiver operating characteristic (ROC) curve and (B) Precision recall (PR) curve 
for a null model trained on a randomly shuffled RNAseq matrix. Also provided are the 
area under the ROC (AUROC) and area under the PR (AUPR) curves for training, 
testing, and cross validation sets. (C) ROC curve for three models predicting: 1) Ras 
mutations only; 2) Ras copy number gains only; 3) Combined data (model in Figure 2). 
The AUROC is provided for both training and testing sets. (D) ROC/AUROC across train 
and test sets for dropping different genes from the RNAseq matrix. The Drop Ras model 
is the model provided in Figure 2. (E) ROC/AUROC across train and test sets for using 
expression data or covariates only. The combined model is the model provided in Figure 
2. In all ROC curves, the dashed navy line represents a hypothetical random guess 
classifier. Gene coefficients for the models presented in (F) panel C and in (G) panel D. 
The points are colored by the model presented in Figure 3.3. (H) Differential fold change 
for tumors with active Ras against tumors with wild-type Ras compared against the Ras 
classifier gene coefficients Red points correspond to labelled genes. 
 
We also explored gene coefficient relationships across models. The high weight 
positive genes in the copy-only model included C12orf11 (ASUN), MRPS35, ERGIC2, 
and CMAS; all of which are located on chromosome 12p near KRAS, which may indicate 
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artifacts of common copy gain events and be a result of low sample size in the positive 
copy-only set (Figure 3.4F). Gene coefficients were similar across models when 
dropping different Ras pathway genes (Figure 3.4G). Lastly, we compared our machine 
learning approach to a differential expression analysis of Ras mutant vs. wild-type 
tumors controlled by cancer-type. The differential expression scores aligned closely with 
the learned Ras classifier coefficients, but identified many more genes than the sparse 
classifier (Figure 3.4H). In summary, the Ras classifier differed depending on data-type 
inclusion, but was robust to input genes in the expression matrix, did not rely on 
covariate data, and included similar but fewer genes than a differential expression 
analysis. 
3.3.4. Detecting Ras activation in cell lines 
We sought to determine whether or not predictions from the Ras classifier trained 
with TCGA tumors generalized to cell lines. We applied the classifier to two cell line 
datasets. First, we applied the classifier to 10 small-airway epithelial cell RNAseq 
profiles (GSE94937) (180). The set consisted of 4 wild-type profiles and 6 KRAS G12V 
expressing mutant profiles. Our classifier correctly classified 9 out of 10 profiles and 
ranked all mutant profiles higher than all wild-type profiles (p = 1.16e-2) (Figure 3.5A). 
Though the PanCanAtlas data does not include gene edited tumors that would allow us 
to directly evaluate Ras oncogenicity, the cell lines from this independent test set are 
induced to stably express a bona fide oncogenic KRAS variant.  
Next, we applied our Ras classifier to RNAseq profiles from 737 different cell lines 
from the Cancer Cell Line Encyclopedia (CCLE) with matched expression and mutation 
data (196) (Figure 3.5B). The Ras classifier assigned significantly higher scores to Ras 
mutated (KRAS, HRAS, or NRAS) cell lines than Ras wild-type cell lines (p = 6.35e-36). 
Of the 393 cell lines predicted to be wild-type, 357 were labelled wildtype (negative 
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predictive value = 90.8%). However, only 153 of 344 cell lines predicted to be Ras 
mutated were labeled Ras mutant (precision = 44.5%). In total, 510 of 737 (69.2%) cell 
lines were predicted correctly. In this case, the low precision could indicate either that 
the classifier failed to generalize or that the classifier successfully identified 
phenocopying events, which were negatives from the point of view of evaluations but 
also what we aimed to capture. 
We sought to differentiate between these two possibilities by using independent 
information that was not provided to the classifier. First, we examined mutation status for 
BRAF, a well characterized oncogene downstream of Ras genes (197). BRAF mutations 
that phenocopy Ras would be counted as negatives, and, if they were highly ranked, 
would reduce the observed precision. Indeed, the classifier assigned BRAF mutant cell 
lines with significantly higher scores compared to BRAF wild-type cell lines (p = 1.16e-
11) (Figure 3.5B). Of all 191 false positives, 56 had BRAF mutations (29.3%). The 
remaining false positives either indicated tumors incorrectly assigned, or tumors that 
harbored other phenocopying variants. Next, we tested CCLE pharmacological response 
data to determine if Ras classifier scores were predictive of sensitivity to MEK inhibitors. 
We observed a strong correlation of the Ras classifier scores with sensitivity to two MEK 
inhibitors Selumetinib (AZD6244) and PD-0325901 (Figure 3.5C-D). The correlation was 
primarily driven by cell lines wild-type for Ras genes, implicating several drug sensitive 
cell lines that may have otherwise been missed by direct sequencing of Ras genes. 
Taken together, the evaluation of additional mutations and the drug response data for 
Ras wild-type cell lines strongly suggested that the low precision in this case was related 
to the identification of phenocopying events. 
Lastly, the classifier scored 34 cell lines harboring Ras mutations as Ras wild-type. 
We observed that 22 of these 34 false negatives harbored variants annotated in the 
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COSMIC database (64%) (198). Conversely, 144 of 152 true positives harbored 
COSMIC variants (95%), which is significantly higher than the proportion in false 
negatives (χ2 = 26.1, p = 3.2e-7). Therefore, our classifier detected signal at variant level 
resolution. 
 
Figure 3.5: Cell line predictions of Ras activity by PanCanAtlas Ras classifier 
(A) Ras classifier trained on PanCanAtlas tumors applied to a dataset of small airway 
epithelial cells. The mutant cells included a stably expressed KRAS G12V mutation. (B) 
Ras classifier trained on PanCanAtlas tumors applied to 737 cell lines from CCLE. Cell 
lines with KRAS, HRAS, or NRAS mutations are shown in the right boxes and wild-type 
tumors are shown in the left boxes. Scores for cell lines with BRAF mutations (green) 
and wild-type BRAF (gold) are also shown. Drug activity area for (C) Selumetinib 
(AZD6244) and (D) PD-0325901 compared against Ras classifier scores for 388 CCLE 
cell lines with both gene expression and pharmacologic profiling data. Cell lines with 
mutant (orange) or wild-type (blue) KRAS, HRAS, and NRAS is shown. 
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3.3.5. Other Ras pathway variants phenocopy Ras activation 
The Ras classifier was able to detect NF1 loss events particularly well in central nervous 
system tumors (GBM, low grade glioma (LGG), and pheochromocytoma & 
paraganglioma (PCPG)). Performance was comparable to NF1 classifiers built using 
cancer-type specific and pan-cancer models (Figure 3.6A). These tumors were not 
included in training the Ras classifier. Detection of NF1 inactivating events was also 
improved in COAD, OV, and uterine corpus endometrial carcinoma (UCEC) as 
compared to NF1 specific classifiers (Figure 3.6A).  
D.
 
Figure 3.6: Ras activation across Ras variants and alternative Ras pathway members 
(A) Cross validation area under the receiver operating characteristic curve for predicting 
NF1 inactivation. Within and pan-cancer models are classifiers trained to detect NF1 
inactivation. The Ras model is the classifier trained in Figure 3.3. The NF1 model is the 
classifier trained in Figure 3.7 (B) Ras classifier scores for samples with oncogenic or 
unconfirmed variants in KRAS, HRAS, and NRAS. Variant oncogenicity designations are 
based on curation (see methods). Ras classifier scores stratified by Ras activity (KRAS, 
NRAS, HRAS) status and number of (C) aberrant mutations or (D) copy number 
alterations in other Ras pathway members. The two rows of numbers above each graph 
indicate number of samples in each group (top) and percentage of samples assigned to 
active Ras (bottom). 
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Figure 3.7: TCGA PanCanAtlas NF1 classification performance 
(A) Cancer-type specific percentages of NF1 inactivation by copy number loss and 
deleterious mutation. The colored squares indicate if the cancer type was included in 
model training. (B) Receiver operating characteristic (ROC) curve and Area under the 
ROC curve (AUROC) given for training, testing, and cross-validation (CV) sets. (C) 
Precision Recall (PR) curve and corresponding area under the PR (AUPR) curve for 
each evaluation set. Cancer-type specific CV (D) AUROC and (E) AUPR for the NF1 
pan-cancer model compared to separate models trained on each cancer type 
independently. ROC and PR curves for predicting NF1 inactivation in (F) GBM and (G) 
LGG using the pan-cancer model. The grey lines represent predictions made on a 
shuffled gene expression matrix. 
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The Ras classifier’s performance predicting NF1 loss of function was comparable to 
distinct pan-cancer models trained specifically to detect NF1 loss of function events 
(Figure 3.7). 
We applied the Ras classifier to curated variants in 38 core Ras pathway genes, 
which consisted of 34 oncogenes and 4 tumor suppressor genes (199, 200). We 
observed an enrichment of high scores in tumors with oncogenic variants in KRAS, 
NRAS, and HRAS (Figure 3.6B). Scores for oncogenic BRAF variants were also 
enriched (Figure 3.8A). However, we noted that BRAF V600E mutations in THCA were 
overwhelmingly predicted to be Ras wild-type (Figure 3.8B). We trained a classifier for 
which we removed both of the BRAF dominated cancer-types (THCA and SKCM) 
(Figure 3.8C). In this model, we observed that THCA BRAF V600E mutations were 
predicted to have Ras activation, which aligns with previous understanding of BRAF 
function and our cell line analysis (Figure 3.8D).  
Lastly, in samples wildtype for KRAS, NRAS, and HRAS (blue bars), we observed 
that Ras classifier scores increased after subsequent mutations in other pathway genes 
(Figure 3.6C). In samples with a KRAS, NRAS, or HRAS mutation (red bars), classifier 
scores did not increase after additional mutations to other genes in the pathway (Figure 
3.6C). However, more copy number events in other Ras pathway genes led to lower Ras 
classifier scores in Ras mutated samples (Figure 3.6D). These results potentially 
suggest that multiple hits in Ras pathway genes outside of Ras genes themselves may 
confer an increased Ras activation phenotype. 
3.4. Discussion 
We described a machine learning method to detect malfunctioning genes and 
pathways in cancer and applied our method to detecting Ras activation. The method has 
variable performance across cancer-types, but is generally sensitive and specific overall, 
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is generalizable to cell line data, largely aligns with curated variant oncogenicity, and 
identifies phenocopying events leading to activated Ras. The approach can be applied 
generally to other genes and pathways. 
A. B.
C.
D.
 
Figure 3.8: Predicting BRAF status with the TCGA PanCanAtlas Ras classifier 
(A) Predictions for tumors with oncogenic or unconfirmed variants in BRAF given by the 
Ras classifier evaluated in Figure 2. (B) Ras classifier scores assigned to samples with 
BRAF V600E mutations stratified by cancer type. A score above 0.5 indicates a 
prediction of activated Ras. (C) Ras classifier evaluation after removing THCA and 
SKCM from training. ROC and PR curves for the Ras classifier without THCA and SKCM 
does not indicate reduced performance. The grey lines represent predictions made on a 
shuffled gene expression matrix. (D) Ras classifier without THCA and SKCM classify 
BRAF V600E as Ras wildtype in THCA, but not in SKCM. 
 
The cell line evaluation included accurately detecting isogenic lines transfected to 
express activating KRAS mutations and identifying CCLE cell lines with known Ras and 
BRAF mutations. We also demonstrated that CCLE Ras classifier scores were 
correlated with the drug activity of two MEK inhibitors (Selumetinib and PD-0325901). In 
59	
	
clinical trials, Selumetinib did not increase overall survival in KRAS mutant advanced 
non-small cell lung cancer (NSCLC) patients (201, 202). PD-0325901 also failed to meet 
efficacy endpoints in KRAS mutant NSCLC patients (203). Selumetinib and PD-0325901 
have also been tested across many different cancer-types including ovarian, thyroid, 
skin, hepatocellular, breast, and colon cancers (202, 204–207). Selumetinib has shown 
promising results in treating children with NF1 mutant plexiform neurofibromas (208) 
while PD-0325901 has shown efficacy in treating NF1 mutant neurofibromas in mice and 
human-derived malignant peripheral nerve sheath xenografts (190). Furthermore, the 
classifier automatically learns similar gene coefficients of an 18 gene panel previously 
curated using a targeted differential expression analysis to predict Selumetinib sensitivity 
(210). Overall, our results suggest a useful biomarker application to potentially reveal 
hidden responders that may have otherwise been missed by sequencing. 
Our approach to detecting Ras activation is supervised and, as any supervised 
approach, is penalized by inaccurate labels. We encountered this limitation when 
detecting BRAF mutations in THCA.  BRAF mutations are known to activate ERK, and 
should not be classified as wild-type Ras (211). Our results suggest that in situations 
with predicted confounding mutations, it may be best to withhold a cancer-type entirely 
during training. Withholding such data, as opposed to re-building a new classifier post-
hoc that uses BRAF V600E mutations as positive examples, may help to prevent a 
process of classifier-creep in which the classifier is continually expanded to improve 
metrics. Additionally, it is unclear how to best adjust for hypermutated phenotypes as 
these tumors are more likely have Ras mutations by chance. Unsupervised or semi-
supervised methods to automatically retrieve gene expression signatures may overcome 
labeling issues and may sidestep some of the difficulties modeling hypermutated tumors 
by first separating sources of variation. 
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While mutual exclusivity analyses across pathways drives hypotheses and reveals 
etiological insights (212, 213), our findings suggest that when multiple mutations occur in 
Ras pathway genes, tumors exhibit a transcriptional profile associated with increased 
Ras activity. This is the opposite observation for copy number events as more events 
outside of KRAS, NRAS, and HRAS appear to confer lower scores, which may either 
indicate some sort of dosage response counteracting the effects of hyperactivation or 
alternative events that dampen accurate Ras classification. Furthermore, tumors 
harboring specific Ras pathway isoforms curated by the PanCanAtlas Pathways AWG 
are generally predicted to have higher scores than unconfirmed variants.  
In conclusion, we presented a machine learning method to predict Ras activity in 
individual bulk tumors using transcriptomes. Our approach may side-step requirements 
to profile multiple genomic measurements to detect Ras activation and identify more 
patients with activated Ras. Our approach can be used as an additional method to 
improve precision oncology (175). Sub-clonal mutations may also prevent accurate Ras 
classification by gene sequencing. Training classifiers with single cell RNA-seq data may 
enable detection rare events and can help to characterize intratumor heterogeneity. As 
data increase in scale and algorithms are better constructed to model disease 
heterogeneity, the ability to research downstream responses of pathway misregulation 
and identify multi-model therapies targeting various vulnerabilities of individual tumors 
will improve. 
3.5. Methods 
3.5.1. Contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to 
and will be fulfilled by the Lead Contact, Casey S. Greene (csgreene@upenn.edu). The 
Cancer Genome Atlas will provide instructions on how to access publicly available data. 
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3.5.2. Training machine learning classifiers to detect aberrant gene events 
We integrated Illumina RNAseq, multi-center mutation calls (MC3), and GISTIC2.0 
copy number threshold calls from The Cancer Genome Atlas (TCGA) PanCanAtlas 
project to classify aberrant pathway function (214). We downloaded TCGA datasets from 
the Genome Data Commons (GDC). In total, there were 9,075 tumors that were 
measured on all three platforms that passed quality control filtering. We subset the gene 
expression matrix to the 8,000 most variably expressed genes by median absolute 
deviation (MAD), as genes that do not vary are unlikely to be useful for classification and 
to reduce training time. We dropped the target genes of interest (e.g. KRAS, NRAS, 
HRAS or NF1) when training the models to prevent the model from potentially relying too 
heavily on dosage-specific effects of these genes instead of the downstream response 
to their activation. We also removed the samples with the highest mutation burden to 
remove potential false positives. We defined these samples based on five standard 
deviations above the log10 total non-silent somatic mutation count per sample. Because 
we were interested in a balanced training set based on aberrant gene events, we further 
filtered samples to include only cancer-types with greater than 15 target gene events 
and a proportion of negatives to positives no less than 5%. 
Using this data, we trained a supervised elastic net penalized logistic regression 
classifier with stochastic gradient descent (20).  Our model is trained on RNAseq gene 
expression (X) to predict gene status (y). To control for tumors with a hypermutator 
phenotype and potential tissue-specific expression patterns, we included cancer-type 
dummy variables and per sample log10 mutation count in the model as covariates. We 
defined gold standard gene status using loss of function mutation and deep copy 
number losses for tumor suppressor genes and gain of function mutations and large 
copy number gains for oncogenes. For simplicity and to reduce the requirement for 
62	
	
extensive manual curation, we considered any non-silent mutation including insertion-
deletions in the gene body or mutations in splice site regions of target genes. For the 
specific focus of the paper, we integrated gain of function mutation and copy number 
gains for the oncogenes (KRAS, NRAS, and HRAS), and loss of function and deep copy 
number losses for the tumor suppressors (NF1). For example, if a tumor had a 
deleterious mutation or copy number amplification in one of these genes, we considered 
the Ras status equal to one. 
The objective of the classifier is to determine the probability a given sample (i) has a 
Ras event given the sample’s RNAseq measurements (Xi). In order to achieve the 
objective, the classifier learns a vector of coefficients or gene-specific weights (w) that 
optimize the following penalized logistic function. 
! "# = 1	 '#) = ) '#* = 	 11 + ,-./0 	 
!"#$%&'"	)*#)&+")&ℎ**- = / = 	 - 12log	 6(829: 12 = 1 <2 + (1 −	12)log	 6(12 = 0 <2 	 ! = #$%&'((* + , | ! |.)	 
Where α and l are regularization and elastic net mixing hyperparameters that are 
only active during training, respectively. Using a training set consisting of 90% of the full 
data set, equally balanced for different proportions of included cancer-types and Ras 
status, we performed cross validation over the hyperparameter grid: l = {0.15, 0.155, 
0.16, 0.2, 0.25, 0.3, 0.4} and α = {0.1, 0.13, 0.15, 0.18, 0.2, 0.25, 0.3}. We used 
balanced 5-fold cross validation based on the highest cross-validation area under the 
receiver operating characteristic (AUROC). 
We trained the Ras classifier using optimal hyperparameters (l = 0.15 and α = 0.1) 
and assessed performance on training, testing (held out 10% of data) and across 5-fold 
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cross-validation intervals. In 5-fold cross-validation, the data are partitioned into five 
even sets (balanced by Ras status and cancer-type). Four of the folds, called training 
intervals, are used to construct the model. The model is then evaluated on the fifth fold, 
which is called the evaluation fold. The reported training performance comes from the 
folds used for training, while the cross-validation performance uses the evaluation fold. 
Therefore, performance on cross-validation intervals are the predictions reported on the 
training set samples when they were included in the internal cross-validation evaluation 
fold.  
3.5.3. Evaluating machine learning classifiers 
We evaluated the pan-cancer classifiers in various ways. For every evaluation, we 
reported the AUROC and area under the precision-recall (AUPR) curve. We also 
compared gene specific classifiers built using pan-cancer data to classifiers trained 
independently using only data from individual cancer-types. In these cases, each 
cancer-type specific model was optimized individually. We compared how the pan-
cancer model performed on individual cancer-types compared to individual cancer-type 
optimizations. Additionally, we cataloged the performance of the Ras classifier to predict 
NF1 inactivation in various cancer-types. NF1 is a tumor suppressor of Ras and we 
postulated that it would have similar downstream consequences that could be captured 
by the Ras classifier. Therefore, we performed the same procedure of filtering datasets 
and training pan and within cancer-type classifiers for NF1. We compared these NF1 
evaluations against the Ras classification. Lastly, we evaluated the Ras classifier on 
predicting aberrant mutations of other genes and variants in the Ras pathway and in two 
different cell line datasets. 
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3.5.4. Classifier benchmarking analyses 
We determined the robustness of the classifier by evaluating performance under 
various input features and prediction tasks. We evaluated potential inflation of 
performance metrics by training a null model on a randomly shuffled input gene 
expression matrix. We did not shuffle the covariate information or the y matrix. 
Performance on the random shuffling of genes, while maintaining the same ratio of Ras 
mutations, provides insight into how the model would be expected to perform in a 
scenario lacking Ras activation signal. We also performed the same shuffling and 
classifier testing procedure as internal negative controls in every pan-cancer model and 
report ROC/PR curves and AUROC/AUPRs in each figure. 
To assess value added in combining mutation and copy number data in the 
prediction task (altering the y matrix), we trained pan-cancer classifiers with the same 
procedure described above to predict Ras mutations and Ras copy number gains 
separately. The combined model presented here is the same model trained in Figure 
3.3. To test the effect of dropping KRAS, HRAS, and NRAS from the model (altering the 
X matrix), we trained models with the previously described procedure with the input gene 
expression matrix without dropping Ras genes. We also tested a classifier after dropping 
14 genes from the Expanded RASopathy Panel (215). The genes included BRAF, CBL, 
HRAS, KRAS, MAP2K1, MAP2K2, NF1, NRAS, PTPN11, RAF1, SHOC2, SOS1, 
SPRED1, and RIT1. For the two previous comparisons, we compared the learned gene 
expression coefficients to the classifier trained in Figure 3.3. For the dropping genes 
analysis, we added back all dropped genes as zero weights. We also compared the 
performance of gene expression-only and covariate-only models (altering the X matrix) 
to the combined model presented in Figure 3.3. The y matrix remained the same, but 
each model was trained on only a subset of the combined X matrix. The differentially 
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expressed genes visualized in Figure 3.4H were obtained from the differential 
expression analysis described below. 
3.5.5. Differential expression analysis 
We performed a differential expression analysis using the limma Bioconductor 
package (216). We adjusted the model by cancer-type by including cancer-type indicator 
variables in the limma design matrix. We considered all 9,074 samples and 20,500 
genes in this analysis. We zero-one normalized the input matrix by gene prior to fitting 
with limma. 
3.5.6. Cell line validation 
We applied the Ras classifier to two independent cell line datasets. The first dataset 
was generated by (180) and was deposited in the Gene Expression Omnibus (217) with 
the identifier GSE94937. We used the preprocessed form of the data from (180). We 
also used data from 737 cell lines from the CCLE that had matching RNAseq and 
mutation data (196). Of these 737, 708 also had variant level annotations. In order to 
apply the classifier to both cell-line datasets, we z-score normalized gene expression 
values and subset the data to classifier genes, independently. 177 out of 185 (96%) of 
the features were in common to classifier genes in both datasets, so we proceeded to 
make predictions with this subset. In order to apply the predictions, we used the 
following transformation: 
! = 	$ %&' = 	 11 +	*-,-	 
Where s is the classifier prediction, w is the gene weights, and X is the corresponding 
subset cell line gene expression matrix. 
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We used the CCLE pharmacologic profiling data, which measured the activity of 24 
drugs across 504 CCLE cell lines (CCLE_NP24.2009_profiling_2012.02.20.csv). Data 
were accessed from https://portals.broadinstitute.org/ccle/data (196).  
3.5.7. Ras pathway and oncogenicity curation 
We used the PanCanAtlas Pathways Working Group definition of 38 core Ras 
pathway genes (200). We obtained oncogenicity assignments for mutations in these 
genes using OncoKB (199) and additional manual curation by the PanCanAtlas 
Pathways AWG. The manual curation included referencing MutSig (218), hotspot 
analyses (219), and GISTIC Peaks (214). 
3.5.8. Quantification and statistical analyses 
We performed all machine learning model training, testing, and evaluations using sci-
kit learn (version 0.18.1) with python 3.5.2 (131). We processed data using a 
combination of pandas (version 0.20.3) and dplyr (version 0.7.1) and visualized results 
using a combination of seaborn (version 0.7.1), ggplot2 (version 2.2.1), and 
PathwayMapper (220). R packages were run on R version 3.4.0. Please refer to the Key 
Resources Table and the available GitHub repository 
(https://github.com/greenelab/pancancer) for full software version details (221). We 
evaluated all classifiers using AUROC and AUPR. The AUROC is a metric describing 
the overall trade-off between true positive and false positive rates, while the AUPR 
measures precision against recall for a given classifier. An AUROC of 0.5 constitutes 
random guessing. We describe specific filtering steps for each analysis in various places 
in the methods section. We describe overall sample and gene filtering in the section 
3.5.2. We discuss additional gene filtering for evaluating all alternative genes in section 
3.5.3. We set random seeds in all computational analyses in order to preserve 
reproducibility. We performed independent t-tests with unequal variances when 
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comparing classifier scores for curated variants versus variants of unknown significance 
per Ras pathway gene. We performed the same test comparing CCLE cell line Ras 
classifier scores for Ras wildtype versus Ras (KRAS, HRAS, or NRAS) mutant samples 
and for Ras wildtype, BRAF wildtype versus Ras wildtype, BRAF mutant. Using the up to 
388 cell lines with both gene expression and pharmacology data measured, we fit linear 
regression models comparing drug activity vs. Ras classifier scores for all 24 drugs to 
Ras wild-type and Ras mutant cell lines individually. Using a Bonferroni adjusted p value 
(0.05 / (24 * 2) = 0.001), we implicated two high correlated drugs (AZD6244 
(Selumetinib) and PD-0325901). Selumetinib was tested on 387 cell lines while PD-
0325901 was tested on 388 cell lines. We also used a chi square test for proportions of 
Ras mutations annotated as COSMIC variants in true positives compared to false 
negatives with a null hypothesis that both sets of samples have the same proportion of 
COSMIC variants. 
3.5.9. Data and software availability 
All analytical results can be reproduced using the code available at 
https://github.com/greenelab/pancancer (221). Here, we provide instructions to replicate 
the computing environment, download versioned data, and all scripts to reproduce the 
entire analysis pipeline. The pipeline is modular and amendable to generate classifiers 
and predictions for any combination of genes, pathways, and TCGA PanCanAtlas 
cancer-types. 
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Chapter 4. 
Machine learning derived expression signature predicts TP53 inactivation 
Portions of this chapter were originally published as: Knijnenburg, Theo, A., Wang, 
Linghua, Zimmerman, Michael, T., Chambwe, Nyasha, Gao, Galen, F., Cherniack, 
Andrew, D., Fan, Huihui, Shen, Hui, Way, Gregory, P., Green, Casey, S., Liu, Yuexin, 
Akbani, Rehan, Feng, Bin, Donehower, Lawrence A., Miller, Chase, Shen, Yang, Karimi, 
Mostafa, Chen, Haoran, Kim, Pora, Jia, Peilin, Shinbrot, Eve, Zhang, Shaojun, Liu, 
Jianfang, Hu, Hai, Bailey, Matthew, H., Yau, Christina, Wolf, Dinse, Zhao, Zhongming, 
Weinstein, John, N., Li, Lei, Ding, Li, Mills, Gordon B., Laird, Peter, W., Wheeler, David 
A., Shmulevich, Ilya, The Cancer Genome Atlas Network, Monnat, Raymond, J. Jr., 
Xiao, Yonghong, Wang, Chen. “Genomic and molecular landscape of DNA damage 
repair deficiency across The Cancer Genome Atlas.” Cell Reports 23 (2018) 239-254. 
doi: 10.1016/j.celrep.2018.03.076.  
Contributions: 
The paper cited above (Knijnenberg et al. 2018) was a large consortium paper. In the 
paper, I trained and evaluated a machine learning classifier to detect TP53 inactivation. 
This was the same approach we used in the Ras pathway paper discussed in Chapter 3. 
My contributions included drafting and editing the TP53 classifier section and generating 
Figure 5 and Supplementary Figure 6 in the original publication. This chapter only 
includes the aforementioned section and an abridged introduction. 
4.1. Introduction 
TP53 is the most frequently mutated gene in cancer. The gene is intricately involved 
in many cellular processes, including response to DNA damage (222). The Cancer 
Genome Atlas (TCGA) has profiled many different datatypes and biological processes 
across 33 different cancer-types totaling over 10,000 tumors (176). One effort profiled 
deficiencies in the DNA repair and response pathway, which included the TP53 mutation 
landscape (38). Machine learning can be used to detect when tumors express specific 
70	
	
gene expression signatures (37). In the following chapter, we train a logistic regression 
classifier to detect samples with TP53 loss of function. We demonstrate that certain copy 
number events phenocopy TP53 inactivation, and we implicate a silent mutation in a 
TP53 splice donor site that appears to ablate TP53 function in a dominant negative 
fashion. 
4.2. Results 
The loss of TP53 function across many cancer types has significant functional 
consequences as measured by genomic instability in association with a higher somatic 
copy number alterations (SCNA) burden and increased HRD scores. Cancer-associated 
TP53 mutations may promote these consequences through simple loss of function, as 
well as by altering transcription or through dominant-negative, gain-of-function 
mechanisms (222–226). A subset of these consequences can also be phenocopied by 
other genomic alterations. In order to better predict the consequences of TP53 
inactivation and identify potential phenocopies of TP53 loss, we constructed a TP53 
classifier that predicts inactivation status from RNA sequencing expression data, 
adjusted for cancer type and mutation burden, then used this to analyze cancer types 
with comparable numbers of TP53 alterations. The resulting classifier was highly 
sensitive and specific (Figure 4.1A), and when trained using PanCanAtlas data, it 
outperformed individual cancer models in 14 out of 19 cases (Figures 4.2). 
Individual weights of the TP53 classifier identified 10 top negative-weighted genes, of 
which 9 are confirmed TP53 target genes (222) (Figure 4.1B). The remaining gene, 
MPDU1, may have been identified by virtue of being located 80 kb downstream of 
TP53 and thus sensitive to TP53 copy loss. Of note, our classifier was able to predict 
TP53 deficiency independent of cancer type with a high AUROC (area under the  
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Figure 4.1: Machine learning to predict TP53-inactivating mutations in cancer 
(A) Robust classifier performance by receiver operating characteristic (ROC) and area 
under the ROC curve (AUROC). Training data, cross validation assessment, and held 
out test set (10%) for 19 cancer types were used. (B) Model-derived gene weighting. 
Classifier weights indicate individual gene influence on classification accuracy. Negative 
weights indicate increased gene expression in TP53 wild-type samples. (C) SCNA 
burden is correlated with known/predicted TP53 status. Plots show SCNA/CNV burden 
as fraction altered for known or predicted TP53 status. The SCNA profile for TP53 
mutation c.375G>T in TP53 exon 4 appears similar to other TP53 loss events. (D) SCNA 
in TP53-interacting genes MDM2 and CDKN2A phenocopies TP53 loss. Results shown 
are for PanCanAtlas TP53 wild-type samples. (E) TP53 network gene alterations 
phenocopy TP53 deficiency. Mutations were manually curated and selected a priori. All 
mutation tests including only TP53 wild-type/non-hypermutated cancers are indicated by 
orange edges. Node color indicates event class (red, mutation; blue, copy-number loss; 
and purple, copy-number amplification); edge values indicate Cohen’s d effect size. Thin 
blue edges indicate predicted interactions from the STRING database. NS is “not 
significant” with p > 0.005. 
 
receiver operating characteristic curve; 0.94), and in samples initially removed from 
training. These included cancer types with few TP53 events (THCA and UVM), as well 
as those dominated by TP53 events (OV and UCS) (Figures 4.2C – 4.2F). 
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Figure 4.2: Pan-Cancer TP53 classifier scores by cancer-type 
(A) Cancer types display a broad distribution of TP53 deep copy number loss and 
deleterious mutation events. Loss represents GISTIC ≤ -2. The bottom bar indicates 
cancer types included during model training (teal fill). (B) Cancer-specific models may 
identify tissue-level effects. CV AUROC for a pan-cancer model (Pan) compared to 
models optimized individually for each cancer-type (Within). (C-F) Pan-cancer TP53 
classifier applied to cancer-types with imbalanced class sizes and not used in training. 
“Other” tumors have either TP53 mutation or deep copy loss. (G-H) Pan-cancer TP53 
classifier applied to BRCA and UCEC stratified by subtype. Samples in red indicate wild-
type TP53 and samples in blue indicate TP53 loss of function (mutation or deep copy 
loss). 
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The classifier was also able to distinguish TP53 mutant from wild-type BRCA and UCEC, 
with nearly all basal-subtype BRCA cancers predicted to be TP53 deficient (Figures 
4.2G and 4.2H). We used analogous approach has been used to predict RAS pathway 
activation in PanCanAtlas cancers (37). 
The classifier enabled the identification of phenocopying mutations both in TP53 and 
in other functionally related genes. Consistent with previous pan-cancer analyses (227), 
we observed that predicted TP53 loss-of-function samples, including cancers with 
synonymous TP53 c.375G>T mutation, had an increased SCNA burden when compared 
with wild-type samples (Figure 4.1C). This synonymous mutation may act by altering a 
splice donor to produce alternatively spliced transcripts that compromise TP53 function 
(228, 229). Samples with c.375G>T or c.375G>A mutations were also enriched for a 
200-base pair truncation in exon 4 when compared with wild-type TP53 samples (Figure 
4.3; OR (odds ratio) = 61.9, p < 2.2e−16). This mutation/truncation pairing was 
previously observed in a pancreatic cancer cell line and as a SNP (rs55863639) likely 
pathogenic for Li-Fraumeni syndrome (230). 
Significantly increased classifier scores were also noted for cancers with MDM2 
copy-number amplification and CDK2NA copy-number deletion in an analysis including 
only non-hypermutated cancers without deleterious TP53 mutation (Figure 4.1D). We 
had observed a copy-number dosage effect for CDK2NA copy-number deletions, where 
loss of the CDKN2A-encoded P14ARF protein can phenocopy TP53 alterations (231). 
Among eight other tested genes, MDM4 and PPM1D copy-number amplification and 
ATM and CREBBP gene mutations were associated with increased TP53 classifier 
scores, while ATR, CHEK1/2, or RP6SKA3 mutations were not (Figure 4.1E). These 
results suggest the general utility of this approach, even in circumstances where a 
diversity of molecular events and potential downstream consequences might occur. 
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Figure 4.3: TP53 exon-exon junctions for samples with c.375G>T mutations in TP53 
Shown are TP53 exon-exon junctions on chromosome 17 between canonical exons 4 
and 5. All samples are annotated as wild-type TP53. The horizontal bars indicate 
different exon-exon junctions in this region. The same sample can have multiple 
observed junctions. The blue bar represents the canonical exon-exon junction between 
exon 5 (black dotted line) and exon 4 (blue dotted line). The red dotted line indicates a 
junction event occurring exactly 200 base pairs upstream of the exon 4 splice donor that 
corresponds to the observation in Suwa et al., 1994 (232). Also listed are each sample’s 
expression classifier probability of TP53 loss. Left – The 19 samples with the c.375G>T 
mutation resulting in ablation of the traditional splice donor site on exon 4 (blue dotted 
line). c.375G>T is the only TP53 mutation in these samples. We observe many more 
alternative splice forms in these samples, including an enrichment of a previously 
reported splicing event at the red site. Right – 19 randomly selected wild-type samples 
without the c.375G>T mutation show only canonical TP53 transcript splicing at this site. 
4.3. Methods 
4.3.1. In-silico prediction of TP53 inactivation 
We trained a classifier to use RNA-seq expression data to predict TP53 status. 
Specifically, we trained a logistic regression classifier with an elastic net penalty using 
the sci-kit learn implementation of stochastic gradient descent (131). The labels (y) for 
the supervised task included samples with MC3 annotated deleterious TP53 mutations 
(samples with silent mutations were considered TP53 wild-type) and samples with TP53 
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deep copy number loss as predicted by the GISTIC2.0 algorithm (214, 233). We 
included cancer-types in the model that had greater than 15 samples in each class and 
between 5% and 95% of samples in both classes and removed all others (see Figure 
4.2A). The features (X) consisted of the 8000 most variably expressed genes by median 
absolute deviation (MAD). We dropped expression of TP53 itself from the features to 
prevent the model from relying on the target gene. MAD genes were z-scored and 
concatenated with binarized dummy variables for all cancer types and mutation burden 
(total log10 mutation count) to adjust for potential confounding factors. To reduce the 
effect of mutation burden confounding, we also removed the outlier samples with the 
most extreme hypermutation phenotypes (greater than 5 standard deviations above the 
mean log10 mutation count). The goal of the classification scheme was to determine the 
weights (w) that minimize the objective function described in section 3.5.2. 
We selected optimal hyperparameters by balanced 5-fold cross validation with the 
goal of inducing a sparse solution. We also used a balanced 10% held out set to test the 
performance of the classifier on data never used for training or hyperparameter 
optimization. We fit the final model on the remaining 90% of the data and report 
performance using receiver operating characteristic (ROC) curves and area under the 
ROC curve (AUROC) metrics.  
We manually selected an a priori set of genes known to interact with TP53 for our 
phenocopying experiment (Lawrence Donehower, personal communication). We tested 
MDM2, MDM4, and PPM1D amplifications, CDKN2A deletions, and ATM, ATR, CHEK1, 
CHEK2, CREBBP, and RPS6KA3 mutations. For the copy number tests, we included 
both deep and shallow alterations in the altered set compared to tumors with wild-type 
profiles only. We removed tumors with deleterious TP53 mutations or deep copy number 
loss (n = 4,037). From the remaining 5,629 tumors, we removed 219 hypermutated 
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tumors leaving an analytic set of 5,410 tumors. We performed independent t-tests and 
calculated Cohen’s D effect sizes comparing the assigned TP53 classifier scores for 
wild-type against altered tumors. We considered variants significant if they were less 
than a Bonferroni adjusted p value (p > 0.005). We visualized the results in a network 
diagram presented in Figure 4.1E. The underlying interaction network was downloaded 
from the STRING database (version 10.5). The thickness of edges in the STRING 
network display interaction confidence and were generated by experimental data. Note 
that there are no direct interaction edges between RPS6KA3 and TP53 and PPM1D and 
TP53. We provide materials under an open source license to reproduce and expand 
upon this analysis at https://github.com/greenelab/pancancer. 
4.4. Conclusions 
TP53 is the most mutated gene in cancer and is central to many essential tumor 
suppressing processes, including the coordination of the response to DNA damage 
(224). However, it remains unclear how TP53 mutations alter the molecular state of 
tumors, and TP53 mutations have many unknown downstream consequences. 
Therefore, we sought to develop an algorithm that can detect when a tumor has aberrant 
TP53. Using TCGA Pan Cancer data, we trained an elastic net penalized logistic 
regression classifier to detect when TP53 is misregulated. Performance on the training, 
cross validation, and held out test set was highly sensitive and specific. We also 
observed that the Pan Cancer model outperformed the within-disease type models in 14 
out of 19 cases. In 3 of the 5 cases where the within-disease type model was better, we 
observed only marginal gains. However, in 2 of the cases, esophageal (ESCA) and 
cervical (CESC) cancer types, performance increased substantially. This result could 
suggest that TP53 aberrations play a tissue specific role in both diseases. For example, 
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results for CESC could indicate a signature of inactivation specific to human 
papillomavirus infection (234).  
The elastic net penalty induced sparsity in the features, selecting only 319 genes. 
Many of these genes are well-known regulators and targets of TP53 including MDM2 
and CDKN1A, well known apoptosis associated genes including AEN and BAX, genes 
associated with homologous recombination (EEPD1), and cell cycle related genes such 
as CDC123. The genes associated with negative weights represent genes that are 
commonly upregulated in TP53 wild-type tumors while genes with positive weights are 
genes that are upregulated in TP53 aberrant tumors. 
We observed that one annotated silent mutation, c.375G>T, occurred 27 times (19 
times it was the only TP53 mutation in a non-hypermutated sample) across all Pan 
Cancer samples and was consistently predicted to have TP53 loss of function. We also 
observed a c.375G>A silent mutation 6 times, which was also predicted deleterious. 
These mutations occur in the last nucleotide on the 3’ end of TP53 exon 4. This location 
is a SNP (rs55863639) that has been previously associated with Li Fraumeni syndrome 
(235, 236). While the mutation does not alter the threonine amino acid, c.375G>T was 
observed to impact splicing in a pancreatic cell line (232). Therefore, we were able to 
identify a TP53 loss of function phenocopying variant that was previously annotated as a 
silent variant. This approach can be extended to other genes and pathways to identify 
variants and patients who may harbor specific variants that would have been missed by 
alternative means. 
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Chapter 5.  
Comprehensive cross-population analysis of high-grade serous ovarian cancer 
supports no more than three subtypes 
This chapter was originally published as: Way, Gregory, P., Rudd, James, Wang, 
Chen, Hamidi, Habib, Fridley, Brooke, L., Konecny, Gottfried, E., Goode, Ellen, L., 
Greene, Casey, S., Doherty, Jennifer, A. “Comprehensive cross-population analysis of 
high-grade serous ovarian cancer supports no more than three subtypes.” G3: Genes, 
Genomes, Genetics 6 (2016) 4097 – 4103. doi: 10.1534/g3.116.033514 
Conceptualization: G.P.W., J.R., C.S.G., J.A.D.; Methodology: G.P.W., C.S.G., J.A.D.; 
Software: G.P.W.; Investigation: G.P.W.; Writing – Original Draft: G.P.W., J.R., C.S.G., 
J.A.D.; Writing – Review and Editing: G.P.W., J.R., C.W., H.H., B.L.F., G.E.K., E.L.G., 
C.S.G., J.A.D.; Resources: C.W., H.H., B.L.F., G.E.K., E.L.G.; Visualization: G.P.W. 
 
Contributions: 
For the paper, I performed all analyses and wrote the full manuscript. The additional 
authors contributed as stated above. 
5.1. Abstract 
Four gene expression subtypes of high-grade serous ovarian cancer (HGSC) have 
been previously described. In these early studies, a fraction of samples that did not fit 
well into the four subtype classifications were excluded. Therefore, we sought to 
systematically determine the concordance of transcriptomic HGSC subtypes across 
populations without removing any samples. We created a bioinformatics pipeline to 
independently cluster the five largest mRNA expression datasets using k-means and 
nonnegative matrix factorization (NMF). We summarized differential expression patterns 
to compare clusters across studies. While previous studies reported four subtypes, our 
cross-population comparison does not support four. Because these results contrast with 
previous reports, we attempted to reproduce analyses performed in those studies. Our 
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results suggest that early results favoring four subtypes may have been driven by the 
inclusion of serous borderline tumors. In summary, our analysis suggests that either two 
or three, but not four, gene expression subtypes are most consistent across datasets. 
5.2. Introduction 
Invasive ovarian cancer is a heterogeneous disease typically diagnosed at a late 
stage, with high mortality (237). The most aggressive and common histologic type is 
HGSC (238), which is characterized by extensive copy number variation and TP53 
mutation (239). Given the genomic complexity of these tumors, mRNA expression can 
be thought of as a summary measurement of these genomic and epigenetic alterations, 
to the extent that the alterations influence gene expression in either the cancer or 
stroma.  
Four gene expression subtypes with varying components of mesenchymal, 
proliferative, immunoreactive, and differentiated gene expression signatures have been 
reported in all studies of HGSC to date (239–243). Two of these studies also observed 
survival differences across subtypes (240, 243). Tothill et al. (2008) first identified four 
HGSC subtypes (as well as two other subtypes that largely included low-grade serous 
and serous borderline tumors) in an Australian population using k-means clustering 
(240). Later, The Cancer Genome Atlas (TCGA) used NMF and also reported four 
subtypes that were labeled as: “mesenchymal,” “differentiated,” “proliferative,” and 
“immunoreactive” (239). The TCGA group also applied NMF clustering to the Tothill data 
and observed similar subtypes (239). Konecny et al. (2014) applied NMF to cluster an 
independent set of HGSC samples and reported four subtypes, which they labeled as 
C1–C4 (243). These subtypes were similar to those in the TCGA, but a subtype 
classifier trained on these subtypes better differentiated survival in their own data, data 
from TCGA, and Bonome et al. (2008).  
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Despite the extensive research in the area, work to date has several limitations. In 
both the TCGA and Tothill studies, 8–15% of samples were excluded from analyses. A 
reanalysis of the TCGA data showed that over 80% of the samples could be assigned to 
more than one subtype (244). In more recent TCGA analyses by the Broad Institute 
Genome Data Analysis Center (GDAC) Firehose initiative, with the largest number of 
HGSC cases evaluated to date (n = 569), three subtypes fit the data better than four 
(245, 246). This uncertainty in HGSC subtyping led us to determine if four homogeneous 
subtypes exist across study populations.  
Our goal is to rigorously assess the number of HGSC subtypes. We reanalyze data 
from the five largest independent studies to date (and add an analysis of our own 
collection of samples) using a standardized bioinformatics pipeline. We apply k-means 
clustering as well as NMF to each population and do not remove “hard-to-classify” 
samples, as was done in previous studies (239, 240). We perform independent analyses 
within each dataset and compare subtyping results across studies. We summarize each 
subtype’s expression patterns using moderated t-score vectors and comprehensively 
characterize correlations between subtypes across populations. This method contrasts 
with earlier reanalyses that pooled HGSC datasets together to identify subtypes (242). 
We sidestep gene expression platform or dataset biases, which could affect clustering if 
under or overcorrected, by comparing dataset- and subtype-specific summary statistics 
instead of pooling raw gene expression data. 
Our cross-population comparative analysis does not support the conclusion that four 
HGSC subtypes exist; rather, the data more strongly support an interpretation that there 
are either two or three subtypes. We show that the support for four subtypes observed in 
TCGA’s reanalysis of the Tothill data (239) is lost when serous borderline tumors, which 
have very different genomic profiles and survival compared to HGSC (241, 247), are 
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excluded before clustering. Our work also highlights the impact that a single study can 
have on the trajectory of subtyping research and suggests the importance of periodic 
histopathologic review and rigorous reanalysis of existing data for cross-study 
commonalities. 
5.3. Methods 
5.3.1. Data inclusion 
We used data from the R package, curatedOvarianData (248), and our own dataset 
(“Mayo”). A subset of these data has been published previously (GSE53963) (243), but 
the present dataset (GSE74357) contains 343 more samples. Briefly, these criteria 
selected HGSC samples from studies including at least 130 cases assayed on standard 
microarrays. We included only HGSC and high-grade endometrioid samples, which are 
molecularly similar to HGSC (249) as identified by study-specific pathological review. 
Data from the new Mayo HGSC samples, as well as other samples with mixed 
histologies and grades, for a total of 528 additional ovarian tumor samples, were 
deposited in NCBI’s Gene Expression Omnibus (GEO) (217); these data can be 
accessed with the accession number GSE74357 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74357). All study participants 
provided written informed consent, and this work was approved by the Mayo Clinic and 
Dartmouth College Institutional Review Boards. 
After applying the unified inclusion criteria, our final analytic datasets included: TCGA 
(n = 499) (239, 245); Mayo (n = 379; GSE74357) (243); Yoshihara (n = 256; 
GSE32062.GPL6480) (250); Tothill (n = 242; GSE9891) (240); and Bonome (n = 185; 
GSE26712) (241) (Table 5.1). We restricted analyses to the 10,930 genes measured 
successfully in all five populations. 
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 TCGA Mayo Yoshihara Tothill Bonome 
GEO  GSE74357 GSE32062 GSE9891 GSE26712 
Platform HGU1133 Agilent 4x44K Agilent 4x44K HGU1133 HGU1133 
Population USA USA Japan Australia USA 
Original n =  578 528 260 285 195 
Analytic n =  499 379 256 242 185 
Age [Mean 
(SD)] 
60.0 (11.6) 62.9 (11.3) NA 60.3 (10.3) 61.5 (11.9) 
Stage:      
    I 10 (2%) 7 (3%) 0 (0%) 11 (5%) 0 (0%) 
    II 17 (4%) 11 (3%) 0 (0%) 8 (4%) 0 (0%) 
    III 351 (80%) 275 (73%) 202 (79%) 178 (83%) 146 (80%) 
    IV 63 (14%) 86 (23%) 54 (21%) 17 (8%) 36 (20%) 
Grade:      
    2 55 (12%) 3 (1%) 130 (51%) 80 (37%) NA 
    3 386 (88%) 376 (99%) 126 (49%) 134 (63%) NA 
Debulking      
Optimal 325 (74%) 287 (76%) 101 (39%) 132 (62%) 89 (49%) 
Suboptimal 116 (26%) 87 (23%) 155 (61%) 82 (38%) 93 (51%) 
 
Table 5.1: Characteristics of the populations included in the five HGSC data sets 
 
5.3.2. Clustering 
We performed independent clustering within each dataset to avoid potential biases 
from different platforms or studies. We identified the 1500 genes with the highest 
variance from each dataset and used the union of these genes (n = 3698) for clustering. 
We performed clustering within each dataset using each potential k from 2 to 4 clusters. 
We performed k-means clustering in each population using the R package “cluster” 
(version 2.0.1) (251) with 20 initializations. We repeated these analyses using NMF in 
the R package “NMF” (version 0.20.5) (52) with 100 different random initializations for 
each k. As done in prior studies, we calculated cophenetic correlation coefficients to 
select appropriate k for each dataset after NMF clustering with 10 consensus runs. The 
cophenetic correlation identifies appropriate solutions and tends to decrease with 
increasing k unless a more accurate solution is observed at a larger k.  
83	
	
5.3.3. Identification of analogous clusters within and across studies 
We performed significance analysis of microarray (SAM) (252, 253) analysis on all 
clusters from each study using all 10,930 genes. This resulted in a cluster-specific 
moderated t statistic for each of the input genes (254). To summarize the expression 
patterns of all 10,930 genes for a specific cluster in a specific population, we combined 
gene-wise moderated t statistics into a vector of length 10,930. We repeated the SAM 
analysis using only the MAD subset genes and the results were similar. The TCGA 
subtype labels have become widely used in the field. To generate comparable labels 
across k and across studies, we mapped our TCGA subtype assignments back to the 
original TCGA labels to define reference clusters at k = 4 (that is, mesenchymal-like, 
proliferative-like, etc.). Clusters in other populations that were most strongly correlated 
with the TCGA clusters were assigned the same label. 
5.3.4. Clustering analysis of randomized data 
Any clustering procedure is expected to induce strong correlational structure across 
clusters within a dataset, even if there is no true underlying structure. However, if there 
is no true underlying structure, clusters across datasets are not expected to be 
correlated. To assess this, we used the same datasets but shuffled each gene’s 
expression vector to disrupt the correlative structure. We performed within- and cross 
study analyses of cluster identification using this set of data that were parallel to those 
performed using the nonrandomized data. 
5.3.5. Assessing the reproducibility of single population studies 
We compared our sample assignments at k = 2–4 to the four subtypes reported in 
the Tothill, TCGA, and Konecny publications (239, 240, 243). Because the labels that 
were assigned in TCGA’s reanalysis of the Tothill data were not available, we performed 
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NMF consensus clustering of Tothill’s data without removing low malignant potential 
(LMP) samples in order to generate labels for comparison. 
5.3.6. Data availability 
We provide software under a permissive open source license to download the 
required data and reproduce our analyses (255). Analyses were run in a Docker 
container, allowing the computing environment to be recreated (142). Our Docker image 
can be pulled from: https://hub.docker.com/r/gregway/hgsc_subtypes/. This allows 
interested users to freely download the software, reproduce the analyses, and then build 
on this work. All data used in this analysis is publicly available including data we 
generated (accessible under GEO accession GSE74357). 
5.4. Results 
5.4.1. Clustering 
To visually inspect the consistency and distinctness of clusters, we compared 
sample-by-sample correlation heatmaps. For k = 2–4 within each study, we observed 
high sample-by-sample correlations within clusters and relatively low sample-by-sample 
correlations across clusters (Figure 5.1). Clustering results using NMF were similar to k 
means results (Figure 5.2). 
5.4.2. Correlation of cluster-specific expression patterns 
Across datasets, we observed strong positive correlations of moderated t score 
vectors between analogous clusters in TCGA, Tothill, Mayo, and Yoshihara (Figure 5.3 
and Table 5.2). However, clustering of the Bonome data did not correlate strongly with 
clusters identified in the other datasets (Table 5.2). We believe that we were unable to 
assign parallel subtypes in Bonome because of either RNA contamination or 
inappropriate grading assignments. However, more work is required in order to identify 
exactly why we were unable to classify. 
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Figure 5.1: Sample by sample Pearson correlation matrices across HGSC populations 
Top panel: k = 2. Middle panel: k = 3. Bottom panel: k = 4. The color bars are coded as 
blue for cluster 1, red for cluster 2, green for cluster 3, and purple for cluster 4. In the 
matrices, red represents high correlation, blue low correlation, and white intermediate 
correlation. The scales are slightly different in each population because of different 
correlational structures. The clusters in the Bonome study are depicted in grey scale 
because in cross-population analyses to identify analogous clusters, those from Bonome 
did not correlate with those observed in the four other studies. 
 
 In contrast to our analyses, which independently cluster data from each study, 
Konecny et al. (2014) assigned subtypes to the Bonome data by applying a Predictive 
Analysis of Microarray (PAM) (63) to their own subtypes to define reduced, subtype-
specific predictive gene lists. They then assigned Bonome samples based on the highest 
Spearman correlation against subtype centroids (243). To assess our analytical 
approach, we performed an analysis using randomized data. This showed that within-
population correlation structure was induced by clustering, but structure between 
populations was not (Figure 5.4). The off-diagonals in this figure are close to, but not 
exactly, zero. Permutation induces more independent features than in real gene 
expression data and therefore may produce much lower correlations if structure is 
present in real data. Comparing Figure 5.2 with Figure 5.4, we observed much higher 
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Figure 5.2: NMF consensus matrices for HGSC datasets when k = 2, k = 3, and k = 4 
 
The first track represents cluster membership for k means clusters and the second track 
represents silhouette widths. Note that NMF clusters are not ordered in the same way as 
the k means clusters.  
 
 
Figure 5.3: Pearson correlation heatmaps reveal consistency across HGSC datasets 
 
(A) Correlations across datasets for k means k = 2. (B) Correlations across datasets for 
k means k = 3. (C) Correlations across datasets for k means k = 4. TCGA, The Cancer 
Genome Atlas. 
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correlation across datasets (Figure 5.2), which was lost after randomization (Figure 5.4). 
For example, for k = 2, the TCGA and Mayo cluster correlations for analogous clusters 
was high (top left panel in Figure 5.3). Conversely, the same relationship in randomized 
data (second row, first column panel in Figure 5.4) showed correlations near zero. This 
indicates that the high correlations observed across datasets in Figure 5.3 are induced 
by similar underlying structure in the data. 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 
k = 2 0.62 – 0.81 0.62 – 0.81 NA NA 
k = 3 0.77 - 0.85   0.80 - 0.90 0.65 - 0.77 NA 
k = a 0.77 - 0.85  0.83 - 0.89 0.51 - 0.76  0.61 - 0.75 
Bonome k = 2 -0.08 – 0.24 -0.08 – 0.24 NA NA 
Bonome k = 3 0.45 – 0.46 -0.02 - 0.12 0.22 - 0.42 NA 
Bonome k = 4 0.50 - 0.57 -0.04 - 0.04 0.13 - 0.29 0.26 - 0.43 
 
Table 5.2: SAM moderated t score vector Pearson correlations between analogous 
clusters across populations 
 
 
Figure 5.4:  Pearson correlation heatmaps of randomly shuffled HGSC datasets 
 
The within dataset correlations are artificially induced because the clustering algorithm 
will find clusters even without true underlying structure. However, the across dataset 
clusters are not correlated in the randomized data indicating that the results we observe 
in Figure 1 are not artifacts of the clustering algorithm. 
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Across studies, positive correlations between analogous clusters and negative 
correlations between nonanalogous clusters were stronger for clusters identified when k 
= 2 and k = 3 than when k = 4 (Figure 5.3), with comparable statistical precision. These 
cross-population comparisons suggested that two and three subtypes fit HGSC gene 
expression data more consistently than the four widely accepted subtypes. 
Within each population, clusters identified by NMF were similar to those identified 
using k-means clustering (Figure 5.5), suggesting that these results were independent of 
clustering algorithm. With NMF, both positive and negative correlations were stronger for 
k = 2 and k = 3 than for k = 4. Across k = 3 and k = 4, correlations were strongest for 
clusters 1 and 2. 
 
Figure 5.5: Pearson correlations comparing k means and NMF clustering HGSC 
subtypes 
Within dataset results are shown for both methods when setting each algorithm to 
find 2, 3, and 4 clusters. NMF, nonnegative matrix factorization; TCGA, The Cancer 
Genome Atlas. 
 
5.4.3. Comparison with previously-identified HGSC clusters 
Our clustering results for the Tothill, TCGA, and Mayo datasets were highly 
concordant with the clustering described in the original publications (239, 240, 243) as 
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evidenced by the high degree of consistent overlap in sample assignments to the 
previously-defined clusters (Table 5.3). Our cross-study cluster 1 was mostly mapped to 
the “Mesenchymal” label from TCGA, “C1” from Tothill, and “C4” from Mayo. This cluster 
was the most stable in our analysis within all datasets, across k = 2, 3, and 4, and across 
clustering algorithms. Cross-study cluster 2, which was also observed consistently, was 
most similar to the “Proliferative” label from TCGA, “C5” from Tothill, and “C3” from 
Mayo. Cross-study cluster 3 for k = 3 was associated with both the “Immunoreactive” 
and “Differentiated” TCGA labels, “C2” and “C4” in Tothill, and “C1” and “C2” in Mayo.  
 
 k = 2 1 2 k = 3 1 2 3 k = 4 1 2 3 4 
TCGA Mes 98 1  98 1 0  97 1 0 1 
Pro 7 127  2 111 21  4 85 5 40 
Imm 93 2  20 0 75  12 0 80 3 
Dif 68 60  11 11 106  12 0 3 113 
NC 21 22   6 16 21   5 13 12 13 
Tothill C1 78 0  77 1 0  74 1 3 0 
C2 39 5  22 0 22  0 0 42 2 
C3 1 5  0 0 6  0 0 0 6 
C4 0 44  0 3 41  0 1 1 42 
C5 0 35  0 35 0  0 34 1 0 
C6 0 2  0 2 0  0 2 0 0 
NC 11 22   6 5 22   0 5 14 14 
Konecny C1 36 6  16 0 26  7 0 29 6 
C2 21 39  13 16 31  12 9 6 33 
C3 2 41  2 36 5  3 31 0 9 
C4 26 0  26 0 0  25 0 1 0 
NA 114 94  82 56 70  62 41 57 48 
 
Table 5.3: Distributions of sample membership in the clusters identified in our study 
compared to the original cluster assignments in the TCGA, Tothill, and Konecny studies 
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For analyses where k = 4, the third cluster was associated with “Immunoreactive”, “C2,” 
and “C1,” while the fourth cluster was associated with “Differentiated,” “C4,” and “C2” for 
TCGA, Tothill, and Mayo, respectively. 
5.4.4. Meta-research into previous HGSC subtyping studies 
Each of the publications that only considered high-grade samples (239, 243) found 
clustering coefficients consistent with k = 2, k = 3, and k = 4. Nevertheless, each 
publication concludes the existence of four subtypes, while our cross-population analysis 
suggested that two or three clusters fit HGSC data better than four clusters. The only 
results in previous studies that contradicted this work were from TCGA’s reanalysis of 
the Tothill data. According to Figure S6.2 in the TCGA paper, the reanalysis included 
serous borderline tumors (i.e., tumors with low malignant potential) (n = 18). The 
inclusion of these tumors in the TCGA HGSC reanalyses was done even though, in the 
original Tothill paper, the serous borderline tumors had a unique gene expression 
pattern and clustered entirely in a group labeled “C3.” 
To assess the extent to which serous borderline tumors inclusion drove the TCGA 
reanalysis results, we reproduced TCGA’s reanalysis of the Tothill dataset, including the 
serous borderline tumors (n = 18); we indeed observed that the cophenetic correlation is 
higher for k = 4 than k = 3 (Figure 5.6A). However, when we appropriately removed 
these serous borderline tumors, we observed an increase in the k = 3 cophenetic 
correlation (Figure 5.6B). The results that support four subtypes were generated during 
clustering of HGSC and serous borderline tumors combined. Subtyping analyses of 
HGSC alone reveal less than four subtypes. 
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Figure 5.6: Comparing NMF consensus clustering in the Tothill dataset  
 (A) Tothill dataset (n = 260) with borderline samples (n = 18) not removed prior to 
clustering. (B) Tothill dataset with borderline samples removed (n = 242). 
 
5.5. Discussion 
Although prior studies have reported the existence of four molecular subtypes of 
HGSC ovarian cancer (239, 240, 243, 245), our analysis suggests the existence of only 
two or three subtypes. This conclusion is based on our observation that concordance of 
analogous subtypes across study populations was stronger for two or three clusters as 
opposed to four. Previous studies used either k-means or NMF clustering, and because 
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our results contradicted prior work, we performed analyses using both of these methods. 
Results for each population were similar for the k means and NMF clustering algorithms, 
suggesting that the clustering algorithm did not drive the observed differences. 
In the previous literature, the only report that suggested four subtypes represented 
the data better than three was TCGA’s reanalysis of the Tothill data (Figure S6.2 in their 
publication); the cophenetic coefficient dropped dramatically at k = 3 before recovering 
at k = 4 (239). Notably, TCGA’s figure legend for this supplemental result indicates that 
they did not remove serous borderline tumors from the Tothill data. Our analysis of the 
Tothill data differed from TCGA’s in that we excluded serous borderline tumors, and 
instead supports the existence of two or three subtypes. To evaluate the influence of 
these serous borderline tumors in the Tothill data, we repeated our analyses including 
serous borderline tumors, and observed a drop in the cophenetic coefficient for k = 3 
relative to k = 4 (Figure 5.6). This suggests that the four subtypes observed in TCGA’s 
analysis of the Tothill data may be due, in part, to the inclusion of serous borderline 
tumors. 
There are several limitations to note in the HGSC data we analyzed. Given the 
intratumor heterogeneity that is likely to exist (256), our approach would be strengthened 
by having data on multiple areas of the tumors. Additionally, since histology and grade 
classification have changed over time (257, 258), it is unclear whether the populations 
we studied used comparable guidelines to determine histology and grade. We attempted 
to exclude all low-grade serous and low-grade endometrioid samples because they often 
have very different gene expression patterns and more favorable survival compared to 
their higher-grade counterparts (238). It is unclear why the Bonome clusters did not 
correspond to the clusters observed in other populations. Lack of consistency could 
result from unreported biological differences. 
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In summary, our study demonstrates that two clusters of HGSC, “mesenchymal-like” 
and “proliferative-like,” are clearly and consistently identified within and between 
populations. This suggests that there are two reproducible HGSC subtypes that are 
either etiologically distinct, or acquire phenotypically determinant alterations through 
their development. Our study also suggests that the previously described 
“immunoreactive-like” and “differentiated-like” subtypes appear to be more variable 
across populations, and tend to be collapsed into a single category when three subtypes 
are specified. These may represent, for example, steps along an immunoreactive 
continuum or could represent the basis of a third, but more variable, subtype. 
Understanding the underlying biology of the robust, well-defined “mesenchymal-like” and 
“proliferative-like” subtypes universally observed across populations could lead to 
targeted treatments that might influence survival. More work needs to be done to 
determine whether the heterogeneous samples that do not fall into one of these clear 
groups can be classified into homogeneous subtypes using other characteristics such as 
methylation markers or a combination of genomic measures. Our analysis reveals the 
importance of critically reassessing molecular subtypes across multiple large study 
populations using parallel analyses and consistent inclusion criteria. New systematic 
approaches hold promise for the implementation of such analyses (259, 260). Our 
results underscore the importance of ovarian cancer histopathology, contradict the four 
HGSC subtype hypothesis, and suggest that there may be fewer HGSC molecular 
subtypes with variable immunoreactivity and stromal infiltration. 
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6.1. Abstract 
The Cancer Genome Atlas (TCGA) has profiled over 10,000 tumors across 33 
different cancer-types for many genomic features, including gene expression levels. 
Gene expression measurements capture substantial information about the state of each 
tumor. Certain classes of deep neural network models are capable of learning a 
meaningful latent space. Such a latent space could be used to explore and generate 
hypothetical gene expression profiles under various types of molecular and genetic 
perturbation. For example, one might wish to use such a model to predict a tumor’s 
response to specific therapies or to characterize complex gene expression activations 
existing in differential proportions in different tumors. Variational autoencoders (VAEs) 
are a deep neural network approach capable of generating meaningful latent spaces for 
image and text data. In this work, we sought to determine the extent to which a VAE can 
be trained to model cancer gene expression, and whether or not such a VAE would 
capture biologically-relevant features. In the following report, we introduce a VAE trained 
on TCGA pan-cancer RNA-seq data, identify specific patterns in the VAE encoded 
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features, and discuss potential merits of the approach. We name our method “Tybalt !” 
after an instigative, cat-like character who sets a cascading chain of events in motion in 
Shakespeare’s “Romeo and Juliet”. From a systems biology perspective, Tybalt could 
one day aid in cancer stratification or predict specific activated expression patterns that 
would result from genetic changes or treatment effects.  
6.2. Introduction 
Deep learning has improved the state of the art in many domains, including image, 
speech, and text processing, but it has yet to make significant enough strides in 
biomedicine for it to be considered transformative (261). Nevertheless, several studies 
have revealed promising results. For instance, Esteva et al. used convolutional neural 
networks (CNNs) to diagnose melanoma from skin images and Zhou and Troyanskaya 
trained deep models to predict the impact of non-coding variants (262, 263). However, 
several domain specific limitations remain. In contrast to image or text data, validating 
and visualizing learning in biological datasets is particularly challenging. There is also a 
lack of ground truth labels in biomedical domains, which often limits the efficacy of 
supervised models. New unsupervised deep learning approaches such as generative 
adversarial nets (GANs) and variational autoencoders (VAEs) harness the modeling 
power of deep learning without the need for accurate labels (47, 90, 91). Unlike 
traditional CNNs, which model data by minimizing inaccurate class predictions, 
autoencoder models, including VAEs, learn through data reconstruction. Reconstructing 
gene expression input data using autoencoder frameworks has been previously shown 
to reveal novel biological patterns (86, 87, 101). 
VAEs and GANs are generative models, which means they learn to approximate a 
data generating distribution. Through approximation and compression, the models have 
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been shown to capture an underlying data manifold – a constrained, lower dimensional 
space where data is distributed – and disentangle sources of variation from different 
classes of data (264, 265). For instance, a recent group trained adversarial 
autoencoders on chemical compound structures and their growth inhibiting effects in 
cancer cell lines to learn manifold spaces of effective small molecule drugs (266, 267). 
Additionally, Rampasek et al. trained a VAE to learn a gene expression manifold of 
reactions of cancer cell lines to drug treatment perturbation (94). The theoretical basis 
for modeling cancer using lower dimensional manifolds is established, as it has been 
previously hypothesized that cancer exists in “basins of attraction” defined by specific 
pathway aberrations that drive cells toward cancer states (3). These states could be 
revealed by data driven manifold learning approaches. 
The Cancer Genome Atlas (TCGA) has captured several genomic measurements for 
over 10,000 different tumors across 33 cancer-types (176). TCGA has released this data 
publicly, enabling many secondary analyses, including the training of deep models that 
predict survival (268). One data type amenable to modeling manifold spaces is RNA-seq 
gene expression because it can be used as a proxy to describe tumor states and the 
downstream consequences of specific molecular aberration. Biology is complex, 
consisting of multiple nonlinear and often redundant connections among genes, and 
when a specific pathway aberration occurs, the downstream response to the 
perturbation is captured in the transcriptome. In the following report, we extend the 
autoencoder framework by training and evaluating a VAE on TCGA RNA-seq data. We 
aim to demonstrate the validity and specific latent space benefits of a VAE trained on 
gene expression data. We do not aim to comprehensively profile all learned pan-cancer 
VAE features nor survey clinical implications.  We also do not compare our approach to 
alternate dimensionality reduction algorithms, but instead present our model as an 
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additional tool in the toolkit for extracting knowledge from gene expression. We shall 
name this model “Tybalt !”. 
6.3. Methods 
6.3.1. Model summary 
VAEs are data driven, unsupervised models that can learn meaningful latent spaces 
in many contexts. In this work, we aim to build a VAE that compresses gene expression 
features and reveals a biologically relevant latent space. The VAE is based on an 
autoencoding framework, which can discover nonlinear explanatory features through 
data compression and nonlinear activation functions. A traditional autoencoder consists 
of an encoding phase and a decoding phase where input data is projected into lower 
dimensions and then reconstructed (89). An autoencoder is deterministic, and is trained 
by minimizing reconstruction error. In contrast, VAEs are stochastic and learn the 
distribution of explanatory features over samples. VAEs achieve these properties by 
learning two distinct latent representations: a mean and standard deviation vector 
encoding. The model adds a Kullback-Leibler (KL) divergence term to the reconstruction 
loss, which also regularizes weights through constraining the latent vectors to match a 
Gaussian distribution. In a VAE, these two representations are learned concurrently 
through the use of a reparameterization trick that permits a back propagated gradient 
(90). Importantly, new data can be projected onto an existing VAE feature space 
enabling new data to be assessed. 
6.3.2. Model implementation 
VAEs have been shown to generate “blurry'' data compared with other generative 
models, including GANs, but VAEs are also generally more stable to train (269). We 
trained our VAE model, Tybalt, with the following architecture: 5,000 input genes 
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encoded to 100 features and reconstructed back to the original 5,000 (Figure 6.1A). The 
5,000 input genes were selected based on highest variability by median absolute 
deviation (MAD) in the TCGA pan-cancer dataset. 
 
Figure 6.1: A variational autoencoder (VAE) applied to gene expression data 
(A) Model wire diagram of Tybalt encoding a gene expression vector (p = 5,000) into 
mean and standard deviation vectors (h = 100). A reparameterization trick (90, 91) 
enables learning z, which is then reconstructed back to input. (B) Training and validation 
VAE loss across training epochs (full pass through all training data). Shown across 
vertical and horizontal facets are values of kappa and batch size, respectively. (C) Final 
validation loss for all parameters with kappa = 1. (D) VAE loss for training and testing 
sets through optimized model training. 
 
We initially trained Tybalt without batch normalization (270), but observed that when 
we included batch normalization in the encoding step, we trained faster and with 
heterogeneous feature activation. Batch normalization in machine learning is distinct 
from normalizing gene expression batches together in data processing. In machine 
learning, batch normalization adds additional feature regularization by scaling activations 
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to zero mean and unit variance, which has been observed to speed up training and 
reduce batch to batch variability thus increasing generalizability. We trained Tybalt with 
an Adam optimizer (271), included rectified linear units (272) and batch normalization in 
the encoding stage, and sigmoid activation in the decoding stage. We built Tybalt in 
Keras (version 2.0.6) (273) with a TensorFlow backend (version 1.0.1) (274). For more 
specific VAE illustrations and walkthroughs refer to an extended tutorial (275) and these 
intuitive blog posts (276, 277). 
6.3.3. Parameter selection 
We performed a parameter sweep over batch size (50, 100, 128, 200), epochs (10, 
25, 50, 100), learning rates (0.005, 0.001, 0.0015, 0.002, 0.0025) and warmups (kappa) 
(0.01, 0.05, 0.1, and 1). Kappa controls how much the KL divergence loss contributes to 
learning, which effectively transitions a deterministic autoencoder to a VAE (278, 279). 
For instance, a kappa = 0.1 would add 0.1 to a weight on the KL loss after each epoch. 
After 10 epochs, the KL loss will have equal weight as the reconstruction loss. We did 
not observe kappa to influence model training (Figure 6.1) so we kept kappa = 1 for 
downstream analyses. We evaluated train and test set loss at each epoch. The test set 
was a random 10% partition of the full data. In general, training was relatively stable for 
many parameter combinations, but was consistently worse for larger batches, 
particularly with low learning rates. Ultimately, the best parameter combination based on 
validation loss was batch size 50, learning rate 0.0005, and 100 epochs (Figure 6.1C). 
Because training stabilized after about 50 epochs, we terminated training early. Training 
and testing loss across all 50 epochs is shown in Figure 6.1D. We performed the 
parameter sweep on a cluster of 8 NVIDIA GeForce GTX 1080 Ti GPUs on the PMACS 
cluster at The University of Pennsylvania. 
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6.3.4. Input data 
The input data consisted of level 3 TCGA RNA-seq gene expression data for 9,732 
tumors and 727 tumor adjacent normal samples (10,459 total samples) measured by the 
5,000 most variably expressed genes. The full dataset together is referred to as the pan-
cancer data.  The level 3 RNA-seq data consists of a preprocessed and batch-corrected 
gene abundance by sample matrix measured by log2(FPKM + 1) transformed RSEM 
values. The most variably expressed genes were defined by median absolute deviation 
(MAD). In total, there were 33 different cancer-types (including glioblastoma, ovarian, 
breast, lung, bladder cancer, etc.) profiled, each with varying number of tumors. We 
accessed RNA-seq data from the UCSC Xena data browser on March 8th, 2016 and 
archived the data in Zenodo (280). To facilitate training, we min-maxed scaled RNA-seq 
data to the range of 0 to 1. We used corresponding clinical data accessed from the 
Snaptron web server (39). 
6.3.5. Interpretation of gene weights 
Much like the weights of a deterministic autoencoder, Tybalt’s decoder weights 
captured the contribution of specific genes to each learned feature (86, 281, 101). For 
most features, the distribution of gene weights was similar: Many genes had weights 
near zero and few genes had high weights at each tail. In order to characterize patterns 
explained by selected encoded features of interest, we performed overrepresentation 
pathway analyses (ORA) separately for both positive and negative high weight genes; 
defined by greater than 2.5 standard deviations above or below the mean, respectively. 
We used WebGestalt (282), with a background of the 5,000 assayed genes, to perform 
the analysis over gene ontology (GO) biological process terms (145). P values are 
presented after an Benjamini-Hochberg FDR adjustment. 
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6.3.6. The latent space of ovarian cancer subtypes 
Image processing studies have shown the remarkable ability of generative models to 
mathematically manipulate learned latent dimensions (283, 284). For example, 
subtracting the image latent representation of a neutral man from a smiling man and 
adding it to a neutral woman, resulted in a vector associated with a smiling woman. We 
were interested in the extent to which Tybalt learned a manifold representation that 
could be manipulated mathematically to identify state transitions across high grade 
serous ovarian cancer (HGSC) subtypes. The TCGA naming convention of these 
subtypes is mesenchymal, proliferative, immunoreactive, and differentiated (239). To 
characterize the largest differences between the mesenchymal/immunoreactive and 
proliferative/differentiated HGSC subtypes, we performed a series of mean HGSC 
subtype vector subtractions in Tybalt latent space: 
!	# = 	 %&,( )# = *+&,( -# , …	, %&,(// )# = *+&,( -# 			!	immunoreactive	-		!	mesenchymal = 	!	immuno-mes		!	differentiated	-		!	proliferative = 	!	diff-prolif		
Where 	"# = %		 is an indicator function if sample i has membership with subtype k and z is 
the encoded layer. We used tumor subtype assignments provided for TCGA samples in 
Verhaak et al. 2013 (244). If Tybalt learned a biological manifold, this subtraction would 
result in the identification of biologically relevant features stratifying tumors of specific 
subtypes with a continuum of expression states. 
6.3.7. Enabling exploration through visualization 
We provide a Shiny app to interactively visualize activation patterns of 
encoded Tybalt features with covariate information at 
https://gregway.shinyapps.io/pancan_plotter/. 
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6.3.8. Reproducibility 
We provide all scripts to reproduce and to build upon this analysis under an 
open source license at https://github.com/greenelab/tybalt (285). 
6.4. Results 
Tybalt compressed tumors into a lower dimensional space, acting as a nonlinear 
dimensionality reduction algorithm. Tybalt learned which genes contributed to each 
feature, potentially capturing aberrant pathway activation and treatment vulnerabilities. 
Tybalt was unsupervised; therefore, it could learn both known and unknown biological 
patterns. In order to determine if the features captured biological signals, we 
characterized both sample- and gene-specific activation patterns. 
6.4.1. Tumors were encoded in a lower dimensional space 
The tumors were encoded from original gene expression vectors of 5,000 MAD 
genes into a lower dimensional vector of length 100. To determine if the sample 
encodings faithfully recapitulated large, tissue specific signals in the data, we visualized 
sample-specific Tybalt encoded features (z vector for each sample) by t-distributed 
stochastic neighbor embedding (t-SNE) (55). We observed similar patterns for Tybalt 
encodings (Figure 6.2A) as compared to 0-1 normalized RNA-seq data (Figure 6.2B). 
Tybalt geometrically preserved well known relationships, including similarities between 
glioblastoma (GBM) and low grade glioma (LGG). Importantly, the recapitulation of 
tissue-specific signal was captured by non-redundant, highly heterogeneous features 
(6.2C). Based on the hierarchical clustering dendrogram, the features appeared to be 
capturing distinct signals. For instance, tumor versus normal and patient sex are large 
signals present in cancer gene expression, but they were distributed uniformly in the 
clustering solution indicating non-redundant feature activations. 
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Figure 6.2: Samples encoded by a variational autoencoder retain biological signals 
(A) t-distributed stochastic neighbor embedding (t-SNE) of TCGA pan-cancer tumors 
with Tybalt encoded features. (B) t-SNE of 0-1 normalized gene expression features. 
Tybalt retains similar signals as compared to uncompressed gene expression data. (C) 
Full Tybalt encoding features by TCGA pan-cancer sample heatmap. Given on the y axis 
are the patient’s sex and type of sample. 
 
6.4.2. Features represent biological signal 
Our goal was to train and evaluate Tybalt on its ability to learn biological signals in 
the data and not to perform a comprehensive survey of learned features. Therefore, we 
investigated whether or not Tybalt could distinguish patient sex and patterns of 
metastatic activation. We determined that the model extracted patient sex robustly 
(Figure 6.3A). Feature encoding 82 nearly perfectly separated samples by sex. 
Furthermore, we identified a set of nodes that together identified skin cutaneous 
melanoma (SKCM) tumors of both primary and metastatic origin (Figure 6.3B). The 
weights used to decode the hidden layer (z vector) back into a high-fidelity 
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reconstruction of the input can capture important and consistent biological patterns 
embedded in the gene expression data (86, 101, 281). For instance, there were only 17 
genes needed to identify patient sex (Figure 6.3C). These genes were mostly located on 
sex chromosomes. The two positive weight genes were X inactivation genes XIST and 
TSIX, while the negative weight genes were mostly Y chromosome genes such as 
EIF1AY, UTY, and KDM5D. This result served as a positive control that the 
unsupervised model was able to construct a feature that described a clearly biological 
source of variance in the data. 
There were several genes contributing to the two encoded features that separated 
the SKCM tumors (Figure 6.3D). Several genes existed in the high weight tails of each 
distribution for feature encodings 53 and 66. We performed an ORA on the high weight 
genes. In general, several pathways were identified as overrepresented in the set as 
compared to random. The samples had intermediate to high levels of feature encoding 
53, which did not correspond to any known GO term, potentially indicating an unknown 
but important biological process. The samples also had intermediate to high levels of 
encoding 66 which implicated GO terms related to cholesterol, ethanol, and lipid 
metabolism including “regulation of intestinal cholesterol absorption” (adj. p = 3.0e-2), 
“ethanol oxidation” (adj. p = 4.0e-02), and “lipid catabolic process” (adj. p = 4.0e-02). 
SKCM samples had consistently high activation of both encoded features, which 
separated them from other tumors. Nevertheless, more research is required to 
determine how VAE features could be best interpreted in this context. 
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Figure 6.3: Specific examples of Tybalt features capturing biological signals 
(A) Encoding 82 stratified patient sex. (B) Together, encodings 53 and 66 separated 
melanoma tumors. Distributions of gene coefficients contributing to each plot above for 
(C) patient sex and (D) melanoma. The gene coefficients consist of the Tybalt learned 
weights for each feature encoding. 
 
6.4.3. Interpolating the lower dimensional manifold of HGSC subtypes 
We performed an experiment to test whether or not Tybalt learned manifold 
differences of distinct HGSC subtypes. Previously, several groups identified four HGSC 
subtypes using gene expression (239, 240, 243). However, the four HGSC subtypes 
were not consistently defined across populations; the data suggested the presence of 
three subtypes or fewer (57). The study observed that the immunoreactive/mesenchymal 
and differentiated/proliferative tumors consistently collapsed together when setting 
clustering algorithms to find 2 subtypes (57). This observation may suggest the presence 
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of distinct gene expression programs existing on an activation spectrum driving 
differences in these subtypes. Therefore, we hypothesized that Tybalt would learn the 
manifold of gene expression spectra existing in differential proportions across these 
subtypes. 
The largest feature encoding difference between the mean HGSC mesenchymal and 
the mean immunoreactive subtype (!	immuno-mes		) was encoding 87 (Figure 6.4A). 
Encoding 77 and encoding 56 (Figure 6.4B) also distinguished the mesenchymal and 
immunoreactive subtypes. The largest feature encoding differences between the mean 
proliferative and the mean differentiated subtype (!	diff-prolif		) were contributed by 
encoding 79 (Figure 6.4C) and encoding 38 (Figure 6.4D). Interestingly, encoding 38 
had high mean activation in both the immunoreactive and differentiated subtypes.	
The mesenchymal subtype had the highest encoding 87 activation. Encoding 87 was 
associated with the expression of genes involved in collagen and extracellular matrix 
processes (Table 6.1), which has been previously observed to be an important marker of 
the mesenchymal subtype (239, 240). Encoding 56 was associated with immune system 
responses (Table 6.1), and the immunoreactive subtype displayed the highest activation. 
Encoding 79 is mostly expressed in the proliferative subtype and has low activation in 
differentiated tumors. The high weight negative genes of encoding 79 were associated 
with glucuronidation processes (Table 6.1). The negative genes of encoding 38, which 
also distinguished differentiated from proliferative tumors but in the opposite direction, 
were also associated with glucuronidation. Previously, glucuronidation processes were 
observed to be associated with response to chemotherapy and survival in colon cancer 
patients (286, 287). Our results indicate that differential activation of glucuronidation is a 
strong signal distinguishing HGSC subtypes.  
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Figure 6.4: Largest mean differences in HGSC subtype vector subtraction for each 
subtype 
Subtracting the mesenchymal subtype by the immunoreactive result in distribution 
differences in (A) feature encoding 87 and (B) encoding 56. Subtracting the proliferative 
subtype by the differentiated subtype results in differences between (C) feature encoding 
79 and (D) encoding 38. 
 
 
Encoding Tail Subtype Enriched Pathway Adj.P Value 
87 + Mesenchymal Collagen Catabolic Process 1.8e-9 
87 + Mesenchymal Extracellular Matrix Organization 4.2e-6 
87 - Immunoreactive Urate Metabolic Process 1.5e-2 
56 + Immunoreactive Immune Response 1.3-12 
56 + Immunoreactive Defense Response 2.9e-12 
56 - Mesenchymal No Sig. Pathways  
79 + Proliferative Chemical Synaptic Transmission 9.1e-3 
79 - Differentiated Xenobiotic Glucuronidation 2.1e-9 
38 + Differentiated No Sig. Pathways  
38 - Proliferative Xenobiotic Glucuronidation 7.2e-6 
 
Table 6.1: Summary of significantly overrepresented pathways separating HGSC 
subtypes identified by latent space arithmetic with VAE features 
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This observation may also help to explain increased survival in HGSC patients with 
differentiated tumors (243). Lastly, encoding 77 also separated immunoreactive from 
mesenchymal tumors and did not display any significant terms, which may indicate novel 
biology explaining undiscovered subtype differences. 
6.5. Conclusions 
Tybalt is a promising model but still requires careful validation and more 
comprehensive evaluation. We observed that the encoded features recapitulated tissue 
specific patterns. We determined that the learned features were generally non-redundant 
and could disentangle large sources of variation in the data, including patient sex and 
SKCM. It is also likely that the features learn tissue specific patterns distinguishing other 
cancer-types (our shiny app enables full exploration of VAE features by cancer-type). 
While we identified specific features separating HGSC subtypes, there are likely several 
other features that describe other important biological differences across cancer-types 
including differentiation state and activation states of specific pathways. Interpretation of 
the decoding layer weights helped to identify the contribution of different genes and 
pathways promoting disparate biological patterns. However, interpretation by pathway 
analysis must be performed with caution as these analyses rely on incomplete pathway 
databases and may contain many false positive results. 
VAEs provide similar benefits as autoencoders, but they also have the ability to learn 
a manifold with meaningful relationships between samples. This manifold could 
represent differing pathway activations, transitions between cancer states, or indicate 
particular tumors vulnerable to specific drugs. We performed initial testing to determine if 
we could traverse the underlying manifold by subtracting out cancer-type specific mean 
activations. While we identified several promising functional relationships existing in a 
spectrum of activation patterns, rigorous experimental testing would be required to draw 
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strong conclusions about the biological implications. The specific subtype associations 
must be confirmed in independent datasets and the processes must be confirmed 
experimentally. It must also be assessed if Tybalt features learned from TCGA pan-
cancer are generalizable to other, potentially more heterogeneous datasets. Further 
testing is required to confirm that Tybalt catalogued an interpretable manifold capable of 
interpolation between cancer states. In the future, we will develop higher capacity 
models and increased evaluation/interpretation efforts to catalog Tybalt encoded RNA-
seq expression patterns present in specific cancer-types. This effort may lead to 
widespread stratification of expression patterns and enable accurate detection of 
patients who may benefit from specific targeted therapies. 
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Chapter 7. 
Sequential compression across latent space dimensions enhances gene 
expression signatures 
This chapter will be submitted for publication as: Way, Gregory, P., Zietz, Michael, 
Himmelstein, Daniel, S., and Greene, Casey, S. “Sequential compression across latent 
space dimensions enhances gene expression signatures”.  
Conceptualization: G.P.W., C.S.G.; Methodology: G.P.W., C.S.G.; Software: G.P.W., 
M.Z., D.S.H.; Investigation: G.P.W., C.S.G.; Writing – Original Draft: G.P.W.; 
Visualization: G.P.W. 
 
7.1. Abstract 
7.1.1. Background 
Unsupervised machine learning algorithms applied to gene expression data extract 
latent, or hidden, signals representing technical and biological sources of variation. 
However, these algorithms require a user to select a biologically-appropriate 
dimensionality. 
7.1.2. Results 
We compressed gene expression data from three large transcriptomic datasets 
consisting of adult normal tissue, adult cancer tissue, and pediatric cancer tissue. We 
compressed these data using principal components analysis (PCA), independent 
components analysis (ICA), non-negative matrix factorization (NMF), denoising 
autoencoders (DAE), and variational autoencoders (VAE). Rather than selecting a single 
latent dimensionality, we sequentially compressed input data into many dimensions 
ranging from 2 to 200. Each algorithm has various tradeoffs. We observed high model 
stability and model similarity between PCA, ICA, and NMF algorithms across latent 
dimensions. We identified more unique biological signatures in ensembles of DAE and 
VAE models. Using all compressed features across algorithms, ensembles, and latent 
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dimensions captured the highest proportion of biological features. We used compressed 
features across algorithms and dimensions to identify gene expression signatures 
representing sample sex, neuroblastoma MYCN amplification, and blood cell types, 
which generalized to external datasets. In supervised machine learning tasks, 
compressed features can be used to predict cancer type and gene alteration status. In 
this setting, the best performing supervised models used features from different 
dimensionalities and compression algorithms indicating that there was no single best 
dimensionality or compression algorithm. 
7.1.3. Conclusions 
Ensembles of features from different unsupervised algorithms discovers biological 
signatures in large transcriptomic datasets. In order to optimize biological signature 
discovery, rather than compressing input data into a single pre-selected dimensionality, 
it is best to perform compression on input data over many different latent 
dimensionalities. 
7.2. Introduction 
Dimensionality reduction algorithms compress input data into feature representations 
that capture major sources of variation. Applied to gene expression data, compression 
algorithms identify latent biological and technical processes. These processes reveal 
important information about the samples and can help to generate hypotheses that are 
difficult or impossible to observe in the original genomic space. For example, applying 
PCA to a large cancer transcriptomic compendium determined the influence of copy 
number alterations in gene expression measurements (76). ICA applied to transcriptome 
data aggregated gene modules to identify core pathways and hidden transcriptional 
programs (51, 79). NMF is often applied to estimate cell type proportion in bulk gene 
expression data (33, 288). DAEs have revealed latent signals representing oxygen 
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exposure and transcription factor targets in gene expression data (87, 101). VAEs have 
identified biologically relevant latent features discriminating cancer subtypes and drug 
response (93, 94). Nevertheless, a major challenge to all compression applications is the 
fundamental requirement that a researcher must first determine the number of latent 
dimensions (k) to compress the input data into.  
We hypothesize that different latent space dimensionalities and algorithms best 
capture various biological signatures. Therefore, in the following paper, we train and 
evaluate compression models across a wide range of latent space dimensionalities, from 
k = 2 to k = 200, using PCA, ICA, NMF, DAE, and VAE models. We use RNAseq gene 
expression data from three different datasets: The Cancer Genome Atlas (TCGA) 
PanCanAtlas (176), the Genome Tissue Expression Consortium Project (GTEx) (289), 
and the Therapeutically Applicable Research To Generate Effective Treatments 
(TARGET) Project (290). We integrate gene set networks using Molecular Signatures 
Database (MSigDB) and xCell data to interpret the biological signals activated in 
compressed latent features (102, 291, 292).  
Across algorithms and latent dimensionalities, we report training and testing 
performance, including reconstruction cost, model stability, and gene set coverage. We 
demonstrate various tradeoffs between models, and we determine that compressing 
gene expression data using various latent dimensions and algorithms enhances 
biological signature discovery. We name our sequential compression approach 
BioBombe after the large mechanical device developed by Alan Turing and other 
cryptologists in World War II to decode encrypted messages sent by Enigma machines. 
BioBombe sequentially compresses gene expression input with increasing dimensions to 
optimize biological signature discovery and decipher biological signals embedded within 
compressed gene expression features. 
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7.3. Results 
7.3.1. BioBombe implementation 
We compressed RNAseq data from TCGA, GTEx, and TARGET using PCA, ICA, 
NMF, DAE, and VAE across 28 different latent dimensions (k) ranging from k = 2 to k = 
200. We used real and permuted data and initialized each model five times per latent 
dimension resulting in a total of 4,200 different compression models (Figure 7.1). We 
evaluated hyperparameters for DAE and VAE models across dimensions and trained 
models using optimized parameter settings. See Figure 7.2 for an outline of our 
approach. We provide full results for all compression models for both real (293–295) and 
permuted data (296–298) as publicly available resources. 
7.3.2. Assessing compression algorithm reconstruction 
Reconstruction cost, a measurement of the difference between the input and output 
matrices, is often used to describe the ability of compression models to capture 
fundamental processes in latent space features that recapitulate the original input data. 
We tracked the reconstruction cost for the training and testing data partitions for all 
datasets, algorithms, latent dimensions, and random initializations. As expected, we 
observed lower reconstruction costs in models trained with real data and with higher 
latent dimensions (Figure 7.3). Because PCA and ICA are rotations of one another, we 
used these scores as a positive control. All compression algorithms had similar 
reconstruction costs, with the highest variability at low latent dimensions (Figure 7.3). 
7.3.3. Evaluating model stability and similarity within and across latent dimensions 
We applied singular vector canonical correlation analysis (SVCCA) to algorithm 
weight matrices to assess model stability within algorithm initializations, and to 
determine model similarity between algorithms (299). Briefly, SVCCA calculates the 
average similarity between two compression algorithm weight matrices and identifies the  
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Figure 7.1: Representing our BioBombe implementation workflow  
We independently apply our approach to three transcriptome compendia including The 
Cancer Genome Atlas PanCanAtlas Project (TCGA), Genome-Tissue Expression 
Project (GTEx), and Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) initiative. For each dataset, we split 90% of the data into a 
training data partition and 10% of the data into a testing data partition. The data is split to 
match the proportion of cancer-types or tissue-types in each partition. We also randomly 
permute the gene expression values by gene for all samples in the training set. We 
proceed with the downstream approach for both real and permuted data in parallel. We 
apply five compression algorithms including principle components analysis (PCA), 
independent components analysis (ICA), non-negative matrix factorization (NMF), 
denoising autoencoders (DAE), and variational autoencoders (VAE). We compress the 
testing data partition using the trained weights learned from the training set. We 
sequentially compress the input data into various bottleneck dimensions (k) from 2 
dimensions to 200 dimensions. We use k = 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 
25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 125, 150, and 200 for a total of 28 different 
dimensions. For each model, we train five independent times using five different random 
seed initializations. Combined, this yields a total of 4,200 different compression matrices 
that can be interpreted for biological processes. 
116	
	
 
 
Figure 7.2: Overview of the BioBombe approach 
We implemented BioBombe on three datasets using five different algorithms. We 
sequentially compressed input data into various bottleneck dimensions. We calculated 
various metrics that describe different benefits and trade-offs of the algorithms. Lastly, 
we implemented a network projection approach to interpret the compressed latent 
features. We used MSigDB collections and xCell gene sets in our network. 
	
Figure 7.3: Reconstruction cost across datasets, algorithms and dimensions 
Reconstruction performance for (A) Genome-Tissue Expression Project (GTEx) (B) The 
Cancer Genome Atlas PanCanAtlas Project (TCGA) and (C) Therapeutically Applicable 
Research to Generate Effective Treatments (TARGET) initiative data. Only real testing 
data is shown for GTEx and TCGA to highlight specific performance differences that 
would be unable to visualize with the other data present. 
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highest correlating feature across all latent space features. Training with TCGA data, we 
observed highly stable models within algorithms and within all latent dimensions for 
PCA, ICA, NMF (along the matrix diagonal in Figure 7.4A). VAE models were also 
largely stable, with some decay in higher latent dimensions. However, DAE models were 
highly instable, particularly at low latent dimensions (Figure 7.4A). PCA and ICA were 
highly similar, and because the two algorithms are rotations of one another, we used this 
as a positive control for SVCCA estimates. NMF was also highly similar to PCA and ICA, 
particularly at low latent dimensions (Figure 7.4A). The AE models were less similar to 
other algorithms. VAE models were more similar to PCA, ICA, and NMF than DAE 
models, particularly at low latent dimensions, and the instability patterns within DAE 
models also lead to large differences across algorithms (Figure 7.4A). We observed 
similar patterns in GTEx and TARGET data (Figure 7.5) 
We also used SVCCA to compare the similarity of weight matrices across latent 
dimensions. Both PCA and ICA found highly similar solutions across all dimensions 
(Figure 7.4B). This is not surprising since the solutions are deterministic and are 
arranged with decreasing amounts of variance. NMF also identified highly similar 
solutions in low dimensions, but solutions were less similar in higher dimensions. DAE 
solutions were the least similar, with intermediate dimensions showing the lowest mean 
similarity. VAE models displayed relatively high model similarity, but there were regions 
of modest model stability in intermediate and high dimensions (Figure 7.4B). We 
observed similar patterns in GTEx and TARGET data, despite TARGET containing only 
about 700 samples (Figure 7.6). 
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Figure 7.4: Assessing algorithm and dimension stability with singular vector canonical 
correlation analysis (SVCCA) 
(A) SVCCA applied to the weight matrices learned by each compression algorithm in 
gene expression data from The Cancer Genome Atlas (TCGA). The mean of all 
canonical correlations comparing independent iterations is shown. The distribution of 
mean similarity represents a comparison of all pairwise iterations within and across 
algorithms. The upper triangle represents SVCCA applied to real gene expression data, 
while the lower triangle represents permuted expression data. Both real and permuted 
data are plotted along the diagonal. (B) Mean correlations of all iterations within 
algorithms but across k dimensions. SVCCA will identify min(i, j) canonical vectors for 
bottleneck dimensions ki and kj. The mean of all pairwise correlations is shown for all 
combinations of k dimensions. 
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Figure 7.5: Across algorithm stability as measured by singular vector canonical 
correlation analysis (SVCCA) 
Stability is measured for the weight matrices in (a) Genome-Tissue Expression Project 
(GTEx) and (b) Therapeutically Applicable Research to Generate Effective Treatments 
(TARGET). The boxplots represent all pairwise estimates of SVCCA mean similarity for 
all initializations (across seeds) for real data (upper triangle) and permuted data (lower 
triangle).  
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Figure 7.6: Across latent dimension stability as measured by singular vector canonical 
correlation analysis (SVCCA) 
Stability is measured for the weight matrices in (A) Genome-Tissue Expression Project 
(GTEx) and (B) Therapeutically Applicable Research to Generate Effective Treatments 
(TARGET). SVCCA can be measured in two weight matrices of different dimensions. 
The mean similarity represents the mean of all pairwise estimates across all algorithm 
initializations. There is some numerical instability observed in the PCA assessment of 
both plots.  
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7.3.4. Sequential compression can optimize gene expression signature discovery 	
We tested the ability of the BioBombe sequential compression approach to isolate 
biological signatures. First, we sought to identify a latent space feature that identified 
sample sex, which has been previously observed to be captured in latent spaces (69, 
93, 300). We performed a two-tailed t-test comparing male and female samples in GTEx 
across all initializations, algorithms, and latent dimensions. This signal was optimally 
identified in higher latent dimensions, particularly in VAE and NMF models (Figure 7.7A). 
The top feature separating GTEx males and females was VAE feature 108 in k = 200 (t 
= 49.0, p = 2.7 x 10-285) (Figure 7.7B). We performed the same approach using 
sequentially compressed features in TCGA data. Whereas the largest models appeared 
to capture sex optimally in GTEx data, intermediate latent dimensions best captured sex 
in TCGA data (Figure 7.7C). Additionally, the top latent dimension identified was not 
consistent across algorithms. The top feature distinguishing TCGA males and females 
was VAE feature 16 in the k = 20 model (t = -13.9, p = 1.8 x 10-40) (Figure 7.7D) 
We also tested the ability of the sequential compression approach to distinguish 
MYCN amplification in neuroblastoma (NBL) tumors. MYCN amplification is a biomarker 
associated with poor prognosis in NBL patients (301). Using latent features derived from 
the full TARGET data, we performed a two-tailed t-test comparing MYCN amplified vs. 
MYCN not amplified NBL tumors. Each algorithm discovered optimal signal at various 
latent dimensions, but the best aligned feature was identified in VAE models at k = 200 
(Figure 7.7E). Although there were some potentially mischaracterized samples, feature 
111 in VAE k = 200 robustly separated MYCN amplification status in NBL tumors (t = 
17.5, p = 3.0 x 10-37) (Figure 7.7F). This feature also robustly separated MYCN 
amplification status in NBL cell lines (302) that were previously unseen by the 
compression model (Figure 7.7G). 
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Figure 7.7: Using BioBombe as a signature discovery tool 
Detecting GTEx sample sex across (A) various latent dimensions and algorithms, and 
(B) the latent feature with the highest enrichment. Detecting TCGA patient sex across 
(C) various latent dimensions, and (D) the latent feature with the highest enrichment. 
Detecting TARGET MYCN amplification in neuroblastoma (NBL) tumors (E) across 
various latent dimensions, and (F) the latent feature with the highest enrichment. (G) 
Applying the MYCN signature to an external dataset of NBL cell lines implicates MYCN 
amplified cell lines. 
 
7.3.5. Assessing gene set coverage of compressed features 
We sought to identify biological patterns present in compressed latent features 
learned across all latent dimensions, algorithms, and initializations. Using various 
collections as curated by the molecular signatures database (MSigDB) and xCell 
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genesets, we generated gene set networks. We projected these networks onto 
compressed gene expression features to assess the proportion of gene sets covered by 
the various compression features (see methods for more details). Specifically, we 
tracked coverage of three MSigDB gene set collections representing transcription factor 
(TF) targets, cancer modules, and Reactome pathways across latent dimensions in 
TCGA data (Figure 7.8). In all cases, we observed higher gene set coverage in models 
with larger latent dimensionalities. Using individual models, we observed higher 
coverage in the linear methods. In particular, ICA seemed to outperform all other 
algorithms (Figure 7.8A). However, while the linear methods showed the highest 
coverage, the features identified had relatively low enrichment scores compared to other 
algorithms (Figure 7.9).  
Aggregating all five random initializations into an ensemble model, we observed 
substantial AE coverage increases (Figure 7.8B). VAE models had high coverage for all 
gene sets in intermediate dimensions, while DAE improved in higher dimensions. 
However, at the highest dimensions, ICA demonstrated the highest coverage. NMF 
consistently had the highest enrichment scores, but the lowest coverage (Figure 7.8B). 
When considering all models combined (forming an ensemble of algorithm ensembles) 
within latent dimensions, we observed substantially increased coverage of all gene sets. 
However, most of the unique gene sets were contributed by the AE models (Figure 
7.8B). Lastly, when we aggregated all features across all algorithms and all dimensions 
together into a single large ensemble model, we observed the highest gene set 
coverage (Figure 7.8C). While models compressed with larger latent space dimensions 
had higher gene set coverage, many individual gene sets were captured with the highest 
enrichment in models with low and intermediate dimensions (Figure 7.10). These results 
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indicated that optimal biological signature discovery occurs using various compression 
algorithms with various latent space dimensions. 
 
	
Figure 7.8: Assessing gene set coverage of specific gene set collections 
Tracking results in TCGA data for three gene set collections representing transcription 
factor (TF) targets (C3TFT), Reactome pathways (C2CPREACTOME), and cancer 
modules (C4CM). (A) Tracking coverage in individual models, which represents the 
distribution of scores across five algorithm iterations. (B) Tracking coverage in ensemble 
models, which represents coverage after combining all five iterations into a single model. 
The size of the point represents relative enrichment strength. (C) Tracking coverage in 
all models combined within k dimensions. The number of algorithm-specific unique gene 
sets identified is shown as bar charts. Coverage for all models combined across all k 
dimensions is shown as a dotted navy blue line. 
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Figure 7.9: Absolute ranking of the top gene set BioBombe z scores across algorithms  
We ranked all BioBombe z scores of top scoring gene sets within specific collections 
across algorithms. All gene sets within a specific collection are visualized within each 
algorithm box plot and whether or not they were identified as a top feature in model 
dimensions less than k = 25. 
 
7.3.6. Assessing sample type correlation differences across latent dimensions 
We measured the Pearson correlation between all samples’ gene expression input and 
reconstructed output. In TCGA data, we observed increased mean correlation and 
decreased variance as the latent dimensions increased (Figure 7.11A). We also 
observed similar patterns in GTEx and TARGET data (Figure 7.12). Across all datasets, 
in randomly permuted data, we observed correlations near zero (Figure 7.12). The 
correlation with real data was not consistent across all algorithms as PCA, ICA, and 
NMF generally outperformed the AE models. We also tracked correlation differences to 
determine the latent dimensions at which specific sample types could be detected. Most 
cancer types, including breast invasive carcinoma (BRCA) and colon adenocarcinoma 
(COAD), displayed relatively gradual increases in sample correlation as the latent 
dimensions increased (Figure 7.11B). However, in other cancer types, such as low 
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Figure 7.10: Tracking the dimensions of highest BioBombe enrichment signal  
The latent space dimension at which a gene set was identified with the highest 
enrichment across k dimensions is shown. Observing the relative density of top features 
identified for several gene set collections across algorithms in (A) TCGA (B) TARGET 
data. Comparing (C) total counts and (D) relative density of xCell gene sets enrichment 
across k dimension in GTEx data. 
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grade glioma (LGG), pheochromocytoma and paraganglioma (PCPG), and acute 
myeloid leukemia (LAML), we observed large correlation gains with a single increase in 
latent dimension (Figure 7.11C). We also observed similar performance spikes in GTEx 
data for several tissues including liver, pancreas, and blood (Figure 7.11D). This sudden 
and rapid increase in correlation in specific tissues occurred at different latent 
dimensions for different algorithms, but was consistent across algorithm initializations. In 
some cases, certain structure present in data was captured by increasing model 
capacity by a single k, but the specific k at which this happened varied across methods. 
	
Figure 7.11: Tracking sample correlation across latent dimensions 
(A) Sample Pearson correlation for all data in the testing data partition for The Cancer 
Genome Atlas (TCGA). The different algorithms follow the legend provided in panel d. 
(B) Mean Pearson correlation for select cancer types in the testing data partition. 
Pearson correlation gain between sequential latent dimensions for (c) select cancer 
types in TCGA and (d) select tissue-types in GTEx.  
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Figure 7.12: Pearson correlation between input and reconstructed samples in real and 
permuted data 
Pearson sample correlation for real (top) and permuted (bottom) data in (A) Genome-
Tissue Expression Project (GTEx) and (B) Therapeutically Applicable Research to 
Generate Effective Treatments (TARGET). (C) Pearson correlations in permuted data 
from The Cancer Genome Atlas PanCanAtlas Project (TCGA). (D) Pearson correlations 
between input and reconstructed output in permuted data to mirror select cancer-types 
in Figure 3. The data are permuted before input to the compression algorithms. Results 
across all specific cancer-types and tissue-types for GTEx, TARGET, and TCGA are 
provided in: https://github.com/greenelab/BioBombe/blob/master/4.analyze-components/ 
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7.3.7. Interpretation of GTEx blood with VAE compression features 
We examined the sharp increase in GTEx blood tissue correlation observed in VAE 
models between latent space dimensions 2 and 3 (See Figure 7.11D). We assigned 
enrichment scores using an xCell gene set network across all compressed features in 
both VAE models. xCell gene sets represent computationally derived cell type signatures 
and we sought to identify specific signatures detected by each compressed gene 
expression feature (291). The top features identified for the VAE k = 2 model included 
skeletal muscle, keratinocyte, and neuronal gene sets (Figure 7.13A). Skeletal muscle 
was the likely most significant gene set identified because it is the most represented 
tissue type in GTEx. Similar gene sets were enriched in the k = 3 model, but we also 
observed new enrichment for a specific neutrophil gene set (“Neutrophils_HPCA_2”) 
(Figure 7.13A). Neutrophils represent 50% of all cell types in blood, which may explain 
the increased correlation in blood tissue observed in VAE k = 3 models. 
We also calculated the mean absolute value z scores for xCell gene sets in all 
compression features for VAE models with k = 2 and k = 3 dimensions (Figure 7.13B). 
Again, we observed skeletal muscle, keratinocytes, and neuronal gene sets to be 
enriched in both models. Importantly, we also observed a cluster of monocyte gene sets 
with modest enrichment in k = 3, but low enrichment in k = 2 (Figure 7.13B). Monocytes 
are also important cell types found in blood tissue, and it is possible these signatures 
also contributed to the increased correlation in VAE k = 3 models. 
We scanned all other algorithms and latent dimensions to identify other compression 
features with high enrichment scores in the “Neutrophils_HPCA_2” gene set (Figure 
7.13C) and “Monocytes_FANTOM_2” gene set (Figure 7.13D). We observed the same 
sharp increase in neutrophil signature enrichment between VAE k = 2 and k = 3 (Figure 
7.13C). We also observed stronger enrichment of the “Neutrophil_HPCA_2” gene set in 
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AE models compared to PCA, ICA, and NMF, especially at lower latent dimensions. We 
observed the highest score for the “Neutrophil_HPCA_2” gene set at k = 14 in VAE 
models (Figure 7.13C). Conversely, PCA, ICA, and NMF identified the 
“Monocytes_FANTOM_2” signature with higher enrichment than the AE models (Figure 
7.13D). We also observed a large spike at k = 7 for both PCA and NMF models, but the 
highest enrichment for “Monocytes_FANTOM_2” occurred at k = 200 in NMF models. 
7.3.8. Validating GTEx neutrophil and monocyte signatures in external datasets 
We downloaded a processed gene expression dataset (GSE103706) that applied 
two treatments to induce neutrophil differentiation in two leukemia cell lines (303). We 
hypothesized that transforming the dataset by the learned “Neutrophil_HPCA_2” 
signature would reveal differential scores in the treated cell lines. We observed large 
differences in sample activations of treated vs untreated cell lines in the top Neutrophil 
signature (VAE k = 14) (Figure 7.13E). We also tested the “Monocytes_FANTOM_2” 
signature on a different publicly available dataset (GSE24759) measuring gene 
expression of isolated cell types undergoing hematopoiesis (304). We observed 
increased scores for isolated monocyte cell population (MONO2) and relatively low 
scores for several other cell types for top VAE features (Figure 7.13F). Applying all top 
compressed feature signatures to each dataset, we observed various dimensions and 
algorithms that optimally isolated differences between each group (Figure 7.13G). These 
separation patterns were associated with network projection scores in NMF models, but 
were not consistent in other algorithms (Figure 7.13H). Taken together, we determined 
that features capturing Neutrophil and Monocyte activity patterns improved signal 
detection in GTEx blood tissues, signatures are optimally learned at various latent 
dimensions across algorithms, and that the signatures generalized to datasets that were 
not encountered during training. 
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Figure 7.13: Interpreting compressed features learned from GTEx using xCell gene sets   
(A) Comparing BioBombe scores of all compressed latent features for variational 
autoencoder (VAE) models when bottleneck dimensions are set to k = 2 and k = 3. (B) 
Comparing mean BioBombe Z scores of aggregated latent features across two VAE 
models with k dimensions 2 and 3. Tracking the BioBombe Z scores of (C) 
“Neutrophils_HPCA_2” and (D) “Monocytes_FANTOM_2” gene sets across dimensions 
and algorithms. Only the top scoring feature per algorithm and dimension is shown. (E) 
Projecting the VAE feature k = 3 feature and the highest scoring feature (VAE k = 14) 
that best captures a neutrophil signature to an external dataset measuring neutrophil 
differentiation treatments (GSE103706). (F) Projecting the VAE k = 3 feature that best 
captures monocytes and the feature of the top scoring model (NMF k = 200) to an 
132	
	
external dataset of isolated hematopoietic cells (GSE24759). (G) Tracking neutrophil 
and monocyte signatures across all top dimensions. (H) Observing how the BioBombe z 
scores correlated with t test estimates of top dimension correlations. 
 
7.3.9. Using compressed features in supervised learning applications 
We used the latent features generated from the compression algorithms as input 
features into supervised machine learning tasks. We first trained logistic regression 
models using the compressed features within each algorithm iteration to predict each of 
the 33 different cancer types in TCGA. All cancer types could be predicted with high 
precision and recall using compressed features. We observed multiple performance 
spikes at varying dimensions for different cancer types and algorithms, and typically in 
small latent dimensions (Figure 7.14A). We also input the unsupervised compression 
features into the supervised classification framework to predict samples with alterations 
in the top 50 most mutated genes in TCGA. We focused on the prediction performance 
of four cancer genes and one negative control; TP53, PTEN, PIK3CA, KRAS, and TTN 
(Figure 7.14B). TTN is a particularly large gene and is associated with high passenger 
mutation burden and should provide no predictive signal (305). As expected, we did not 
observe any signal in TTN across latent dimensions (Figure 7.14B). Again, we observed 
performance increases at varying model capacities across algorithms. However, 
predictive signal for mutations occurred at higher latent dimensions compared to cancer 
types (Figure 7.14C, D). Compared to features trained within algorithm and within 
iteration, an ensemble of five VAE models and an ensemble of five models representing 
one iteration of each algorithm, identified cancer type and mutation status in earlier 
dimensions compared to single model iterations (Figure 7.14C, D). 
We also tracked the logistic regression coefficients assigned to each compression 
feature. Many models were sparse, meaning they included a high percentage of 
coefficients with zero weights (Figure 7.14E). DAE models consistently displayed sparse 
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models. The VAE ensemble and model ensemble also induced high sparsity (Figure 
7.14E). Lastly, we trained logistic regression classifiers using all 30,850 compressed 
features generated across iterations, algorithms, and latent dimensions. These logistic 
regression models were sparse and high performing; comparable to logistic regression 
models trained using raw features (Figure 7.14E, F, G). Of all 30,850 compressed 
features in this model, only 317 were assigned non-zero weights (1.03%). We applied 
the network projection approach with Hallmark gene sets to interpret the biological 
signatures of the top supervised model coefficients. The top positive feature was derived 
from a VAE trained with k = 200. The top hallmarks of this feature included 
“HALLMARK_ESTROGEN_RESPONSE_EARLY”, 
“HALLMARK_ESTROGEN_RESPONSE_LATE”, and “HALLMARK_P53_PATHWAY”. 
The top negative feature was derived from a VAE trained with k = 150 and was 
associated with hallmark genesets including “HALLMARK_BILE_ACID_METABOLISM”, 
“HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION”, and 
“HALLMARK_FATTY_ACID_METABOLISM”. Overall, the features selected by the 
logistic regression classifier were distributed across algorithms and latent dimensions 
suggesting that combining signatures across dimensionalities and algorithms provided 
the best representation of the signal (Figure 7.14H). 
7.4. Discussion 
Unsupervised learning algorithms applied to gene expression data extract biological 
and technical signals present in input samples. When applying these algorithms, 
researchers must determine how many latent dimensions to compress their input data 
into. A study that applies compression algorithms to gene expression data can have a 
variety of goals. If the goal is visualization, compression algorithms can be used to  
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Figure 7.14: Using compressed features as features in supervised machine learning 
Predicting (A) cancer-type status and (B) gene mutation status for select cancer-types 
and important cancer genes using five compression algorithms and two ensemble 
models. The area under the precision recall (AUPR) curve for cross validation (CV) data 
partitions is shown. The blue lines represent predictions made with permuted data input 
into each compression algorithm. The dotted lines represent AUPR on untransformed 
RNAseq data. The dotted gray line represents a hypothetical random guess. TTN is 
used as a negative control. Tracking the average change in AUPR between real and 
permuted data across latent dimensions and compression models in predicting (C) 
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cancer types and (D) mutation status. The average includes the five cancer types and 
mutations tracked in panels a and b. (E) Tracking the sparsity and performance of 
supervised models using BioBombe compressed features in real and permuted data. (F) 
Receiver operating characteristic (ROC), (G) PR curves, (H) and the average absolute 
value weight per algorithm for the all-compression-feature ensemble model predicting 
TP53 alterations.  
stratify samples revealing the largest sources of variation (55, 306–310). For 
visualization tasks, selecting a small number of latent dimensions is best, and there is no 
need for sequential compression. However, if the analysis goals include learning 
biological signatures that are differentially active in input samples, then there may not be 
a single optimal latent dimension or optimal algorithm. While it is likely that compressing 
data into a single latent dimension will capture many biological signals, the “correct” 
dimension is not always clear, and several biological signatures may be better revealed 
in alternative latent dimensions.  
In the current paradigm, a researcher will use one or many mechanisms to decide 
upon an optimal latent dimension. Measurements such as Akaike information criterion 
(AIC), Bayesian information criterion (BIC), stability, and cross validation (CV) can be 
applied to a series of latent dimensions and a heuristic, like the elbow method, can 
enable model selection (311, 312). Other algorithms, like Dirichlet processes, can 
naturally arrive at an appropriate dimension through several algorithm iterations (313). In 
unsupervised neural networks, hidden layer dimensions are tunable hyperparameters 
that a user must define based on input data complexity and performance expectations. 
In recent genomic applications, researchers have used a variety of methods to estimate 
the latent dimensions. For example, through a combination of outlier detection and PCA, 
the method Thresher is used to identify optimal number of clusters (314). Stability of 
compression modules is also considered when determining the optimal number of 
dimensions (110). Applied to nearly 100,000 publicly available gene expression profiles, 
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ICA revealed a total of 139 reproducible modules (108). Researchers analyzing a 
transcriptome compendium of over 5,000 samples determined that only the first three 
PCA components represented biological signatures (106). However, biological signature 
discovery was impacted by sample types proportion (107). Instead, we argue that it is 
best to maximize signature discovery using a sequential compression approach that 
compresses input gene expression data into many different latent space dimensions. 
In an application to predict sample sex and MYCN amplification, we demonstrated 
that BioBombe maximized biological signature discovery. In each case, various 
dimensions and different algorithms identified automatically learned biological features at 
varying association strengths. We also demonstrated that the highest coverage of 
various gene set collections was achieved by using a combination of models across 
dimensions and algorithms. We showed that subtle differences in compression model 
dimensionality impacted identification of tissue specific signatures, including neutrophil 
and monocyte signatures in blood. Compressed features can also be used to predict 
cancer type and gene mutations in TCGA gene expression data, and a sparse classifier 
implicated features across latent dimensions and algorithms. Although performance was 
higher in models trained using raw gene expression features, compression feature 
models used less features to generate predictions. These isolated features also offer 
important clues into the biological processes activated in samples with the specific 
alteration, and the supervised learning approach can associate these features with 
specific sample types. The analysis also revealed insight into the impact of latent 
dimensionality on capturing different biology. For instance, cancer types were predicted 
with high accuracy, and models arrived at good solutions at low latent dimensions. 
Conversely, gene mutations were predicted at higher latent dimensions. In genomic 
applications of supervised learning, the labels of the samples are often inaccurate. 
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Mutations may be missed by the specific caller, the gene may be activated by alternative 
means, or there is incomplete knowledge on the pathway being studied (315). Therefore, 
unsupervised approaches that aggregate validated signatures may also be useful in 
overcoming sample label limitations.  
An additional benefit of compressing gene expression data is to identify novel genes 
involved in specific biological functions. The compressed features aggregate input 
signals, and can be used as evidence linking genes together with similar functions. A 
major benefit of unsupervised algorithms is they do not require external datasets or other 
resources. Therefore, they can subvert biases present in incomplete gene set collections 
or other potentially noisy resources. It is possible that many genes we aggregated are 
part of processes that have been previously undiscovered. For example, in features with 
high enrichment among specific gene sets, we observed many other unassigned genes 
with similar weights. Therefore, it is possible that these genes participate in similar 
biological functions. Additionally, analyzing and extracting knowledge from rapidly 
expanding publicly available resources will require automated approaches. These 
approaches can learn signal across different datasets, which can then be applied to 
smaller datasets that lack power to identify robust biological signatures (84). Extracted 
from large transcriptomic compendia, compression features can help researchers to 
interpret and stratify samples in their own datasets. While we did not assess these 
questions directly, we provide all compression models as publicly available resources for 
others to test and validate various hypotheses. 
Nevertheless, there are many limitations to our approach and analysis. First, our 
approach takes a long time to run. We are training many different algorithms across 
many different latent dimensions and iterations, which requires a lot of compute time. 
However, because we are training many models independently, this task can be 
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parallelized. Additionally, we did not evaluate dimensions above k = 200. It is likely that 
many more signatures can be learned, and possibly with even higher association 
strengths in higher dimensions. Additionally, we did not explore adding hidden layers in 
AE models. Many models trained on gene expression data have benefited from using 
multiple hidden layers in neural network architectures (68, 101). Additional methods, like 
DeepLift, can be used to reveal gene importance values in internal representations of 
deep networks (46, 316).  
An additional challenge is interpreting the biological content of the compressed gene 
expression features. Overrepresentation analysis (ORA) and gene set enrichment 
analysis (GSEA) are commonly applied but have significant limitations (102, 282). ORA 
requires a user to select a cutoff, typically based on standard deviation, to build 
representative gene sets from each feature. ORA tests also do not consider the weights, 
or gene importance scores, in each compression feature. Conversely, GSEA operates 
on ranked features, but often requires many permutations to establish significance. 
Furthermore, ORA requires each tail of the compressed feature distribution to be 
interpreted separately in algorithms that also learn negative weights. The weight 
distribution is dependent on the specific compression algorithm, and the same cutoff 
may not be appropriate for all algorithms and all compressed features. Instead, we 
implemented a network based approach to interpret compressed latent gene expression 
features (317, 318). The network projection approach is applied to the full and 
continuous distribution of gene weights, operates independently of the algorithm feature 
distribution, does not require arbitrary thresholds, and obviates the need to consider both 
tails of the distribution separately. Nevertheless, additional downstream experimental 
validation is required to determine if the constructed feature actually represents the 
biology it has been assigned. We also do not have a mechanism to detect compressed 
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features that represent technical artifacts. While we showed that compressed signatures 
representing MYCN amplification, neutrophils, and monocytes generalized to external 
datasets, more research is required and additional validation should be performed.  
The algorithms we used had various tradeoffs. The linear models consistently 
displayed lower reconstruction costs and higher correlations between input and output 
samples compared with AE models. The AE models were also not as stable as the linear 
methods. DAE models were particularly unstable in low latent dimension. However, this 
likely benefited the AE models in their ability to capture biological signatures in ensemble 
models. In the NMF models we observed a particularly higher gene set enrichment in 
high latent dimensions. If training an NMF model on gene expression data, it is best to fit 
models with many latent dimensions to maximize biological signature discovery. 
Furthermore, ICA captured the most biological signatures when applying individual 
models, especially at high latent dimensions. ICA outperformed all other algorithms 
across datasets and gene set collections. However, when detecting biological signatures 
using ensemble models, the AE models often outperformed other algorithms, particularly 
in intermediate latent dimensions. Nevertheless, when combining all models together 
across latent dimensionalities, we identified nearly 100% of gene sets in many 
collections. Additionally, the highest performing supervised algorithms used features 
derived from various algorithms across latent dimensionalities. Therefore, combining 
features across our BioBombe sequential compression approach optimized biological 
signature discovery. 
7.5. Conclusions 
To enhance biological signature discovery, it is best to compress gene expression 
data using several algorithms and many different latent space dimensionalities. These 
signatures represent important biological signals including various cell types, 
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phenotypes, and biomarkers. We present BioBombe as an approach to sequentially 
compress gene expression data to enhance biological signature discovery. BioBombe 
can be considered an ensemble of ensemble models that can be used to engineer many 
different gene expression signatures. We showed, through several experiments tracking 
gene set coverage and supervised learning performance, that optimal gene expression 
signatures are learned using a variety of latent space dimensionalities and different 
compression algorithms. As unsupervised machine learning continues to be applied to 
derive insight from biomedical datasets, researchers should shift focus away from 
optimizing a single model based on certain mathematical heuristics, and instead towards 
learning good, reproducible biological representations that generalize to alternative 
datasets regardless of compression algorithm and latent dimensionality. 
7.6. Methods 
7.6.1. Transcriptomic compendia acquisition and processing  
We downloaded all transcriptomic compendia from publicly available resources. We 
downloaded the batch-corrected TCGA PanCanAtlas RNAseq data from the National 
Cancer Institute Genomic Data Commons (https://gdc.cancer.gov/about-
data/publications/pancanatlas). These data consisted of 11,069 samples with 20,531 
measured genes quantified with RSEM and normalized with log transformation. We 
converted Hugo Symbol gene identifiers into Entrez gene identifiers and discarded non-
protein coding genes and genes that failed to map. We also removed tumors that were 
measured from multiple sites. This resulted in a final TCGA PanCanAtlas gene 
expression matrix with 11,060 samples and 16,148 genes, which included 33 different 
cancer-types. 
We downloaded the TPM normalized GTEx RNAseq data (version 7) from the GTEx 
data portal (https://gtexportal.org/home/datasets). There were 11,688 samples and 
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56,202 genes in this dataset.  After selecting only protein-coding genes and converting 
Hugo Symbols to Entrez gene identifiers, we considered 18,356 genes. There are 53 
different detailed tissue-types described in GTEx.  
Lastly, we retrieved the TARGET RNAseq gene expression data from the UCSC 
Xena data portal (127). The TARGET data was processed through the FPKM UCSC Toil 
RNA-seq pipeline and was normalized with RSEM and log transformed (319). The 
original matrix consists of 734 samples and 60,498 Ensembl gene identifiers. We 
converted the Ensembl gene identifiers to Entrez gene names and retained only protein-
coding genes. This procedure resulted in a total of 18,753 genes measured in TARGET. 
There are 7 cancer-types profiled in TARGET. All specific downloading and processing 
steps can be viewed and reproduced at 
https://github.com/greenelab/BioBombe/tree/master/0.expression-download.  
7.6.2. Training unsupervised neural networks  
Autoencoders (AE) are unsupervised neural networks that learn through minimizing 
the reconstruction of input data after passing the data through one or several 
intermediate layers (320). Typically, these layers are of a lower dimension than the input, 
so the algorithms must learn the most important sources of variation in the data. 
Denoising autoencoders (DAE) add noise to input layers during training to regularize 
solutions and improve generalizability (89). Variational autoencoders (VAE) add 
regularization through an additional penalty term imposed on the objective function (90, 
91). In a VAE, the latent space dimensions (k) are penalized with a Kullback-Leibler (KL) 
divergence penalty restricting the distribution of samples in the latent space to Gaussian 
distributions. We independently optimized each AE model across a grid of 
hyperparameter combinations including 6 representative bottleneck dimensions. 
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7.6.3. Optimizing training hyperparameters in neural network architectures  
We applied BioBombe using five compression algorithms. Two of the five models, 
variational autoencoders (VAE) and denoising autoencoders (DAE), are based on 
autoencoder (AE) frameworks and include several hyperparameters that must be tuned 
to optimize signal reconstruction. Our primary concern in training the AE models was to 
ameliorate potential performance biases as the bottleneck dimension increased if 
hyperparameters were kept static. In other words, we sought to isolate performance 
differences to the effects of changing k dimensions. Therefore, we performed a grid 
search around several hyperparameters for both AE models including 6 representative k 
dimensions.  
Training autoencoders, and neural networks in general, requires architectural and 
hyperparameter decisions to optimize learning important signals in input data. We 
searched through a grid of various combinations of learning rates, epochs, batch sizes, 
sparsity, and noise parameters for DAE models, and learning rates, epochs, batch sizes, 
and kappa values for VAE models. We included 6 representative k dimensions in this 
grid (k = 5, 25, 50, 75, 100, and 125). We selected the hyperparameter combinations for 
the top performing models and used these in training downstream models. 
7.6.4. Training compression algorithms with sequential latent dimensions  
Independently for each dataset (TCGA, GTEx, and TARGET), we performed the 
following procedure to train the compression algorithms. First, we randomly split data 
into 90% training and 10% testing partitions. We balanced each partition by cancer type 
or tissue type, which meant that each split contained relatively equal representation of 
tissues. Before input into the compression algorithm, we transformed the gene 
expression values by gene to a range between 0 and 1 independently for the testing and 
training partitions. We used the training set to train each compression algorithm. We 
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used the Sci-Kit Learn implementations of PCA, ICA, and NMF, and the Tybalt 
implementations of VAE and DAE (see Chapter 6 for more details) (93, 131). 
After learning optimized compression models with the training data, we transformed 
the testing data using these models. We assessed performance metrics using both 
training and testing data to reduce bias. In addition to training with real data, we also 
trained all models with randomly permuted data. To permute the training data, we 
randomly shuffled the gene expression values for all genes independently. We also 
transformed testing partition data with models trained using randomly permuted data. 
Training with permuted data removes the correlational structure in the data and can help 
set performance metric baselines.  
One of our goals was to assess differences in performance and biological signal 
detection across a range of latent dimensions (k). To this end, we trained all algorithms 
with various k dimensionalities including k = 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 
25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 125, 150, and 200 for a total of 28 different 
dimensions. All of these models were trained independently. Lastly, for each k 
dimension we trained five different models initialized with five different random seeds. In 
total, considering the three datasets, five algorithms, randomly permuted training data, 
all 28 k dimensions, and five initializations, we trained 4,200 different compression 
models. Therefore, in total, we generated 185,100 different compression features. 
7.6.5. Evaluating compression algorithm performance 
We evaluated all compression algorithms on three main tasks: Reconstruction, 
sample correlation, and weight matrix stability. First, we evaluated how well the input 
data is reconstructed after passing through the bottleneck layer. Because the input data 
was transformed to a distribution between 0 and 1, we used binary cross entropy to 
measure the difference between algorithm input and output as a measure of 
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reconstruction cost. The lower the reconstruction cost, the higher fidelity reconstruction, 
and therefore the higher proportion of signals captured in the latent space features. We 
also assessed the Pearson correlation of all samples comparing input to reconstructed 
output. This value is similar to reconstruction and can be quickly tracked at an individual 
sample level. Lastly, we used singular vector canonical correlation analysis (SVCCA) to 
determine model stability within and model similarity between algorithms and across 
latent dimensions (299). The SVCCA method consisted of two distinct steps. First, 
singular value decomposition (SVD) was performed on two input weight matrices. The 
singular values that combined to reconstruct 98% of the signal in the data were retained. 
Next, the SVD transformed weight matrix was input into a canonical correlation analysis 
(CCA). CCA aligned different features in the weight matrix based on maximal correlation 
after learning a series of linear transformations. Taken together, SVCCA outputs a single 
metric comparing two input weight matrices that represents stability across model 
initializations and average similarity of two different models. Because we used the 
weight matrices, the similarity describes biological signature discovery. We use the 
distribution of SVCCA similarity measures across all pairwise algorithm initializations and 
latent dimensionalities to indicate model stability (299). 
7.6.7. Using BioBombe as a signature discovery tool  
We tested the ability of BioBombe sequentially compressed features to distinguish 
sample sex in GTEx and TCGA data, and MYCN amplification in TARGET NBL data. 
We performed a two-tailed independent t-test assuming equal variance comparing male 
and female samples, and NBL samples with and without MYCN amplification. We 
applied the t-test to all compression features identified across algorithms, initializations, 
and dimensions. Shown in the figures are the top scoring feature per latent space 
dimension and algorithm. 
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We applied each optimal signature learned in GTEx, TCGA, and TARGET to 
alternative datasets. We applied the GTEx sex feature to TCGA data and vice versa. We 
applied the TARGET MYCN amplification signature to a series of publicly available NBL 
cell lines (302). The data were processed using STAR, and we accessed the processed 
FPKM matrix from figshare (321).  We transformed the datasets with the identified 
signatures using the following operation: !"'$*&"'	x	) = &+	,	)' 		 
Where D represents the respective RNAseq data to transform, S represents the specific 
signature, g’ represents the overlapping genes measured in both datasets, n represents 
samples, and D’s represents the signature scores in the transformed dataset.	
7.6.8. Gene network construction and processing 
We constructed networks using gene set collections compiled by version 6.2 of the 
Molecular Signatures Database (MSigDB) and cell types derived from xCell (102, 291, 
292). These gene sets represent a series of genes that are involved in specific biological 
processes and functions. We integrated all openly licensed MSigDB collections which 
included hallmark gene sets (H), positional gene sets (C1), curated gene sets (C2), motif 
gene sets (C3), computational gene sets (C4), Gene Ontology (GO) terms (C5), 
oncogenic gene sets (C6) and immunologic gene sets (C7). We omitted KEGG, 
BioCarta, and AAAS/STKE gene sets because of copyright restrictions. The C2 gene set 
database was split into chemical and genetic perturbations (C2.CPG) and Reactome 
(C2.CP.Reactome). The C3 gene set was split into microRNA targets (C3.MIR) and 
transcription factor targets (C3.TFT). The C4 gene set was split into cancer gene 
neighborhoods (C4.CGN) and cancer modules (C4.CM). Lastly, the C5 gene set was 
split into GO Biological Processes (C5.BP), GO Cellular Components (C5.CC), and GO 
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molecular functions (C5.MF). xCell represents a gene set compendia of 489 
computationally derived gene signatures from 64 different human cell types. In 
BioBombe network projection, only a single collection is projected at a time. 
To build the gene set network, we used heterogeneous network (hetnet) software 
(322). Briefly, hetnets are networks that include multiple node types and edge 
relationships. We used only a single edge relationship in this application, which indicated 
if a gene participated in a given gene set. We used hetnets to build a single network 
containing all MSigDB collections and xCell gene sets listed above. The network 
consisted of 17,451 unique gene sets and 2,159,021 edges representing gene set 
membership among 20,703 unique gene nodes. In addition to generating a single hetnet 
using curated gene sets, we also generated 10 permuted hetnets. The hetnets are 
permuted using the XSwap algorithm, which preserves node degree, or the amount of 
gene set relationships per gene (324). Therefore, the permuted networks are not 
restricted by biases induced by uneven gene participation. We compared the real hetnet 
score and against the distribution of permuted network scores to interpret the biological 
signatures in each compression feature. 
7.6.9. Rapid interpretation of compressed gene expression data  
Our goal was to quickly interpret the automatically generated compressed latent 
features learned by each unsupervised algorithm. To this end, we constructed gene set 
adjacency matrices with specific MSigDB or xCell gene set collections using hetnet 
software. We then performed the following matrix multiplication against a given 
compressed weight matrix to obtain a raw score for all gene sets for each latent feature. 
!"	x	%*'%	x	( = *"	x	(		 
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Where H represents the gene set adjacency matrix, c is the specific gene set collection, 
and n represents genes. W represents the specific compression algorithm weight matrix, 
which includes n genes and k latent space features. The output of this matrix 
multiplication, G, is represented by c gene sets and k latent dimensions. Through a 
single matrix multiplication, the matrix G tracks raw BioBombe scores. 
Because certain hub genes are more likely to be implicated in gene sets and longer 
gene sets will receive higher raw scores, we compared G to the distribution of permuted 
scores against all 10 permuted hetnets. 
 !"#	x	&'(')*+&	x	, = ."		 
!"-$%&'( = 	!%	x	,-	!-	.(!-) 	 
Where HP1-10 represents the adjacency matrices for all 10 permuted hetnets and Gp 
represents the distribution of scores for the same k features for all permutations. We 
calculated the z score for all gene sets by latent features (Gz-score). This score represents 
the BioBombe Score. Other network based gene set methods consider geneset 
influence based on network connectivity of gene set genes (317, 318). Instead, we used 
the latent feature weights derived from unsupervised compression algorithms as input, 
and the compiled gene set networks to assign biological function. 
7.6.10. Calculating gene set coverage of sequentially compressed gene expression 
data 
We were interested in determining the proportion of gene sets within gene set 
collections that were captured by the features derived from various compression 
algorithms. We considered a gene set “captured” by a compression feature if it had the 
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highest positive or highest negative BioBombe z score compared to all other gene sets 
in that collection. We converted BioBombe z scores into p values using the pnorm() R 
function using a two-tailed test. We removed gene sets from consideration if their p 
values were not lower than a Bonferroni adjusted value determined by the total number 
of k dimensions in the model. We calculated coverage (C) by considering all unique top 
gene sets (U) identified by all features in the compression model (w) and dividing by the 
total number of gene sets in the collection (TC). 
C	=	 $%&' 		 
We calculated the coverage metric for all models independently (Ci), for ensembles, or 
individual algorithms across all five iterations (Ce), and for all models across k 
dimensions (Ck). We also calculated the total coverage of all BioBombe features 
combined in a single model (Ca). A larger coverage value indicated a model that 
captured a larger proportion of the signatures present in the given gene set collection.  
7.6.11. Downloading and processing publicly available expression data for neutrophil 
GTEx analysis  
We used an external dataset to validate the neutrophil feature that we identified to 
contribute to detecting blood signatures in GTEx. To assess the performance of this 
neutrophil signature, we downloaded data from the Gene Expression Omnibus (GEO) 
with accession number GSE103706 (303). RNA was captured in this dataset using 
Illumina NextSeq 500. The dataset measured the gene expression of several replicates 
of two neutrophil-like cell lines, HL-60 and PLB-985, which were originally derived from 
acute myeloid leukemia (AML) patients. The PLB-985 cell line was previously identified 
as a subclone of HL-60, so we expect similar signature activity between the two lines 
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(324). Gene expression of the two cell lines was measured with and without neutrophil 
differentiation treatments. In this dataset, DMSO treatment was used to induce 
neutrophil differentiation. Gene expression was also collected in Nutridoma 
supplemented media, which has also been used to induce neutrophil differentiation. We 
tested the hypothesis that our neutrophil signature would distinguish the samples with 
and without neutrophil differentiation treatment. We transformed external datasets with 
the following operation: 
!"	x	%'' *)%'	x	* = )"	x	*' 		 
Where D represents the processed RNAseq data from GSE103706. Of 8,000 genes 
measured in W, 7,664 were also measured in D (95.8%). These 7,664 genes are 
represented by g’. All of the “Neutrophils_HPCA_2” signature genes were measured in 
W. D’ represents the GSE103706 data transformed along the specific compression 
feature. Each sample in D’ is then considered transformed by the specific signature 
captured in k. 
7.6.12. Downloading and processing publicly available expression data for monocyte 
GTEx analysis  
We used an additional external dataset to validate the identified monocyte signature. 
We accessed processed data for the publicly available GEO dataset with accession 
number GSE24759 (304). The dataset was measured by Affymetrix HG-U133A (early 
access array) and consisted of 211 samples representing 38 distinct and purified 
populations of cells, including monocytes, undergoing various stages of hematopoiesis. 
The samples were purified from 4 to 7 independent donors each. Many xCell gene sets 
were computationally derived from this dataset as well (291). Not all genes in the weight 
matrices were measured in the GSE24759 dataset. For this application, 4,645 genes 
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(58.06%) corresponded with the genes used in the compression algorithms. Additionally, 
168 out of 178 genes (94.38%) in the “Monocyte_FANTOM_2” gene set were measured. 
We investigated the “Monocytes_FANTOM_2” signature because of its high enrichment 
in VAE k = 3 and low enrichment in VAE k = 2. 
7.6.13. Machine learning classification of cancer types and gene alterations in TCGA  
We trained supervised machine learning models to predict cancer type from RNAseq 
features in TCGA PanCanAtlas RNAseq data. We implemented a logistic regression 
classifier with an elastic net penalty. More details about the specific implementation are 
described in Chapter 3 and in Way et al. 2018 (37). Here, we predicted all 33 cancer 
types using all 11,060 samples. These predictions were independent per cancer type, 
which meant that we trained models with the same input gene expression data, but used 
33 different status matrices.  
We also trained models to predict gene alteration status in the top 50 most mutated 
genes in the PanCanAtlas. We defined the status in this task using all non-silent 
mutations identified with a consensus mutation caller (233). We also considered large 
copy number amplifications for oncogenes and deep copy number deletions for tumor 
suppressor genes as previously defined (325). We also used the threshold GISTIC2.0 
calls for large copy amplifications (score = 2) and deep copy deletions (score = -2) in 
defining the status matrix (214). For each gene alteration prediction, we removed 
samples with a hypermutator phenotype, defined by having log10 mutation counts 
greater than five standard deviations above the mean. For the mutation prediction task, 
we also did not include certain cancer types in training. We omitted cancer types if they 
had less than 5% or more than 95% representation of samples with the given gene 
alteration. The positive and negative sets must have also included at least 15 samples. 
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We filtered out cancer types in this manner to avoid the classifiers from artificially 
detecting differences induced by unbalanced training sets. 
 We trained models with raw RNAseq data subset by the top 8,000 most variably 
expressed genes by median absolute deviation. The training data used was the same 
training set used for the sequential compression procedure. We also trained models 
using all compression matrices for each k dimension, and using real and permuted data. 
We combined compressed features together to form three different types of ensemble 
model. The first type grouped all five iterations of VAE models per latent dimension to 
make predictions. The second type grouped features of five different algorithms (PCA, 
ICA, NMF, DAE, VAE) of a single iteration together to make predictions. The third 
ensemble aggregated all features learned by all algorithms, all initializations, and across 
all latent dimensions, which included a total of 30,850 features. In total, considering the 
33 cancer types, 50 mutations, 28 k dimensions, ensemble models, raw RNAseq 
features, real and permuted data, and 5 initializations per compression, we trained and 
evaluated 32,868 different supervised models.  
We optimized each model independently using 5-fold cross validation (CV). We 
searched over a grid of elastic net mixing and alpha hyperparameters. The elastic net 
mixing parameter represents the tradeoff between l1 and l2 penalties (where mixing = 0 
represents an l2 penalty) and controls the sparsity of solutions (20). Alpha is a penalty 
tuning the impact of regularization, with higher values inducing higher penalties on gene 
coefficients. We searched over a grid for both hyperparameters (alpha = 0.1, 0.13, 0.15, 
0.2, 0.25, 0.3 and mixing = 0.15, 0.16, 0.2, 0.25, 0.3, 0.4) and selected the combination 
with the highest CV AUROC. For each model, we tested performance using the original 
held out testing set that was also used to assess compression model performance. 
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Chapter 8. 
Conclusions 
Signal embedded in transcriptome data can be used to inform disease subtypes, cell 
type activation patterns, pathway misregulation, response to molecular and 
environmental perturbation, and many other important biological signatures. By viewing 
the transcriptome from a systems biological perspective, researchers can develop many 
different biomedical applications and biological hypotheses. As transcriptome data 
continues to be generated at a rapid pace, analysis methods to identify patterns and 
generate hypotheses are becoming increasingly important. Machine learning is one 
class of tools that can be helpful with these problems. 
There are two major classes of machine learning: supervised and unsupervised 
learning. Both tools are useful in biological applications. Supervised learning can be 
used to target specific hypotheses. For example, supervised learning can be used to 
prioritize genes or target compounds, to inform treatment of patients who are likely to 
respond to specific therapies, and many other important applications. In the first aim of 
my dissertation (Chapters 2 – 4), we used transcriptome data to distinguish tumors with 
NF1, TP53, and Ras pathway aberration. We showed that supervised machine learning 
can be used to detect wild type Ras cell lines sensitive to MEK inhibitors. Measuring 
gene mutation status in these cell lines alone would have missed many potential 
responders to this therapy.  
Labels in biomedical and biological applications are not often reliable. Class 
assignment is noisy, labels are often expensive to acquire, and biological signatures are 
seldom discrete. Therefore, data driven methods, such as unsupervised machine 
learning, can be helpful to generate hypotheses and identify patterns of activity in 
transcriptome data. In the second aim of my dissertation (Chapters 5 and 6), we applied 
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unsupervised learning to gene expression data. We showed that unsupervised learning 
can help detect high grade serous ovarian cancer subtypes across different populations. 
Other, more recently developed methods, often coming from different fields, can be 
repurposed and used effectively in biological domains. For instance, we trained a 
variational autoencoder, a model developed primarily for image processing applications, 
on gene expression data and, leveraging the compressed latent space, isolated 
continuous gene expression signatures that were differentially active in HGSC subtypes. 
While unsupervised learning methods alleviate certain biases present in labelled 
data, there remain many obstacles to successful applications. Unsupervised models 
compress input data into a lower dimensional representation that aggregates various 
biological and technical signatures that describe input data. Major challenges include 
determining the number of latent features to compress and interpreting the biological 
signal embedded in compressed features. Therefore, in the third aim of my dissertation 
(Chapter 7), we developed an approach to sequentially compress gene expression data 
using several compression algorithms and many different bottleneck dimensions. We 
constructed gene set and cell type networks to rapidly interpret the biological signatures 
captured in the compressed features. We observed that different compression 
algorithms and various latent dimensions capture biological signatures at variable 
association strengths. Rather than training models to optimize traditional performance 
metrics, biomedical researchers should shift focus to models that identify useful 
biological representations. However, experimental validation is essential to confirm that 
the signatures identified are sound, reproducible, and valuable.  
 Gene expression data captures important signatures activated in biological data. 
However, other data types capture additional, and potentially orthogonal, signals as well. 
For example, measuring DNA methylation, protein, DNA sequence, biological images, 
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and other data modalities can provide additional insight. There are many data types and 
views that can be leveraged across biomedical domains. Applying a holistic perspective, 
and embracing an integrative approach, will aid in the next generation of target 
discovery, drug development, and healthcare decisions. We are entering an exciting 
time with many unknowns and a deluge of data. Computational scientists are developing 
new analysis tools while molecular biologists are developing new data collection 
methods to measure new and exciting biological data types. As the open science 
movement continues to grow, tools and data will continue to be shared, and biomedical 
progress and discoveries can help advance patient care. Machine learning and 
transcriptomics are currently underused in biomedicine, and they can play an important 
role in advancing human health. Biomedical integration of different data types and 
interdisciplinary collaboration will improve the pace of progress.  
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